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ABSTRACT
The rewarding properties of nicotine, which reinforce its self-administration, are 
related to increased dopamine (DA) release, mediated by nicotinic acetylcholine receptors 
(nAChRs), in areas of the brain that form the principal terminal fields of the mesolimbic DA 
system. Currently, bupropion (Zyban®), an atypical antidepressant that has been approved 
for smoking cessation, inhibits reuptake of DA and noradrenaline (NA). Recently, it has 
been shown to block nAChRs too. However, the exact mechanisms by which it reduces 
nicotine intake are still unclear. The present thesis examined the relative importance of 
these activities, with respect to nicotine-evoked DA release, using various models of 
increasing complexity.
The effects of bupropion on nicotine-evoked [3H]dopamine ([3H]DA) release were 
examined in rat striatal synaptosomes and slices using in vitro superfusion (Chapter 2). 
Nomifensine, an established DA transporter (DAT) blocker, was used as a comparison. 
Bupropion’s ability to block DAT and nAChRs appeared to be separated with respect to its 
concentration. Bupropion (10 pM) reduced nicotine-evoked [3H]DA release in both 
synaptosomes and slices consistent with its specific inhibition of nicotine-evoked 
increases in Ca2+ fluorescence in SH-SY5Y cells. At the lower concentration of bupropion 
(0.1 pM) that was proposed to inhibit DAT, an unexpected decrease in nicotine-evoked 
[3H]DA release was observed in striatal slices. As this effect was reversed by raclopride, a 
DA D2 receptor antagonist, we postulate that blockade of DAT by bupropion (0.1 pM) 
results in feedback inhibition via D2 receptors. The effects of a high concentration of 
nomifensine (10 pM) in slices were consistent with DAT blockade. However, in 
synaptosomes and SH-SY5Y cells data suggested that nomifensine may also block 
nAChRs and voltage-operated Ca2+ channels (VOCC).
In Chapter 3, the effects of bupropion on nicotine-evoked DA release in the ventral 
striatum were examined using in vivo microdialysis (the construction of a home-made 
microdialysis system is described in the Appendix), to provide a more physiological model 
for comparisons with synaptosomes and slices. Behavioural comparisons were made 
using locomotor activity tests. Systemic administration of bupropion (30 mg/kg) 
augmented nicotine-evoked DA release and nicotine-induced hyperlocomotion. Its weak 
DAT blocking actions were inferred to explain these responses. In vivo, bupropion failed to 
exhibit any discernable effect as a nAChR antagonist.
Through a systematic method of analysis using neuronal models of increasing 
complexity, these studies have demonstrated the intricate effects of bupropion’s 
interactions with DA systems. Indeed better animal models are required to explain its 
efficacy as a smoking cessation agent. However, it seems that in vivo, at least, bupropion 
is likely to facilitate smoking cessation mainly through its ability to block DAT.
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Drug addiction is a chronically relapsing disorder characterised by a compulsion to 
seek and take a drug coupled with the inability to control drug intake despite serious 
negative consequences (Koob et al., 2004). Such activities often involve the development 
of repetitive and nearly automatic behaviours that we call habits. Drug addiction is a 
worldwide public-health crisis, and exerts corrosive effects at family and societal levels, 
which include health care expenditure, lost earning, and costs associated with crime and 
accidents. The World Health Organisation (WHO) estimated that there are 2 billion alcohol 
users, 1.3 billion tobacco users, and 185 million users of illicit drugs (The WHO Report, 
1999). In 2001, these three categories together contributed to 12.4% of deaths worldwide. 
In the United States alone, approximately 590000 deaths are caused by addictive drugs 
(NIDA website, 2005). The costs of drug abuse are an enormous burden that affects all 
society -  those who abuse these substances, and those who do not (Fig. 1.1).
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Fig. 1.1 Epidemiology of major health problems and approximate costs to US society
for substance abuse in the USA.
(source: www.drugabuse.gov)
The likelihood of developing addiction is a complex function of many factors, 
including the individual’s personality and other psychological factors (social adequacy), 
background (family, neighbourhood, school and peer factors), substance availability, an 
individual’s genotype, and the pharmacological properties of the drug (Fig. 1.2). 
Interactions between genes and environmental factors with genes also are likely to be 
important (van den Bree, 2005). When addictive drugs are used repeatedly by vulnerable 
humans, molecular changes in the brain promote continued drug taking that becomes 
increasingly difficult for the individual to control. Once addiction has taken hold, it tends to
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follow a chronic course, in which periods of 
abstinence are followed by relapse to active drug 
use (Hyman and Malenka, 2001).
Addictive drugs, such as cocaine and 
amphetamine, are both rewarding and 
reinforcing. A reinforcer can be defined 
operationally as any event that increases the 
probability of a response. Reward is often 
defined similarly but with some positive affective 
colouring, such as pleasure or hedonia (Koob,
1992). Several sources of reinforcement may 
contribute to addiction. In positive reinforcement, 
a rewarding stimulus increases the probability of 
any behaviour that results in a drug being administered, and so is critical for establishing 
addictive behaviour. In negative reinforcement, the incentive for drug administration is 
relief of a painful or unpleasant state (Roberts and Koob, 1997). Both positive and 
negative reinforcement are important for maintaining drug use following the development 
of addiction.
“Drug dependence” is the clinical term favoured by the Diagnostic and Statistical 
Manual of Mental Disorders (fourth edition). However, “dependence” and “addiction” are 
not scientifically equivalent. Dependence refers to an adapted state of cells, circuits or 
organ systems that occurs in response to excessive drug stimulation, such that when 
unmasked by drug cessation, this adapted state can result in the production of cognitive, 
emotional or physical withdrawal symptoms (Hyman and Malenka, 2001). In addition to 
dependence, addictive drugs can produce sensitisation or tolerance, as well as 
withdrawal. Sensitisation is an increased response to a drug effect following repeated 
administration of the drug (Di Chiara, 1998). A recent conceptualisation of the role of 
sensitisation in drug addiction posits that a motivational state described as “wanting” is 
progressively increased by repeated exposure to drugs of abuse (Robinson and Berridge,
1993). Conversely, tolerance is defined as a decrease in drug-induced effect despite a 
constant dose, or a need for increasing dosage to maintain a stable effect. Both 
sensitisation and tolerance to the stimulant effects of drugs of abuse are the result of 
changes in an individual’s sensitivity to the drugs themselves. These changes are referred 
to as neuroadaptations. Counteradaptation refers to processes that are initiated to oppose 
the effects of drugs of abuse. Withdrawal is a counteradaptive process, which describes a 
state of adverse effects, both physical and psychological, that occurs after cessation of 
drug intake (Rang et al., 2003).
The universal hallmark of addiction is craving (psychological dependence) 
whereby addicts experience an intense desire to reinstate drug use. Drug craving and
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Fig. 1.2 Schematic of various 




relapse are precipitated by re-exposure to a previously abused drug, an environment 
associated with prior drug use, drug paraphernalia or a stressful life event. Such 
encounters are examples of “cues” that are “conditioned” with the experience of drug- 
taking. Cues associated with either the rewarding effects of drug taking (conditioned 
positive reinforcement) or the negative effects of drug withdrawal (conditioned negative 
reinforcement) are two major psychological factors that contribute to drug dependence 
(Fig. 1.3).
Cues associated with drug withdrawal Cues associated with drug taking
social situation social situation
^ ,  non-availability of drug etc. purchase of drug ..
preparation ot drug etc.
Drug withdrawal Drug administration
Negative conditioning Positive conditioning
Positive
reinforcement
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Fig. 1.3 Schematic of psychological factors involved in drug dependence.
(source: Rang et al., 2003)
Many neurotransmitters, including y-aminobutyric acid (GABA), glutamate, 
acetylcholine (ACh), DA, serotonin and endogenous opioid peptides, have been 
implicated in the effects of various types of drugs of abuse (Volkow and Li, 2004). Of 
these, DA has been consistently associated with the reinforcing effects of most drugs of 
abuse (Di Chiara, 1999). Like natural reinforcers such as food, water and sex, virtually all 
drugs of abuse increase extracellular DA concentrations in the mesolimbic DA pathway 
(see section 1.2.2). Drugs such as cocaine, amphetamine, methamphetamine and 
ecstasy increase extracellular DA by inhibiting its reuptake or promoting DA release 
through their effects on DAT (Madras et al., 1989). Other drugs, such as nicotine, alcohol, 
opiates and marijuana, work indirectly by stimulating neurones (GABA-mediated or 
glutamatergic) that modulate DA cell firing through their effects on nicotine, GABA, p- 
opiate or cannabinoid CB1 receptors, respectively (Kreek et al., 2002). However, nicotine 
can also have direct effects on DA release by stimulating nAChRs on DA neurones 
(discussed in section 1.4).
If natural reinforcers increase DA, why do they not lead to addiction? The 
difference lies in the qualitative and quantitative differences in DA increases induced by 
addictive drugs, which are greater in magnitude (at least five- to ten-fold) and duration
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than those induced by natural reinforcers (Wise, 2002). Furthermore, DA increases 
produced by natural reinforcers undergo habituation upon repeated exposure, whilst those 
induced by drugs of abuse do not (Di Chiara, 2002), i.e. non-decremental stimulation of 
DA transmission from repeated drug use strengthens the motivational properties of the 
drug, which does not occur for natural reinforcers (Volkow and Li, 2004).
1.2 Dopaminergic pathways in the brain
relevant to addiction
Dopaminergic neurones form a number of pathways in the central nervous system 
(CNS). The two major systems are the nigrostriatal (see section 1.2.1) and 
mesocorticolimbic system (see section 1.2.2).
1.2.1 The nigrostriatal pathway
The nigrostriatal pathway accounts for about 75% of brain DA and consists of cell 
bodies in the substantia nigra (SN), in particular the pars compacta (SNc), with axons that 
terminate in the striatum. These fibres ascend via the medial forebrain bundle and then 
the internal capsule to innervate the caudate nucleus, the putamen (the caudate and 
putamen are fused in rodents, but not in primates and humans), and the globus pallidus 
(GP; Fig. 1.4). The caudate-putamen in rodents is commonly known as the dorsal 
striatum. The nigrostriatal pathway is vitally important in motor control, and degeneration 
of this system is the key feature of Parkinson’s disease (Quik, 2004). In rats, there are an 
estimated total of 20000 DA cell bodies in the two SN. A single axon from one of these DA 
cells branches substantially to give rise to thousands of synaptic boutons in the striatum. 
Many of these synaptic connections are made with medium-sized spiny neurones that 
form the output pathways of the striatum (see section 1.4.5.2).
1.2.2 The mesocorticolimbic pathway
The mesolimbic and mesocortical dopaminergic systems (Fig. 1.4) arise from 
dopaminergic cells located in the ventral tegmental area (VTA). The dopaminergic cells of 
the VTA and SNc form a continuous layer and project to adjacent and overlapping 
terminal fields. Hence the boundaries between these “systems” are not well defined 
(Bressan and Crippa, 2005). DA cells of the VTA project most strongly to the nucleus 
accumbens (NAc; also known as the ventral striatum) and olfactory tubercule, but also
4
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innervate the septum, amygdala and hippocampus. This subset of projections is known as 
the mesolimbic dopaminergic pathway and is thought to be important for motivational 
function. DA cells in the medial VTA that project to the medial prefrontal, cingulate and 
perirhinal cortex are known as the mesocortical dopaminergic pathway and are involved in 
modulating attention and other cognitive processes. Due to the overlap between the 
mesolimbic and mesocortical DA neurones, the two systems are often referred to as the 













Fig. 1.4 Sagital section through the rat brain depicting the nigrostriatal and 
mesocorticolimbic dopaminergic pathways.
(source: www-unix.oit.umass.edu)
The role of the mesocorticolimbic DA system in reward related functions originates 
from the findings of Olds and Milner in 1954. When electrodes were placed in discrete 
areas of the brain, they observed that rats would actively self-stimulate these areas, often 
to the exclusion of all other activities, including eating. The circuits involved in this process 
have been referred to as the reward system. Since then, much focus has been on the 
mesolimbic dopaminergic pathway, as several studies using animal models of reward, and 
by measuring in vivo DA release with microdialysis, reveal that natural rewarding stimuli 
such as food, water and sex, and drugs of abuse such as cocaine, amphetamine and 
nicotine, increase DA release in the NAc (Di Chiara, 1999; Bressan and Crippa, 2005).
The link to nicotine addiction was obtained from rodent self-administration studies, 
which revealed that nicotine self-administration was abolished by lesions of the 
mesolimbic dopaminergic pathway, and also by DA receptor antagonists (Corrigall and 
Coen, 1991; Corrigall et al., 1992). Since nicotine evoked DA release from the so-called 
reward pathways, the interpretation was made that this system may have a pivotal role in 




Cigarette smoking has been the most popular method of taking nicotine since the 
beginning of the 20th century. In 1989, the U.S. Surgeon General issued a report that 
concluded that cigarettes and other forms of tobacco, such as cigars, pipe tobacco, and 
chewing tobacco, are addictive and that nicotine is the drug in tobacco that causes 
addiction. Smoking is the third leading cause of death in the United States, resulting in 
approximately 440000 premature deaths each year with an annual expenditure of more 
than $75 billion in direct medical costs (NIDA Info Facts, 2005). WHO epidemiologists 
predict that unless there is a dramatic change in present trends, tobacco will be killing 8.4 
million people a year by the late 2020s (Fig. 1.5; The WHO Report, 1999).
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Fig. 1.5 Epidemiology for the growth of cigarette consumption and projected deaths
from tobacco related illnesses.
(source: The World Health Report, 1999)
1.3.1 The history of nicotine
Tobacco is a native plant of the American continent. Historians believe tobacco 
began growing in the Americas around 6000 BC, and that American Indians started the 
use of tobacco as early as the 1st century BC for hedonistic, medicinal and ceremonial 
purposes. These effects were later traced to the actions of nicotine, which is one of many 
cholinomimetics that have been used for these purposes. By the time Europeans arrived 
on the American continent in the 15th century, smoking of tobacco among indigenous 
American people was widespread and native tribes were not only growing and consuming 
tobacco but also trading tobacco leaves. Smoking spread to Europe during the 16th 
century, coming to England mainly as a result of its enthusiastic espousal by Sir Walter 
Raleigh at the court of Queen Elizabeth I. It was then that tobacco plants were given the 
name Nicotiana tabacum (Fig. 1.6) in honour of Jean Nicot (1530-1600), who had 
introduced tobacco chewing to Catherine de Medici of France (1560) and promoted the
6
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importation and cultivation of the 
plant. However, King James I 
strongly disapproved of tobacco 
and initiated the first antismoking 
campaign in the early 17th century.
The first suggestion that tobacco 
smoking might be addictive was 
reported in 1610 when Sir Francis 
Bacon noted that trying to quit the 
habit was very difficult (Leavey,
1998).
Commercial cultivation of tobacco in America began in the early 17th century, and 
the first successful shipload was sent to England in 1616. By the late 1620s, an estimated 
500000 lbs of tobacco was being brought into London every year. Tobacco was now 
common among all sectors of society and people learnt to smoke, usually by sharing a 
communal pipe. In 1730, the first American tobacco factories were constructed producing 
pipe tobacco, cigars and snuff. By the end of the 18th century, snuff-taking was in decline 
and a revival in smoking had begun in the form of cigars. However, it was the invention of 
the manufactured cigarette that transformed tobacco smoking into a truly mass habit. 
James Duke was the first tobacco entrepreneur to use cigarette-making machines. 
Cigarette smoking among men increased during World War I when cigarettes were 
included in soldiers’ rations. It remained socially unacceptable for women to smoke until 
the Suffragette movement in the 1920s, when significant numbers of women started to 
smoke (Leavey, 1998). Currently, cigarettes account for more than 90% of tobacco 
consumption and nicotine has become far better known than most other cholinotropic 
substances as it confers an interoceptive “pleasurable effect” (Di Chiara and Imperato, 
1988) or euphoria that has instigated and sustained tobacco use by large proportions of 
human populations virtually the world over.




in tobacco, is one 
of 4000 chemicals 
found in the smoke
of tobacco products such as cigarettes, cigars and pipes. Nicotine is a colourless liquid
Fig. 1.7 The chemical structure of 
(-)nicotine.
Nicotine is a water and lipid soluble 
drug which, in the free base form, is 
readily absorbed via respiratory tissue, 
skin, and gastrointestinal tract. At pH 
7.4, about 70% of it is ionised in the 
form shown.
Fig. 1.6 Afield of 
tobacco plants in 
Cuba.
Nicotiana tabacum is a 
hardy plant and so is 
grown in many parts of 
the world, with the two 
largest exporters being 
the USA and Brazil.
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that turns brown when burned and acquires the odour of tobacco when exposed to air. 
Nicotine is a tertiary amine consisting of a pyridine and a pyrrolidine ring (Fig. 1.7).
1.3.2.1 Pharm acokinetics of nicotine
Nicotine absorption can vary, partly by the method in which it is consumed. 
Therefore, the time taken for it to reach the brain is a major factor that governs its 
addictive properties. An average cigarette contains about 0.8 g of tobacco and 9-17 mg 
nicotine, of which approximately 10% is normally absorbed by the smoker (Rang et al., 
2003). Nicotine, absorbed from cigarettes through the lungs and then via arterial blood, 
reaches the brain in about seven seconds, almost twice as fast as when the drug is 
administered intravenously (Benowitz, 1996). Absorption of nicotine is pH dependent. At 
an acid pH of smoke from cigarettes (pH 5.5), nicotine is mostly ionised and does not 
readily penetrate cell membranes. At the alveoli of the lungs, nicotine is buffered to 
physiological pH and rapidly crosses cell membranes (Salin-Pascual et al., 2003). 
Nicotine from smokeless tobacco (snuff 
and chewing tobacco) is absorbed 
through the oral mucosa. Absorption 
here is considerably slower than that 
from inhaled cigarette smoke, resulting 
in a later and long-lasting peak in 
plasma nicotine concentration (Fig. 1.8).
Nicotine concentrations in a 
cigarette smoker’s (on average 20 
cigarettes a day) plasma during the day 
typically range from 20-40 ng/ml.
Arteriovenous differences during 
cigarette smoking are substantial, with 
arterial levels exceeding venous levels 
six- to ten-fold (Benowitz, 1996).
Absorption of nicotine from the gum is 
gradual, with plasma levels of nicotine 
much lower than those achieved after 
cigarette smoking. Frequent dosing and 
a correct chewing technique are 
necessary to achieve good nicotine 
absorption from the oral mucosa (Tutka 
et al., 2005). Nicotine from the 
transdermal patch is slowly absorbed. Plasma concentrations rise gradually over 6-10 h,
20  -
•  Cigarettes 
» '« Oral snuff
• Chewing tobacco 
■— *  Nicotine gum
16 -
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Time (min)
Fig. 1.8 Nicotine concentrations in plasma 
during smoking.
Blood concentrations during and after
cigarette smoking (1% cigarettes) for 9 min
and use of oral snuff (2.5 g), chewing tobacco 
(average 7.9 g), and nicotine gum (two 2 mg 
pieces) for 30 min. The points represent 
average values for 10 subjects (adapted from 
Feldman et al., 1997).
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reaching a plateau over the next 8-12 h, followed by a slow decline over the final 6 h. 
Nicotine delivered from the nasal spray is absorbed through the nasal mucosa. The 
absorption is very rapid and peak arterial plasma levels are reached in about 5 min after 
administration (Salin-Pascual et al., 2003).
Following absorption, nicotine readily reaches many organs and tissues and 
undergoes extensive metabolism. The initial distribution half-life (t^d) of nicotine in blood 
is estimated to be 4-10 min, and the elimination half-life (ty2e) is approximately 2 h. 
Repeated exposure to nicotine produces a steady state for about 6-8 h. However, the 
terminal half-life of nicotine is 20 h or more, presumably due to the slow release of 
nicotine from various bodily tissues (Benowitz, 1996). After acute intra-arterial or 
intravenous administration of nicotine in rats, mean ty2d and ty2e of nicotine are 
approximately 10 and 90 min, respectively. Chronic subcutaneous nicotine injections yield 
a global half-life of 44-49 min (Mathieu-Kia et al., 2002). Pharmacokinetic studies in rats 
have shown that levels of nicotine in the brain averages about two or three times higher 
than that in the blood (Rowell and Li, 1997). Whether a similar situation occurs in humans 
is unknown at present.
About 80-90% of nicotine is metabolised in the liver, with small amounts in the 
kidneys, lungs and brain. About 70-80% of nicotine is metabolised to cotinine via C- 






















A m .  TRMIS-












Fig. 1.9 The major pathways of nicotine metabolism in humans.
CYP, cytochrome P450; FMO, flavin mono-oxygenase (adapted from Tutka et al., 2005)
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Cotinine is the most abundant metabolite found in urine. Several cytochrome P450 (CYP) 
enzymes, as well as flavin mono-oxygenases, are purported to play a role in nicotine 
metabolism, but CYP 2A6 and aldehyde oxidase are the principal enzymes involved in 
converting nicotine to cotinine. Cotinine has a much longer half-life than nicotine (14-20 h) 
and consequently is used as a marker for nicotine intake (Salin-Pascual et al., 2003). The 
main organ for nicotine excretion is the kidney. Renal clearance of nicotine, which 
depends on urine pH, accounts for 2-35% of total nicotine clearance. Some nicotine is 
also excreted in the saliva (Tutka et al., 2005).
1.3.3 How does nicotine deliver its effects?
Nicotine can act both as a stimulant and a sedative. Immediately after exposure to 
nicotine, there is a “kick” caused by discharge of adrenaline from the adrenal cortex. This 
stimulates the CNS and other endocrine glands causing a sudden release of glucose as 
well as an increase in blood pressure, respiration and heart rate. In addition, nicotine 
causes the release of DA in the brain regions that control pleasure and motivation (see 
section 1.4.6 for nicotinic modulation of DA release). Nicotine can also exert a sedative 
effect, depending on the level of the smoker’s nervous system arousal and the dose of 
nicotine taken (NIDA Research Report, 1998).
Repeated exposure to nicotine results in the development of tolerance, whilst 
cessation is
followed by a 
withdrawal 
syndrome that may 
last from a few 




nicotine intake by 
self-titration to 
avoid the negative 
psychological 












Impatience Pain in limbs
Irritability Sleep disturbances




Table 1 Possible symptoms as a result of nicotine withdrawal
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after termination of each cigarette, blood levels of nicotine rapidly peak and fall. In addition 
to this intermittent spike pattern, the overall levels of nicotine across the daylight period 
gradually increase in the morning, reaching maximal levels during the afternoon and late 
evening, and finally fall during the night (Mathieu-Kia et al., 2002). Smokers achieve this 
by manipulating nicotine intake through the numbers of puffs per cigarette, the intensity of 
puffing, the depth of inhalation, and changing the puff volume. As tolerance to nicotine is 
lost overnight, smokers often report that the first cigarettes of the day are the strongest 
and/or the “best”.
A smoker’s chronic exposure to nicotine can result in addiction. Part of the reason 
lies in the rapid transit time of nicotine to the brain coupled with its relatively short half-life, 
thus allowing smokers to regulate their nicotine intake throughout the day. However, 
paired associations between nicotine intake (e.g. cigarette puffs) and environmental 
situations (e.g. going to the pub or a party) are more pertinent for its addictive nature. As 
nicotine dependence develops, previously neutral environmental stimuli that are 
associated repeatedly with episodes of smoking behaviour acquire the ability, through 
Pavlovian-conditioning processes, to elicit brain activation and craving for tobacco in 
dependent subjects. Without associated environmental influences, nicotine appears to be 
relatively weak in animal models of reinforcement (Le Foil and Goldberg, 2005).
The ability of nicotine to activate the mesolimbic DA system by stimulating 
nAChRs is also a principal component underlying its addictive characteristics (Corrigall et 
al., 1992).
1.4 Nicotinic acetylcholine receptors
The nAChR belongs to a superfamily of ligand-gated ion channels, which include 
the 5-hydroxytryptamine (5-HT) type 3, GABA type A and C, and glycine receptors 
(Changeux et al., 1998; Picciotto et al., 2001; Karlin, 2002; Hogg et al., 2003; Gotti and 
Clementi, 2004; Jensen et al., 2005). These receptors are known as Cys-loop receptors, 
as all of them have a conserved sequence containing a pair of cysteines separated by 13 
residues and linked by a disulphide bridge (Hogg et al., 2003; Unwin, 2005). These 
receptors are the target for pharmacologically administered nicotine, and normally 
respond to endogenous ACh in the muscle, autonomic ganglia and CNS. Muscle nAChRs 
are confined to the skeletal neuromuscular junction where they mediate neuromuscular 
transmission; ganglionic nAChRs are responsible for mediating transmission at 
sympathetic and parasympathetic ganglia; CNS nAChRs are widespread in the brain and 
are considered to have a modulatory role on neurotransmitter release (Role and Berg, 





Early studies to elucidate the subunit composition and structure of nAChRs were 
performed on receptors isolated from the organs of the electric ray, Torpedo californica, 
and electric eel, Electrophorus electricus, as these tissues were rich in nAChRs (Fig. 
1.10).
Fig. 1.10 Photographs of the electric ray, Torpedo californica, and electric eel,
Electrophorus electricus.
The nAChR is a 290 kDa, hetero-pentameric glycoprotein assembled from a ring 
of five homologous membrane-spanning subunits (a, a, p, y ore, 8). The subunits have in 
common a large extracellular N-terminal ligand-binding domain, four predicted 
transmembrane regions (M1-M4 in each subunit), and an extended cytoplasmic loop 
giving it a total length normal to the membrane plane of about 170 A (Fig. 1.11a; Unwin, 
2003; Unwin, 2005). This pseudo 5-fold arrangement delineates a cation-selective 
pathway across the membrane pore when the channel is open, but a robust barrier to ions 
when it is closed (Fig. 1.11b). The ligand-binding domain shapes a long, approximately 20 
A diameter central vestibule and has two binding sites for ACh (ay and a5), which are 
about 40 A from the membrane surface on opposite sides of the pore (Unwin et al., 2002). 
The pore makes a narrow water-filled path across the membrane and contains the gate, 
which opens when ACh occupies both binding sites. The intracellular domain shapes 
another, small vestibule, having narrow lateral openings for the ions (Karlin, 2002; Unwin, 
2005).
1.4.1.1 Ligand-binding domain
The receptor subunits in the ligand-binding domain are each, presumed to be, 
organised around two sets of p-sheets packed into a curled p-sandwich and joined 
through a disulphide bridge forming the Cys loop, as shown by the structure of the closely 
related soluble protein, ACh-binding-protein (Fig. 1.12a; Brejc et al., 2001). The two ACh- 
bindirig sites, which lie at the a-y arid a-8 subunit interfaces (Fig. 1.12b), are each formed
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of six loops, termed A-F. The a-subunit, which harbours the principal component of the 
binding-site, comprises the A, B and C loops, while the complementary component of the
Extracellular
Intracell Jar
Fig. 1.11 Structure of the nAChR.
(a) Schematic demonstrating the transmembrane topology of a single nAChR subunit. The 
four membrane spanning domains (M1-M4) are separated by extracellular and intracellular 
loops of varying lengths. The large extracellular hydrophilic N-terminal region (200 amino 
acids) forms the ligand-binding domain, possessing sites for agonists, antagonists, ions and 
other modulators. Three closely spaced hydrophobic sequences form the M1-M3 
transmembrane domains. A large intracellular hydrophilic region (100-200 amino acids) that 
is variable in sequence links the M3 and M4 domains. It offers several putative 
phosphorylation sites for intracellular ligands that can modulate and regulate the nAChR.
(b) Schematic representation of the quaternary structure, showing the arrangement of the 
subunits in the muscle-type receptor, the location of the two ACh-binding sites (between an 
a - and a y-subunit, and an a - and a 5-subunit), and the axial cation-conducting channel.
(c) A cross-section through the 4.6 A structure of the nAChR determined by electron 
m icroscopy of tubular crystals of Torpedo membrane embedded in ice. Dashed line 
indicates the proposed path to binding site.
(adapted from Miyazawa et al., 1999; Karlin, 2002).
adjacent subunit comprises the D, E and F loops (Fig. 1.12c; Brejc et al., 2001; Changeux 
and Edelstein, 2001). Modelling of the putative three-dimensional structure of the nAChR 
confirmed that the ACh-binding site must reside at the interface between two subunits and 
that the ligand must penetrate into a gorge to form appropriate chemical bridges and 
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Fig. 1.12 Representation of the pentameric structure of the ACh-binding protein (a) 
and the ligand-binding sites of the nAChR (b, c).
(a) In this representation, each protomer has a different colour. Subunits are labelled 
anticlockwise, with A-B, B-C, C-D, D-E and E-A forming the principal and complimentary 
ligand-binding sites, respectively (ball-and-stick representation).
(b) Side- and plan-view o f the muscle-type nAChR illustrates the two ACh-binding sites in 
the extracellular portion of the nAChR. When ACh binds, the kinked a-helices swing out of 
the way, thus opening the channel pore. Typical dimensions of the extracellular-, 
transmembrane-, and intracellular domains, and channel pore of the nAChR are depicted.
(c) Residues on the ligand-binding site, as identified by affinity labelling and site-directed 
mutagenesis experiments, are indicated on the primary component (on a subunits of 
nAChR) and complimentary component (on y/8 subunits of muscle nAChR, or a subunits of 
homomeric nAChR, or (3 subunits of heteromeric nAChR).
(adapted from Brej et al., 2001; Changeux and Edelstein, 2001; Rang et al., 2003).
1.4.1.2 Membrane-spanning pore
The subunits in the membrane-spanning domain are each made from four a- 
helical segments (M1-M4). The helical segments are arranged symmetrically, forming an 
inner ring of helices (M2), which shape the pore, and an outer shell of helices (M1, M3 
and M4), which coil around each other and shield the inner ring from the lipids (Unwin, 
2005). In each of the subunits, the extracellular part of the M2 helix tilts radially inward 
towards its midpoint. In contrast, the other three helices tilt radially toward and tangentially 
around the central axis (Fig. 1.13). The water-filled cavities between the M2 helices and 
the outer helices are essential for the gating mechanism of the receptor as they provide 
the space needed for agonist-induced conformational changes in the ion channel 






Fig. 1.13 Cross-section of the nAChR pentameric structure illustrating the 
transmembrane topology of the subunits.
Site-directed mutagenesis studies indicate that the M2 region of each nAChR subunit 
contributes to the formation of the ion pore. Each subunit has complimentary amino acids 
within the M2 region, which form rings within the pore (adapted from www.weizmann.ac.il).
Ion selectivity
The nAChR is a cation-selective ion channel. Residues along the entire length of 
the M2 domain and the N-terminal end of the M1 domain form the ion-conducting pore 
(Hogg et al., 2003), which discriminates between ions based on both ion charge and size. 
In the chick a7 receptor, the ionic selectivity of the nAChR can be converted from cationic 
to anionic by a minimum of three amino acid changes in the M2 domain and the M1-M2 
loop (Itier and Bertrand, 2001). The channel pore comprises a tunnel of negative 
electrostatic potential, which favours the entry of cations (Hogg et al., 2003). When this 
negative charge, contributed by a ring of glutamic acid residues, is reduced by substituting 
glutamic acid for amino acids with uncharged side chains, the cation conductance of the 
nAChR is decreased (Fig. 1.14a; Hogg et al., 2003).
The gate and opening mechanism
In the resting and desensitised state of the nAChR, the ion conductance through 
the ion channel is blocked by a molecular barrier known as the “gate”. This region is 
located in the middle of the M2 domain, where it is kinked in two positions (at Pro265 and 
near Leu251 in the a1 subunit) causing a narrowing of the ion channel (Jensen et al., 
2005). The gate consists of a “leucine ring” formed by interactions between the side 
chains of five leucines and a “valine/isoleucine ring” one helix-turn above it (Leu251 and 
Val255 in the a1 subunit; Fig. 1.14a; Miyazawa et al., 2003; Unwin, 2003; Jensen et al., 
2005). In the resting receptor state, the ion channel is only about 6 A wide in this region, 
making permeation of hydrated cations impossible (Fig. 1.14b). In the active receptor
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state, agonist binding to the N-terminal domain elicits a small (15°) axial rotation in the two 
a1-M2 helices, which disrupts or weakens the hydrophobic intersubunit interactions 
stabilising the structure around the ion channel. The relaxation of the structural constraints 
on the ion channel allows the five M2 helices to change orientation toward the outer 
helices and residues in the helices to form hydrophobic interactions with other residues in 
the receptor complex. As a result of this, the ion pore is widened by about 3 A, thereby 
allowing cations to pass through the channel and enter the cell (Fig. 1.14b; Miyazawa et 
al., 2003; Unwin, 2003; Jensen et al., 2005).






















Fig. 1.14 Ion pore of the Torpedo nAChR.
(a) a1 nAChR residues lining the pore. The localisation of the negatively charged residues 
at the mouth of the ion channel, the ion charge selectivity filter, and the resting gates 
proposed by Unwin and Karlin are shown. The upper portion of the ion channel is believed 
to act as a water pore with the lower loop components acting as the selectivity filter 
controlling the lumenal flow of ions through the receptor.
(b) Cross sections of the nAChR in the middle of the membrane, showing the closed and 
open states of the nAChR gate, lined by the M2 membrane spanning segments of each 
subunit around a five-fold axis of pseudosymmetry. Structural changes involved in the 
closing (blue) and opening (white and brown) of the nAChR gate are shown in the inset, 
(adapted from Unwin, 2003; Jensen et al., 2005).
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1.4.2 Modes of signal transduction
The nAChR is an allosteric protein complex as it is composed of multiple subunits 
and contains several orthosteric (binding sites for agonists or antagonists) and allosteric 
sites through which its function can be modulated. Originally the nAChR was thought to 
open and close in a manner similar to that of an enzyme. This scheme is known as the 
‘sequential modei’. However, evidence suggests that this transition does not occur. In 
1965, the Monod-Wyman-Changeux model, termed the “concerted allosteric model”, was 
formulated to describe the allosteric nature of nAChR signalling (Changeux et al., 1998; 
Changeux and Edelstein, 2001). According to this model, the nAChR fluctuates between 
at least three functional states in the absence of agonist: a resting state (R), an active 
state (A), and a desensitised state, which is divided into a fast-onset state (I) and a slow- 
onset (D) state (Fig. 1.15). Transitions between resting, active and desensitised states are 
reversible and different ligands may stabilise different receptor states. Agonists (e.g. 
nicotine) are characterised by having higher affinity for the active state than for the resting
Fig. 1.15 Diagrammatic representation of the multistate allosteric nature of nAChR
function.
Allosteric transitions between the resting, closed state (R), active open channel (A), and 
fast-onset (I) and slow-onset (D) desensitised refractory and high affinity states of the 
nAChR are depicted. The low-affinity resting state occurs in the absence of agonist. For the 
Torpedo nAChR, the timescales of some of the transitions are as follows: R to A = ps to ms, 




state, and conversely, antagonists have higher affinities for resting/inactive receptor 
states. High-affinity binding and very high affinity binding properties characterise the fast- 
onset and slow-onset desensitisation states of the receptor, respectively (Changeux and 
Edelstein, 2001; Jensen et al., 2005).
1.4.3 Classification of nAChR
To date, 17 nAChR subunits have been identified in vertebrate species. These can 
be divided into three classes: (1) muscle nAChRs, (2) neuronal nAChRs that do not bind 
the snake venom toxin a-bungarotoxin (a-Bgt) and (3) neuronal nAChRs that do bind a- 
Bgt. Muscle nAChRs co-assemble into two nAChR subtypes: (a1)2p1yS in the foetus and 
(a1)2pis5 in the adult. The subunits are organised in a clockwise a ly a ip iS  (or a ls a ip iS  
in adult) arrangement, and ACh binds to two orthosteric sites located at the a1-y (or a1-s 
in adult) and a1-8 interfaces of the receptor complex (Fig. 1.16; Hogg et al., 2003; Millar,
2003). Neuronal nAChRs are pentameric combinations of nine a - (a2-a10) and three p- 
(p2-p4) subunits (Millar, 2003; Gotti and Clementi, 2004; Jensen et al., 2005). These 
subunits can form a plethora of different nAChR subtypes characterised by distinct ligand 
pharmacology, activation and desensitisation kinetics, and cation permeability.
1.4.3.1 Neuronal nAChRs with high affinity for nicotine
A particular population of nAChRs can be pharmacologically defined by their high 
affinity binding to the nAChR specific agonist [3H]-epibatidine which is weakly displaced, if 
at all, by a-Bgt (Houghtling et al., 1995). These neuronal nAChRs comprise the a2-a6 and 
p2-p4 subunits, which form heteropentameric nAChR complexes with a prevalent subunit 
stoichiometry believed to be (a)2(p)3, arranged as apapp (Fig. 1.16). However, other 
possible stoichiometries have been demonstrated in vitro (Nelson et al., 2003) and may 
exist in vivo (see below for nAChR stoichiometries when they include a5 and p3 subunits). 
Hence, an asterisk is used in the receptor nomenclature to denote the possible presence 
of additional types of subunit present in the receptor complexes (Lukas et al., 1999). ACh 
and other orthosteric ligands, such as nicotine, bind to a site positioned at the interface 
between an a  and a p subunit, thereby giving rise to two orthosteric sites in the nAChR.
When expressed in Xenopus oocytes or mammalian cell lines, a2, a3 and a4  
subunits have all been shown to form functional heteromeric nAChRs in combination with 
p2 or p4 subunits (Chavez-Noriega et al., 1997; Stauderman et al., 1998; Lukas et al., 
1999). The a6 subunit has also been shown to form functional nAChRs in combination 
with p2 or p4 (Gerzanich et al., 1997; Fucile et al., 1998), even though it seems to function
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more effectively when combined with another a  and p subunit (Fucile et al., 1998). The a5 
and p3 subunits, which lack amino acid residues critical for agonist binding, do not 
participate in the formation of binding sites. However, together with pairs of a2-a6 and (32- 
P4 subunits they can form more complex nAChRs, where they become the fifth subunit 
not involved in orthosteric ligand binding. This is consistent with the (a4)2a5(p2)2 and 
a4a6a5/(33((32)2 nAChRs inferred to reside on midbrain dopaminergic nuclei in rats (Klink 
et al., 2001; Wonnacott et al., 2005). The presence of either a5 or p3 subunits in nAChRs 
has been shown to have profound impact on its pharmacology, Ca2+ permeability and 
desensitisation kinetics (Jensen et al., 2005).
Muscle AChRs Subunits: «1, (31, y, 6, e
(«1)2p1y& («1>2p1e&
Fetal Form Adult Form
ACh Binding Site 
At Subunit Interface
H e te ro m e ric  
Neuronal AChRs
Major Brain 










i«S and |1J may occupy only positions camparablo to |j1 in which thay do not participate in forming ACh binding sites, 
lift can participate in forming ACh binding sites, but can also assemble in AChRs with, for example, at or u4 subunits.
H o m o m e r i c  
Neuronal AChRs
Major Subtype With 
High Affinity for <iBgt 
in Both Brain and Ganglia
Subunits: a7-«9
(tt7)5
u8 found only in chickens. 
a7<i8 heteromers exist in 
chickens.
Fig. 1.16 Assembly and subunit diversity of prominent nAChR subtypes.
a-Bgt, a-bungarotoxin (adapted from www.med.upenn.edu/nscience/ neuro_lindstrom.html).
The majority of heteromeric nAChRs in the CNS (about 90%) are a4p2* receptors. 
The (32 subunit is expressed in almost all CNS regions, where its distribution overlaps with 
at least one of the a2-a4 and a6 subunits (Wada et al., 1989; Jensen et al., 2005). 
Although also abundantly expressed, a4 is less broadly distributed in the CNS than (32.
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The highest concentrations of the a4 and p2 subunits are found in the hippocampus, 
thalamus and cortex (Jensen et al., 2005). In the autonomic ganglia, the most prevalent 
subunits are the a3 and p4, where they combine to form a3p4* nAChRs. The expression 
of the a2 subunit has not been studied in great detail, but it appears to be expressed in 
very few brain regions (Jensen et al., 2005).
1.4.3.2 Neuronal nAChRs with high affinity for a-Bgt
Unlike other neuronal nAChRs, this set of nAChRs can bind with a high affinity to 
a-Bgt. The a7-a9  form homopentameric receptor complexes with five orthosteric binding 
sites for ACh (Fig. 1.16). They are also characterised by higher relative Ca2+ 
permeabilities and faster desensitisation rates than those of the muscle-type and 
heteromeric neuronal nAChRs (Gotti and Clementi, 2004). Like the a4 and p2, the a 7 
subunit is also expressed profusely in the brain, with highest expression levels in the 
hippocampus and cortex (Jensen et al., 2005). However, homomeric a l  nAChRs also 
reside in the autonomic ganglia. The a8-containing nAChRs are only present in the chick 
nervous system, where they not only form homomeric receptors, but also heteromeric 
a7a8  nAChRs (Millar, 2003; Gotti and Clementi, 2004). Although the existence of 
heteromeric a7-conatining nAChRs in vivo is not yet available, rat a7 subunits have been 
shown to co-assemble with p2 subunits, expressed in heterologous systems (Khiroug et 
al., 2002).
The a9 subunit is expressed in bone marrow, nasal epithelium and embryonic 
blood cells, and co-expressed with a10 in cochlear outer hair cells (Jensen et al., 2005). 
The a10 subunit is similar to the a9 subunit by amino acid sequence, but is not able to 
form homomeric nAChRs. The a10 subunit can only form a functional nAChR together 
with the a9 subunit. However, the exact stoichiometry and arrangement of the a9a10  
nAChR in unknown. Both a9 and a9a10 nAChRs are characterised by mixed 
nicotinic/muscarinic pharmacological profile (Gotti and Clementi, 2004; Jensen et al., 
2005).
1.4.4 Cellular localisation of nAChR
The great diversity of neuronal nAChRs is consistent with their varied roles. In the 
muscle and autonomic ganglia, nAChRs are located pre- and post-synaptically. In their 
post-synaptic locations, nAChRs mediate fast synaptic transmission. The most well 
studied example of this is at the neuromuscular junction, which is the synapse between a 
motor neurone and skeletal muscle. Upon arrival of an action potential, the presynaptic
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motor neurone releases ACh, which diffuses across the synaptic cleft and activates 
nAChRs on the postsynaptic muscle. Fast nicotinic transmission has been reported in the 
brain only rarely. Part of the reason is due to the difficulty in demonstrating such a 
function, as cholinergic neurones in the brain are not tightly packed and often make broad, 
diffuse projections, making it complex to stimulate and record from a precise location of 
neuronal innervation. In addition to this, the high Ca2+ permeability of neuronal nAChRs 
has kindled the notion that nAChRs may serve to modulate (rather than mediate) the 
release of ACh and other neurotransmitters in the CNS (Role and Berg, 1996; Wonnacott, 
1997). Facilitation of ACh release by nAChR activation is known as autoregulation, 
whereas for other neurotransmitters, it is termed heterosynaptic modulation (Wonnacott, 
1997; MacDermott et al., 1999; Hogg et al., 2003).
On the basis of electrophysiological and transmitter release studies, it has become 
a common perception that neuronal nAChRs are predominantly presynaptic (Fig. 1.17; 
Role and Berg, 1996; Wonnacott, 1997) and reside on the membranes of nerve terminals. 
Various functional and ultrastructural studies have suggested that neuronal nAChRs may 
also exist on preterminal membranes (Fig. 1.17; Wonnacott, 1997). These nAChRs are 
located before the presynaptic terminal bouton and can indirectly modulate 
neurotransmitter release by activating voltage-gated channels that consequently induces 
neurotransmitter release from the presynaptic terminal. The evidence is strongest in 
GABAergic synapses where preterminal nAChR activation depolarises the membrane 
locally, thereby activating voltage-gated channels that directly mediate the presynaptic 
Ca2+ influx underlying enhanced GABA release (Dani and Lester, 2001). This effect of 
preterminal nAChRs is inhibited by tetrodotoxin (TTX), which blocks sodium channels, 
thereby preventing the regenerative voltage-dependent activation of Ca2+ channels in the 
terminal, which subsequently inhibits the release of neurotransmitter from the presynaptic 
terminal. In contrast, presynaptic nAChRs modulate neurotransmitter release directly, or 
influence the probability of an action potential resulting in exocytosis (Wonnacott, 1997). 
Hence, these nAChRs are Ca2+-dependent but TTX-insensitive. However, studies of 
striatal synaptosomes (defined as presynaptic elements -  see section 2.1.1.1; Marks et 
al., 1995; Marshall et al., 1996) have challenged this simple distinction, by reporting a 
partial block by TTX of nicotine-evoked rubidium (86Rb+) or [3H]DA release. TTX-sensitive 
and insensitive mechanisms might reflect the relative proximity of nAChRs to the synapse 
and exocytotic machinery. Thus, TTX-sensitivity alone does not necessarily distinguish 
preterminal and presynaptic nAChRs. In addition to provoking Ca2+-dependent exocytosis, 
presynaptic nAChRs also modulate neurotransmitter release through Ca2+-mediated 
cellular mechanisms (Dajas-Bailador and Wonnacott, 2004).
Following exogenous application of nicotinic agonists, presynaptic nAChRs can 
directly modulate the Ca2+-dependent release of many neurotransmitters such as ACh, 
DA, NA, 5-HT, glutamate and GABA (Role and Berg, 1996; Wonnacott, 1997). In many
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cases, the a-Bgt-sensitive nAChRs are responsible for regulating glutamatergic 
neurotransmission (Mansvelder et al., 2002), but in other cases different nAChR subtypes 
are involved (Dani and Lester, 2001). The view that dopaminergic transmission is central 
to reward mechanisms makes the associated nAChRs the conduit for the delivery of 





Fig. 1.17 Representation of nAChRs at synaptic locations.
Presynaptic nAChRs are located on presynaptic boutons, where they can influence the 
release of neurotransmitter that is present in synaptic vesicles by depolarising the nerve 
terminal and activating Ca2+-dependent exocytosis. Preterminal nAChRs are located on the 
axon before the synaptic terminal, where they can mediate a depolarisation locally to activate 
voltage-operated Ca2+ channels that consequently induces neurotransmitter release from the 
presynaptic terminal (adapted from Laviolette and van der Kooy, 2004).
1.4.5 Distribution of nAChRs in midbrain DA systems
relevant to nicotine addiction
Although the function of numerous neurotransmitter systems expressing nAChRs 
can be altered by nicotine, the initial reinforcing properties of this alkaloid are thought to 
be mediated primarily through the mesocorticolimbic DA system. In brief, these neuronal 
pathways consist of DA neurones from the VTA that project to the NAc (ventral striatum) 
and other forebrain sites, such as the prefrontal cortex (PFC; see section 1.2.2). Brain 
areas in this system express a variety of nAChR subtypes, which are the major substrate 
of nicotine reward and reinforcement (Pidoplichko et al., 2004; Balfour, 2004; Wonnacott 
et al., 2005).
1.4.5.1 Ventral Tegmental Area
The VTA consists of three cell types shown to express nAChRs: DA neurones, 
GABA neurones and glutamatergic afferents (Fig. 1.18a; Klink et al., 2001; Mansvelder 
and McGehee, 2000; Champtiaux et al., 2002; Champtiaux et al., 2003; Wonnacott et al., 
2005). Most nAChR subunits (a3-a7 and p2-(34) are expressed in the VTA resulting in
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three pharmacologically identifiable nAChRs: one that is likely to be a homomeric a l  
nAChR and two that do not contain the a l  subunit (Klink et al., 2001; Champtiaux et al., 



















Striatum (a4)2(p2)3, (a4)2a5(p2)2, 
(a6)2(p2)2p3, Ct4a6(p2)2p3
Dopaminergic
Fig. 1.18 The mesocorticolimbic DA system, associated circuitry and nAChR
subtypes.
(a) A simplified schematic of afferent and efferent connections between the ventral 
tegmental area (VTA), striatum/nucleus accumbens (NAc), prefrontal cortex (PFC) and 
tegmental pedunculopontine nucleus/laterodorsal tegmental nucleus (TPP/LDT) is depicted. 
The major pathways using dopamine (DA), y-aminobutyric acid (GABA), acetylcholine (ACh) 
and glutamate (Glu), including the locations of a l-  and (32-containing nAChRs, are 
illustrated.
(b) Summary of the somatodendritic nAChR subtypes proposed to reside on dopaminergic 
and GABAergic neurones in the VTA and presynaptic nAChRs on dopaminergic boutons in 
the terminal field.
(adapted from Wonnacott et al., 2005).
DA neurones
A majority of DA neurones express nAChRs that can be blocked by 
mecamylamine (a general nicotinic antagonist), whereas less than half of the DA
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neurones express a l  nAChRs (Klink et al., 2001; Wooltorton et al., 2003). The a6 and p3 
subunits are also expressed by DA cells, and recent studies using transgenic mice lacking 
either of these subunits show that they predominate in presynaptic, relative to 
somatodendritic, nAChRs (Champtiaux et al., 2003; Cui et al., 2003). The subunit 
compositions (a4)2a5(p2)2 and a4a6a5(p2)2 nAChRs are proposed to reside on DA cell 
bodies (Fig. 1.18b; Klink et al., 2001), and these nAChRs occur in the ratio 80:20, 
respectively (Champtiaux et al., 2003). The (33 subunit may replace the <x5 subunit in a 
proportion of somatodendritic nAChRs (Cui et al., 2003). Functional a l  nAChRs have also 
been found to exist on DA neurones (Fig. 1.18b; Klink et al., 2001; Wooltorton et al.,
2003).
GABA neurones
A population of GABA interneurones provides local inhibitory input to the 
mesocorticolimbic DA neurones (Fagen et al., 2003; Wonnacott et al., 2005), and there is 
anatomical evidence for descending GABAergic projections to the brainstem mesopontine 
region (Semba and Fibiger, 1992): the tegmental pedunculopontine nucleus (TPP), which 
has been implicated in various aspects of nicotine-induced DA-independent drug seeking 
and reward (Corrigall et al., 2002; Laviolette et al., 2002; Laviolette and van der Kooy D.,
2004), and the adjacent laterodorsal tegmental nucleus (LDT). In addition to receiving 
GABAergic inputs from the TPP and NAc, the VTA sends GABAergic projections to the 
NAc and PFC (Wonnacott et al., 2005). GABA neurones in the VTA express a similar 
variety of nAChR subunits, but in contrast to DA neurones, a5, a6, (33 and p4 were found 
in less than 25% of the GABA neurones (Klink et al., 2001). Thus, the majority of VTA  
GABA neurones have been suggested to express predominantly (a4)2((32)3 nAChRs (Fig. 
1.18b; Champtiaux et al., 2003), which are blocked by mecamylamine and dihdro-p- 
erythroidine (DHpE), a p2* nAChR-selective antagonist (Mansvelder et al., 2002). The 
remaining GABA neurones are considered to contain a7 nAChRs (Fig. 1.18b; Klink et al.,
2001).
Glutamatergic afferents
The VTA receives glutamatergic synaptic input primarily from the PFC, which has 
been suggested to provide the major excitatory control of VTA neurone activity and 
ultimately DA release in the NAc (Mansvelder and McGehee, 2002). However, the 
glutamatergic projections from the PFC do not synapse onto DA neurones that project to 
the NAc. Rather, they make contact with GABAergic neurones that project to the NAc and 
DA neurones that project back to the PFC (Carr and Sesack, 2000). Ascending inputs 
from the TPP and LDT to the VTA comprise cholinergic and glutamatergic fibres that 
synapse onto DA and GABA neuronal populations of the VTA (Garzon et al., 1999). The
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cholinergic neurones of the mesopontine nuclei can modulate the activity of the 
mesolimbic system, since electrical stimulation of the TPP elicits striatal DA efflux (Forster 
and Blaha, 2003), whereas LDT stimulation evokes a similar DA overflow in the NAc 
through the activation of cholinergic and glutamatergic receptors in the VTA (Forster and 
Blaha, 2000). This is consistent with glutamatergic afferents from the LDT that 
preferentially innervate NAc-projecting VTA DA neurones (Kauer, 2004). Furthermore, the 
non-a6 a4(32* nAChRs on VTA DA neurones are thought to mediate most of the slow 
ACh-elicited currents in the somatodendritic compartment (Zoli et al., 2002; Champtiaux et 
al., 2003). Histochemical iabelling has recently confirmed the presence of a l  nAChRs on 
glutamatergic terminals in the VTA (Fig. 1.18b; Jones and Wonnacott, 2004), where they 
serve to enhance long-term potentiation (LTP) onto DA neurones (Mansvelder et al.,
2002).
1.4.5.2 Striatum vs. Nucleus accumbens
The word striatum is 
derived from the Latin stria, 
meaning a furrow, and is due to 
the large number of myelinated 
axons that run the length of the 
region, giving it a conspicuous, 
lined appearance. The striatum 
belongs to a group of anatomically 
distinct structures that are 
collectively known as the basal 
ganglia. Based on the connectivity 
and function, the striatum is often 
divided into dorsal and ventral 
portions. The dorsal striatum 
comprises the caudate-putamen, 
and is mainly sensorimotor 
related. It receives DA innervation 
primarily from the SNc and to a 
lesser degree from the VTA (see 
section 1.2.1). The medial and 
lateral areas of the dorsal striatum receive glutamatergic inputs preferentially from 
associative- and sensorimotor-related cortical areas (Gerdeman et al., 2003). The 
principal neurones of the striatum are the medium-sized spiny projection neurones, which 












Fig. 1.19 Diagrammatic representation of the 
termination of afferents on a medium-sized 
spiny neurone in the striatum.
Dopamine (blue), glutamate (red), acetylcholine 
(pink) and GABAergic (light green) inputs are 
illustrated (adapted from Hyman and Malenka, 
2001).
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and extensive local axon collaterals (Fig. 1.19). These neurones are inhibitory, using 
GABA as their primary neurotransmitter. The remaining minority of neurones are the 
GABAergic and cholinergic interneurones (Fig. 1.18a; Zhou et al., 2003). Part of the 
medium-sized spiny GABAergic projection neurones in the dorsal striatum project to the 
internal segment of the GP and the SN pars reticulata, forming the so-called “direct 
pathway”. Other striatal medium-sized spiny neurones project to the external segment of 
the GP and are part of the “indirect pathway” (Zhou et al., 2003).
The ventral striatum is composed partly of the NAc and portions of the olfactory 
tubercule, and is mainly limbic related. It receives DA innervation primarily from the VTA 
and to a lesser degree from the SNc. The NAc sends inhibitory projections to the VTA and 
surrounding DA areas, and receives extensive glutamatergic innervation from the PFC, 
hippocampus and amygdala (Fig. 1.18a; Zhou et al., 2002). DA neurones in the NAc form 
synapses at the neck of the medium-sized spiny neurones, whilst glutamatergic 
projections tend to be associated with the head of the spines (Fig. 1.19; Wightman and 
Robinson, 2002).
Fig. 1.20 Sagital section of the rat brain indicating the relative positions of the 
striatum and nucleus accumbens.
The rat striatum comprises the caudate-putamen (CPu) and the core subregion of the 
nucleus accumbens (NAc). The NAc consists of a central core and a surrounding shell 
(adapted from W onnacott et al., 2005).
The N A c  consists of two major subdivisions: a central core (N A c COre), which is part 
of the ventral striatum (Fig. 1 .20 ), and a surrounding shell (N A c sheii), which forms part of 
the limbic system, anatomically being an extension of the amygdala (Voorn et al., 2004). 




[cau d ate -p u tam en  
+ N A c (core)]
26
Chapter 1
projections to the dorsolateral ventral pallidum (VP), which in turn projects to the 
subthalamic nucleus (STN) and SNc (Deutch and Cameron, 1992), the main source of DA 
innervation of the striatum. The NAcsheii circuit is characterised by projections to the 
ventromedial VP, which does not innervate the STN but projects to the VTA (Deutch and 
Cameron, 1992), the primary site of midbrain DA neurones that innervate 
mesocorticolimbic areas (see section 1.2.2). Since the NAcCOre resembles more closely the 
dorsal striatum and sends major projections to areas of the brain concerned with the 
regulation of motor function, it seems to play a pivotal role in responding that is elicited, or 
reinforced, by conditioned stimuli (Ito et al., 2004; Wonnacott et al., 2005; see section 
1.1). The NAcsheii, being part of the mesolimbic sector, is involved in the acquisition of 
responding (such as lever pressing for drug) for motivationally significant stimuli (Di 
Chiara, 2002; Wonnacott et al., 2005).
Various experimental strategies applied to striatal preparations (the NAc being too 
small for such biochemical analyses) have resulted in the consensus concerning 
presynaptic nAChR subtypes in the terminal fields. Histochemical and ion flux 
measurements with synaptosomes have indicated that nAChRs are expressed on all DA 
axon terminals in the striatum (Jones et al., 2001). Co-immunoprecipitation experiments in 
conjunction with ligand binding (Champtiaux et al., 2002; Champtiaux et al., 2003) and 
following 6-hydroxydopamine lesions of the dopaminergic afferents (Zoli et al., 2002) 
provided evidence for subunit composition of nAChRs in the striatum. Further support 
came from pharmacological analysis of nAChR-evoked DA release (Salminen et al., 
2004), with comparisons of transgenic mice lacking a particular nAChR subunit. Together, 
these studies have defined four populations of nAChRs in the rodent striatum: <x4(32 
nAChRs, which are expressed on both dopaminergic and non-dopaminergic neurones; 
a4a5p2, a6p2p3 and a4a6p2p3, which are only expressed on dopaminergic terminals 
(Fig. 1.18b). Electron microscopy coupled with im mu nocytochemistry revealed that all 
striatal DA axon boutons express the p2 nAChR subunit (Jones et al., 2001). The 
significance of the heterogeneity, and whether nAChR subtypes and segregated or co­
localised, is not yet understood. Presynaptic a7 nAChRs have not been detected on 
dopaminergic terminals, but they have been inferred to reside on glutamatergic afferents 
projecting to the striatum (Kaiser and Wonnacott, 2000).
1.4.6 Nicotinic modulation of DA release
As previously stated (see section 1.2.2), it is believed that the reinforcing 
properties of nicotine are due to its capacity to modulate the mesolimbic DA system 
(Corrigall et al., 1992). Like many drugs of abuse, nicotine exerts it addictive properties by 
increasing DA release in the NAc, predominantly in the NAcSheii (Imperato et al., 1986;
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Balfour et al., 1998). This is seen after systemic injections of nicotine, or local application 
of nicotine directly into the VTA or NAc, which stimulates DA overflow in the NAc (Mifsud 
et al., 1989; Marshall et al., 1997; Ferrari et al., 2002). However, local infusion of non­
specific nicotinic antagonists into the VTA prevents nicotine-induced DA release in the 
NAc (Nisell et al., 1994a; Nisell et al., 1994b) and disrupts systemic nicotine self­
administration in rats (Corrigall et al., 1994), whereas perfusion of the NAc with these 
antagonists has no effect on either phenomenon (Corrigall et al., 1994; Nisell et al., 
1994a). Therefore, the gross DA responses in the NAc to systemic nicotine have been 
attributed, at least in part, to the direct activation of nAChRs located on DA neurones of 
the VTA.
1.4.6.1 Burst firing of DA neurones
Under ambient behavioural conditions, DA neurones fire tonically or irregularly at 
frequencies around 4 Hz, but when activated by salient or arousing sensory input, DA 
neurones begin to burst fire (Cooper, 2002). Hence, phasic burst firing (>10 Hz) rather 
than single-spike firing (3-5 Hz) represents a more efficient means of increasing NAc or 
striatal DA concentrations (Gonon, 1988). Systemic injections of nicotine increase the 
proportion of midbrain DA neurones that exhibit burst firing (Nissbrandt et al., 1994; Nisell 
et al., 1996). The supralinear increase in extracellular DA concentration is thought to arise 
from a combination of factors such as rapid saturation of DAT, slow enzymatic breakdown 
of DA, and slow DA autoreceptor activation, all of which usually work together to reduce 
extrasynaptic DA (Cooper, 2002).
1.4.6.2 (32* nAChRs mediate the reinforcing properties of nicotine
Intravenous nicotine self-administration in laboratory animals is one of many 
reliable behavioural measures of the reinforcing properties of nicotine. Transgenic mice 
lacking the p2 nAChR subunit do not self-administer nicotine (Picciotto et al., 1998; 
Epping-Jordan et al., 1999), whereas responding for cocaine is unaffected (Epping-Jordan 
et al., 1999). Additionally, nicotine self-administration is blocked by DH(3E, but not by the 
a7-selective antagonist methylcaconitine (MLA; Grottick et al., 2000). Electrophysiological 
experiments demonstrate that nicotine fails to increase the firing rate of somatic DA 
neurones in mice lacking the p2 nAChR subunit (Picciotto et al., 1998). Nicotine-evoked 
increase in extracellular DA is abolished in striatal synaptosomes from p2 knock-out 
animals (Picciotto et al., 1998; Grady et al., 2001). These observations demonstrate that 
nicotine reinforcement is dependent on the activation of p2* nAChRs.
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Various studies have been conducted to determine the nature of nAChR subunits 
likely to be associated with the p2 subunit. Based on pharmacological data, the a4 and a3  
subunits have been proposed to partner with the p2 subunit on DA terminals (Sharpies et 
al., 2000). Systemic nicotine-evoked DA release, in vivo, is abolished in a4 knock-out 
mice (Marubio et al., 2003). Also, a4* nAChRs have been shown to be sufficient for 
nicotine-induced reward, tolerance and sensitisation (Tapper et al., 2004). Conversely, the 
role of the a3 nAChR subunit in nicotine reinforcement has been challenged. Initially, the 
contribution of the a3 subunit had been proposed in view of its selectivity of a-conotoxin 
Mil (aCtxMII) for recombinant a3p2* nAChRs expressed in Xenopus oocytes and the 
discovery that this toxin partially inhibits nicotine-evoked DA release in striatal 
synaptosomes (Kulak et al., 1997; Kaiser et al., 1998). However, this selectivity has been 
questioned by the observation that high affinity aCtxMII binding sites are preserved in a3  
knock-out animals but completely disappear in a6 knock-out mice (Champtiaux et al., 
2002; Whiteaker et al., 2002), suggesting that the a6 rather than the a3 nAChR subunit in 
DA neurones is likely to associate with the p2 subunit. Altogether, these results reveal that 
a4 and a6 subunits are most likely to associate with the p2 subunit to form functional 
heteromeric nAChRs on DA neurones (Champtiaux and Changeux, 2004; see section 
1.4.5 for nAChR subtypes on midbrain DA neurones).
1.4.6.3 Acute effects of nicotine
Nicotine effects in the VTA
Microdialysis studies in rats have shown that a single injection of systemic nicotine 
produces a sustained elevation of extracellular DA in the NAc for 60-120 min (Imperato et 
al., 1986; Di Chiara, 2000; Ferrari et al., 2002) and subsequent injections of the drug in 
the 90 min period following a nicotine injection have little additional effect on DA overflow 
(Balfour et al., 2000). During cigarette smoking, blood nicotine levels reach 300-500 nM 
within minutes after the initial exposure to nicotine, and concentrations close to 250 nM 
are sustained for 10 min or more thereafter (Henningfield et al., 1993). Therefore, such a 
time course of nicotine would activate high-affinity nAChRs on DA neurones in the VTA, 
which however, desensitise in seconds to minutes when exposed to nicotine (Fig. 1.15; 
Pidoplichko et al., 1997; Wooltorton et al., 2003), and thus cannot account for the long 
lasting increase in DA release observed in vivo upon a single nicotine exposure. 
Mansvelder and colleagues (Mansvelder and McGehee, 2000; Mansvelder et al., 2002) 
argue that the persistent effects of nicotine on DA release in the NAc may be explained by 
nicotine-induced LTP of the excitatory glutamatergic input and nicotine-induced 
depression of GABAergic transmission within the VTA.
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Previous work has indicated that a l  nAChRs residing on glutamatergic terminals 
(Jones and Wonnacott, 2004) may regulate the release of glutamate in the VTA, as this 
effect is blocked by MLA (Schilstrom et al., 2000b). Furthermore, antagonism of NMDA 
receptors on DA neurones and a l  nAChRs in the VTA diminishes nicotine-induced DA 
overflow in the NAc (Shoaib et al., 1994; Schilstrom et al., 1998a; Schilstrom et al., 1998b; 
Schilstrom et al., 2000a). Hence, when nicotine arrives in the VTA, it stimulates nAChRs 
on both presynaptic glutamatergic terminals and on DA neurones, thereby favouring 
conditions of paired electrical stimulation of pre- and postsynaptic partners to potentiate 
excitatory transmission (Mansvelder et al., 2003). Since nicotine excites and depolarises 
VTA DA neurones, the magnesium block of the NMDA receptors is removed. 
Simultaneously, nicotine enhances the release of glutamate via presynaptic a l  nAChRs, 
which assists further postsynaptic NMDA receptor activation, and so is more likely to 
produce LTP of the glutamatergic afferents onto DA neurones (Dani et al., 2001; 
Mansvelder and McGehee, 2002). Low concentrations of nicotine associated with tobacco 
use do not induce significant desensitisation of a l  nAChRs (Mansvelder et al., 2002; 
Wooltorton et al., 2003), as compared to the non-a7 nAChRs (Mansvelder and McGehee,
2002). This allows continuous enhancement of glutamate release onto DA neurones in the 
VTA whilst nicotine is present.
In addition to excitatory inputs, VTA DA neurones are under inhibitory control, 
predominantly by GABAergic interneurones and also by projecting GABA-fibres from other 
brain areas (see section 1.4.5.1). When nicotine reaches the VTA, nAChRs expressed by 
GABA neurones are activated and cause an increase in the firing rate of these neurones 
(Mansvelder et al., 2002), which produces a transient increase in the inhibitory input to the 
DA neurones in the VTA. This effect is likely to offset some of the excitatory effects of 
nicotine during the initial stages of nicotine exposure. However, similar to the a4p2* 
nAChRs on the DA neurones, GABA neurones in the VTA also express a4(32 nAChRs 
(Fig. 1.18b). These nAChRs undergo rapid desensitisation within minutes after the initial 
exposure to low concentrations of nicotine. Consequently, the inhibitory input to VTA DA 
neurones is diminished, making them more active (Mansvelder et al., 2003). Cholinergic 
inputs to the VTA predominantly target non-DA neurones (Garzon et al., 1999), and 
stimulation of these cholinergic inputs increase GABAergic transmission. This is evident 
when breakdown of ACh in the VTA is inhibited with an inhibitor of acetylcholinesterase 
(AChE; Mansvelder et al., 2002). Therefore, desensitisation of the nAChRs of the VTA  
GABA neurones not only prevents further activation by nicotine, it also precludes their 
contribution to endogenous cholinergic transmission (Mansvelder et al., 2002; Mansvelder 
et al., 2003). Through the differential expression of nAChR subtypes and a combination of 
nicotine-induced enhanced glutamatergic and depressed GABAergic transmission onto 
VTA DA neurones, there is a net shift towards stimulation of the mesolimbic DA pathway
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and subsequent maintenance of elevated extracellular DA in the NAc (Laviolette and van 
der Kooy D., 2004). This hypothesis (Mansvelder et al., 2002) is compatible with the 
proposed role for burst firing in the mechanism underlying increases in DA overflow in the 
NAc evoked by nicotine.
Nicotine effects in the striatum
The striatal DA terminals and cholinergic interneurones form an intertwined 
meshwork that allows DA and ACh to spill over from their synapses into the extracellular 
space, thus contributing to volume transmission. The cholinergic interneurones provide an 
ongoing ACh signal by firing action potentials tonically at about 2-5 Hz (Zhou et al., 2002; 
Mansvelder et al., 2003). The ACh in the extracellular space influences neighbouring DA 
terminals by activating presynaptic nAChRs, thereby enhancing the probability of DA 
release when an action potential arrives along the axon of the DA terminal (Role and 
Berg, 1996; Wonnacott, 1997; Zhou et al., 2001). The dense AChE rapidly degrades ACh 
and terminates the ACh signal so that the nAChRs are not strongly desensitised. 
Consequently, DA terminals are not overdriven by prolonged nAChR activation, and 
nAChR desensitisation is also kept low. Although the principal feature of nicotine addiction 
is to increase DA levels in the NAc via an initial effect in the VTA, downstream cholinergic 
modulation of nicotine-evoked DA release in the NAc helps to synchronise and co­
ordinate the influence of DA over striatal output neurones.
1.4.6.4 Chronic effects of nicotine
Repeated daily exposure to systemic nicotine results in increased DA overflow in 
the NAc in response to a subsequent systemic nicotine challenge compared with drug 
naive rats (Benwell and Balfour, 1992). This sensitised response is characteristic of other 
drugs of dependence and is implicated in the neurobiology underlying the transition to 
dependence (Robinson and Berridge, 1993). The sensitised responses to acute systemic 
challenges with nicotine are antagonised by local infusions of mecamylamine into the VTA  
(Nisell et al., 1994b; Balfour et al., 1998). The locomotor stimulant effect of nicotine, which 
is blocked by lesions of the mesolimbic DA system (Clarke et al., 1988), has been shown 
to be more pronounced when nicotine is infused locally into the VTA (Reavill and 
Stolerman, 1990). Furthermore, locomotor sensitisation to nicotine has been 
demonstrated after chronic intermittent treatment with nicotine administered systemically 
as well as when nicotine was microinjected into the VTA (Reavill and Stolerman, 1990; 
Panagis et al., 1996; Domino, 2001). Sensitisation to systemic nicotine is prevented 
following co-administration of an NMDA receptor antagonist with nicotine (Shoaib et al., 
1994; Domino, 2001), implicating a role of NMDA receptors in nicotine-induced 
sensitisation. Together, these results point to a key role of nAChRs located in the VTA
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region to induce sensitisation to nicotinic effects following chronic administration. 
However, chronic nicotine treatment (systemic injections of 0.4 mg/kg nicotine for 7 days 
or 4 mg/kg/day of nicotine via osmotic mini-pumps for 7 days) further enhances 
mecamylamine-sensitive DA release in response to local infusion of nicotine into the NAc 
and striatum (Marshall et al., 1997). This suggests that nAChRs expressed at synaptic 
terminals of midbrain DA neurones are also likely to contribute to the development of 
mesolimbic DA system sensitisation to nicotinic effects.
Sensitised D A  overflow in response to nicotine is regionally dependent, being 
observed in the NACcore but not in the N A c Sheii, whilst acute nicotine injections in drug-naive 
animals preferentially stimulates D A  overflow in the N A c Sheii (Benwell and Balfour, 1992; 
Cadoni and Di Chiara, 2000; lyaniwura et al., 2001). Furthermore, sensitisation of 
nicotine-induced D A  efflux in the NACcore is only observed in rats pretreated with low or 
moderate doses of nicotine that may be rewarding and not in animals pretreated with high, 
aversive doses of the drug (lyaniwura et al., 2001). There is growing consensus that the 
two principal subdivisions of the N A c  play complementary roles in the neurobiology 
underlying drug dependence (Balfour, 2004; Voorn et al., 2004).
Di Chiara (2002) has proposed an associative learning hypothesis that posits that 
the substantial and sustained increases in DA overflow in the NAc, evoked by 
psychostimulant drugs of dependence such as nicotine, result in the stimuli associated 
with delivery of the drug acquiring powerful motivational properties at the expense of non­
drug cues (Di Chiara, 2002). These incentives are known as conditioned stimuli (see 
section 1.1). The hypothesis proposes that substantial and sustained increases in 
extracellular DA, evoked by psychostimulant drugs, greatly enhance the probability that 
animals will learn and repeat behaviours that result in delivery of the drug and the 
predictive nature of stimuli that are associated with these behaviours. Non-contingent 
presentation of a conditioned stimulus evokes a regionally selective increase in DA 
overflow within the NACcore and stimulates drug-seeking behaviour (Ito et al., 2000). 
Regionally selective excitotoxic lesions of neurones in the NACcore (but not the N A c Sheii) 
significantly impair the influence of conditioned stimuli on the acquisition and maintenance 
of drug-seeking behaviour (Ito et al., 2004). Therefore, the primary consequence of the 
increases in DA overflow evoked by such drugs in the N A c COre may be the compulsive or 
Pavlovian drug-seeking behaviour, in response to cues or stimuli associated with delivery 
of the drug, that characterise the transition to dependence (Ito et al., 2000; Balfour, 2004).
Long-term nicotine exposure causes an upregulation of nAChR (Wonnacott, 1990) 
with a high affinity for nicotine, namely the a4p2* nAChRs (Buisson and Bertrand, 2002), 
as they are important for nicotine self-administration (Picciotto et al., 1998). Previously, it 
had been suggested that upregulation of a4p2 nAChRs was caused by numerous 
processes that increased the number of surface nAChRs (Buisson and Bertrand, 2002). 
However, recent studies by Vallejo and colleagues (2005) propose that nicotine exposure
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may, in fact, slowly stabilise a4p2 nAChRs in a high-affinity state that would increase both 
nicotine binding, without altering the number of receptors, and the response of the nAChR 
to nicotine (Vallejo et al., 2005). Hence, it is possible to speculate about a common 
pattern of cigarette smoking. At nicotine levels achieved by smokers, a4|32 nAChRs in the 
brain initially cycle through one set of resting, activated, and desensitised states (Fig. 
1.15). With continued smoking, the same a4p2 nAChRs would slowly shift into the 
upregulated condition with different resting, activated and desensitised states. The 
increased response and sensitivity to nicotine, which are characteristic of the upregulated 
nAChR, and the slow entry and exit from the upregulated state, should provide a long- 
lasting memory of the presence of nicotine in neurones containing the a4p2 nAChRs 
(Vallejo et al., 2005). Therefore, upregulation of a4p2* nAChRs on presynaptic DA- 
releasing terminals of the mesolimbic pathway may lead to an enhanced presynaptic 
depolarisation and an increased release of DA. This sensitised effect (Balfour et al., 1998) 
together with the process of nAChR upregulation, which is likely to affect various nAChR 
subtypes differently, could influence synaptic plasticity (Mansvelder and McGehee, 2000; 
Dani et al., 2001) that contributes to the long-term changes associated with nicotine 
addiction.
1.5 Smoking cessation
Based on the evidence that nicotine has the properties of a psychostimulant drug 
of dependence, a majority of pharamcotherapies for tobacco dependence have been 
targeted on the hypothesis that people smoke tobacco in order to enjoy the primary 
rewarding properties of nicotine, and avoid the adverse consequences of its withdrawal 
following chronic exposure to the drug. However, several secondary effects of nicotine 
and tobacco use may also contribute to both the maintenance of smoking and smoking 
relapse. These include modulation of mood (e.g. reduction of negative affect), stress 
reduction, antinociception, weight control and cognitive enhancement. In addition, 
condition cues can elicit the urge to smoke, even after prolonged periods of abstinence.
Pharmacological therapies for smoking cessation fall into two major categories. 
The first is nicotine replacement therapy (NRT), which enables smokers to substitute the 
nicotine from cigarettes with other nicotine formulations. The second category is non­
nicotine based, and the success of the atypical antidepressant bupropion (Zyban®) as an 
anti-smoking agent, has raised much debate as to how a non-nicotine based drug can aid 
in smoking cessation. This section will summarise various medications currently available 
in the market, or have the potential to aid smoking cessation.
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1.5.1 Nicotine replacement therapy
1.5.1.1 Existing NRTs
NRT is the most commonly used type of medication to treat nicotine dependence 
in the USA and other countries. At present, there are five types of NRTs, which include 
the slow-acting transdermal nicotine patch, and faster acting formulations such as nicotine 
gum, nicotine nasal spray, nicotine vapour inhaler and, most recently, the nicotine 
lozenge. The faster-acting NRTs appear to help satiate the positive effects of nicotine 
administration achieved through smoking, and reduce acute craving. The slow-acting 
nicotine patch, however, supplies constant, low levels of nicotine which, when adequately 
dosed, relieves nicotine-withdrawal symptoms (Foulds et al., 2004; George and O'Malley, 
2004).
Although NRTs may have the capacity to provide nicotine-mediated 
neuropharmacological effects, some of these formulations have their drawbacks. For 
example, nicotine gum is often not used properly and is not effective across all settings. 
Similarly, nicotine nasal spray is aversive for many smokers, and adherence rates tend to 
be lower than those for other forms of NRT (Berrettini and Lerman, 2005). Furthermore, all 
NRTs are perceived by smokers as being markedly less satisfying than cigarettes and 
none of them deliver the same quantity of nicotine to the brain with the speed of a 
cigarette (Foulds et al., 2004). As a result, none of the NRTs enable the majority of people 
who use them, to quit smoking in the long term, as up to 80% of those who try to quit 
using these aids, relapse within a year (Cryan et al., 2003b).
1.5.1.2 Potential new NRTs
Nicotine straw
This is a single-use drinking straw that contains a loose bead formulation of 
nicotine bitartrate. It has a fluid permeable plug at the bottom that facilitates the ingestion 
of nicotine in the product with the first sip of a beverage (Foulds et al., 2004). The hand-to- 
mouth motion makes the Straw user-friendly to smokers who are trying to quit. Presently, 
the Straw is being tested in Phase III clinical trails and preliminary data suggests that it is 
well-tolerated, with some minor side-effects such as nausea and light-headedness. The 
Straw, however, does not provide improved speed of nicotine delivery over other NRTs. 





Nicotine solution drops are another oral delivery method for nicotine replacement. 
These are also presently being examined in Phase III clinical trials. Subjects tested have 
reported that they are well-tolerated with a low quit rate at the 6-month follow-up point. 
The advantage of the nicotine solution is that its dose can be finely adjusted to the 
treatment intensities of nicotine dependence. Furthermore, the slow absorption rate may 
not only reduce the dependence potential, but also minimise the use of the solution as an 
acute craving rescue medication (Foulds et al., 2004).
1.5.2 Non-nicotine based treatments
1.5.2.1 Antidepressants
There is good rationale for testing antidepressants for smoking cessation, as there 
is a strong correlation between smoking and depression. For example, a high prevalence 
of smoking exists among people who have, or have had a history of, depression (Covey,
1999). Furthermore, smokers who are depressed find it more difficult to quit smoking, 
some smokers become depressed when they stop smoking, and post-cessation 
depression is related to relapse (Covey, 1999; Covey et al., 2000).
Bupropion
Bupropion (Fig. 1.21), an atypical 
antidepressant, is the first non-nicotine 
medication to demonstrate efficacy in the 
treatment of tobacco dependence. Although 
the precise mechanism by which bupropion 
aids smoking cessation remains uncertain 
(see section 1.6), it has proven to increase 
abstinence rates (Richmond and Zwar,
2003) and reduce severity of withdrawal 
symptoms experienced by smokers when 
they abstain (Hurt et al., 1997; Jorenby et 
al., 1999; Shiffman et al., 2000; Hays et al., 2001; Durcan et al., 2002).
With the exception of two recent clinical trials (Killen et al., 2004; Simon et al.,
2004), several others have demonstrated the relative efficacy of bupropion as a smoking 
cessation aid. Amongst these were two pivotal outcome studies published in the late 
1990s (Hurt et al., 1997; Jorenby et al., 1999). The first was a randomised, double blind 
trial that compared the effects of three different daily doses of bupropion (100, 150 and
Fig. 1.21 The chemical structure of 
bupropion.
Bupropion has a molecular weight of 
239.7 Daltons. Although initially used as 
an antidepressant (Wellbutrin), it is now 
marketed under the commercial name of 




300 mg) with placebo, on a variety of measures including smoking abstinence, symptoms 
of depression and withdrawal, and body weight (Hurt et al., 1997). Subjects were asked to 
take bupropion or placebo for seven weeks, beginning one week before complete 
cessation of cigarette smoking. Smokers with current depression, but not those with a 
history of depression were excluded. Results showed a linear effect on point-prevalence 
cessation, although no significant difference was found between 150 and 300 mg/day 
bupropion at 12 months follow-up. Additionally, there was no change in depression scores 
for any treatment group, suggesting that the participants did not experience significant 
depressive symptoms during withdrawal. Also, subjects who had quit smoking once 
treatment had ceased showed attenuated weight gain. The second major study was also 
double-blind and randomised smokers to receive either bupropion alone (300 mg/day), 
nicotine patch alone (21 mg/21 h), both bupropion and patch, or placebo (Jorenby et al.,
1999). The recording measures and exclusion criteria were largely similar to those used 
by Hurt and colleagues (1997). The one-year continuous abstinence rates were 18%, 
10%, 23% and 6% in the bupropion alone, patch alone, combination-treatment, and 
placebo groups, respectively. Results of the withdrawal and depression scores were 
similar to those observed by Hurt and colleagues (1997). Jorenby and colleagues (1999) 
concluded that, although bupropion was significantly better than the nicotine patch, 
abstinence rates in the combination regime were not significantly different from bupropion 
alone.
Since these clinical trails, a number of other studies examining the efficacy of 
bupropion have been published, mainly corroborating the findings of the original trials 
(Johnston et al., 2001; Stahl et al., 2004). They confirm its efficacy among patients who 
may be considered difficult populations to treat, because of their illnesses. In particular, 
bupropion has been shown to assist those with cardiovascular disease (Tonstad et al.,
2003) and chronic obstructive pulmonary disease (Tashkin et al., 2001), to quit smoking 
with cessation rates equivalent to healthy populations. In addition, bupropion proved 
efficacious for smoking cessation in patients independent of a former history of major 
depression or alcoholism (Hayford et al., 1999), indicating that the success of bupropion is 
not related to its antidepressant effect. Further trials have achieved positive results for the 
use of bupropion in preventing relapse after initial treatment (Hays et al., 2001; Wileyto et 
al., 2005), and for effective smoking cessation when combined with minimal or moderate 
counselling (Swan et al., 2003). In studies regarding nicotine craving and withdrawal, 
bupropion was found to alleviate some symptoms of nicotine withdrawal but had no effect 
on craving for cigarettes (Shiffman et al., 2000). In contrast, another study showed that 
bupropion contributed to preventing relapse by reducing craving after the initial withdrawal 
from nicotine (Durcan et al., 2002). In non-treatment-seeking smokers, acute doses of 
bupropion has shown to increase smoking without altering rates of craving or withdrawal, 
whilst under controlled conditions, bupropion helped to reduce smoking in patients willing
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to quit (Cousins et al., 2001). Recent trials have failed to provide confirmatory findings on 
the clinical efficacy of bupropion. For example, although a reduction in cigarette 
consumption was noted, a randomised trial in adolescent smokers failed to observe a 
treatment effect of bupropion when combined with the nicotine patch (Killen et al., 2004). 
Similarly, a seven-week course of bupropion in combination with cognitive-behavioural 
counselling and NRT failed to demonstrate a sustained benefit (Simon et al., 2004). Even 
though the majority of studies have showed bupropion to be an effective aid in smoking 
cessation, more so than placebo or the nicotine patch, none of the trials have shed much 
light on how bupropion exerts its clinical efficacy as an anti-smoking agent (see section 
1.6.2 for the pharmacological actions of bupropion).
Bupropion is marketed for smoking cessation under its trade name Zyban. So far, 
no gender- or age-related differences in pharmacokinetics of bupropion have been 
observed (Johnston et al., 2002). Based on this knowledge, the target dose of this agent 
in nicotine dependence is 300 mg/day. It is started seven days before the target quit date 
at 150 mg/day, and is increased to 150 mg/day twice daily after three days so that steady- 
state levels are achieved before the quit attempt. The recommended duration of treatment 
is between 7-9 weeks in Europe and Australia, and 7-12 weeks in USA and Canada. For 
the best chance of success, bupropion should be used in conjunction with regular 
behavioural counselling. If the drug is not efficacious in helping the patient to quit 
smoking, it should be terminated after seven weeks of use (Richmond and Zwar, 2003). 
The primary side-effects associated with bupropion are headache, jitteriness, dry mouth, 
initial insomnia and gastrointestinal problems. Bupropion is contraindicated in patients 
with seizure disorders and in those with bulimia or anorexia nervosa, or a history of these 
disorders (Holm and Spencer, 2000).
Nortriptyline
Nortrptyline, a tricyclic antidepressant (TCA), is believed to aid smoking cessation 
via its ability to block the reuptake of NA (and possibly 5-HT), and thereby reduce 
withdrawal and depressive symptoms (Covey et al., 2000; Foulds et al., 2004). The 
database for nortriptyline is not as extensive as that for some NRTs or bupropion. So far 
six randomised-controlled trials have been conducted for the efficacy of nortriptyline as an 
anti-smoking agent (Hughes et al., 2005). Pooled results from the studies that compared 
nortriptyline with placebo, found nortriptyline to at least double the chance of long-term 
abstinence. In contrast, when nortriptyline was tested as an add-on to nicotine patch 
treatment, it produced a significant benefit in one study but not in the other (Hughes et al.,
2005). The side-effects of nortrptyline include dry mouth, light-headedness, shakiness, 
blurred vision, urinary retention, constipation, and sexual difficulties. Nortriptyline is 
contraindicated in those who have experienced recent myocardial infarction or 
arrhythmias, or have a history of epilepsy or psychosis, liver disease, or women who are
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pregnant or breast-feeding (Covey et al., 2000; Hughes et al., 2005). Despite the evidence 
of efficacy and relatively low cost, nortriptyline has not obtained regulatory approval for 
treating tobacco dependence nor been marketed for this indication (Foulds et al., 2004).
Reboxetine
Nicotine increases cortical NA in rats (Benwell and Balfour, 1997). Furthermore, 
locus coeruleus a2-noradrenergic autoreceptors are markedly down-regulated in smokers 
(Klimek et al., 2001), suggesting that nicotine-induced NA release may result in adaptive 
processes in feedback mechanisms that regulate NA function. A recent animal study 
shows that the antidepressant reboxetine, a selective NA reuptake inhibitor, dose- 
dependently decreases nicotine self-administration in rats (Rauhut et al., 2002). Its effects 
may be facilitated by its ability to inhibit nAChR function or by indirectly modulating the 
firing pattern of DA cells in the VTA and selectively increasing DA availability in the PFC 
(Cryan et al., 2003b). Hence, there is reason to suspect that reboxetine may have the 
potential be an effective tobacco-dependence treatment.
Monoamine oxidase inhibitors
Monoamine oxidase (MAO) inhibitors degrade monoamine neurotransmitters. 
MAO-A preferentially degrades 5-HT and NA, and MAO-B selectively metabolises DA 
(George and O'Malley, 2004). Smoking is known to inhibit MAO-A and MAO-B (Covey et 
al., 2000). Thus, MAO inhibitors such as selegiline, lazabemide and moclobemide, may 
aid smoking cessation through their ability to inhibit DA metabolism.
Selegiline, a selective MAO-B inhibitor and an indirect DA agonist, is used to treat 
Parkinson’s disease. A number of small randomised-controlled trials, comparing selegiline 
to placebo or nicotine patch, have suggested that salegiline may alleviate withdrawal 
symptoms and reduce craving for nicotine (Foulds et al., 2004).
Moclobemide is a reversible MAO-A inhibitor that is available in Europe and 
Canada to treat major depression (George and O'Malley, 2004). It has been examined in 
one long-term trial, which found a significant effect on smoking cessation at 6 months, but 
not 1 year, compared to placebo (Berlin et al., 1995).
Recently, an exploratory trial on lazabemide, a reversible MAO-B inhibitor, found 
that it increased short-term abstinence to smoking compared to placebo (Berlin et al., 
2002). However, the study had to be terminated prematurely, as there were reports of liver 
toxicity from studies investigating this drug for other purposes.
Other antidepressants
Trials of other antidepressants as smoking cessation aids have reported with 
generally promising but as yet inconclusive results. One study suggested that doxepin, a
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TCA, reduced urges to smoke, but failed to show a significant effect on abstinence (Covey 
et al., 2000). A few studies have examined the efficacy of selective serotonin reuptake 
inhibitors (SSRI), fluoxetine and paroxetine, in smoking cessation. One study showed a 
significant short-term effect of fluoxetine on abstinence in smokers with a history of major 
depression (George and O'Malley, 2004). However, none of the other studies reported 
any long-term benefit with either SSRI (Covey et al., 2000).
1.5.2.2 nAChR ligands
Varenicline
Verenicline (CP-526555; Pfizer) is presently in Phase III clinical trials as a smoking 
cessation aid. It is an active a4|32 nAChR partial agonist and exhibits in vivo properties 
that demonstrate its ability to attenuate the central dopaminergic response to nicotine 
while providing sufficient and sustained dopaminergic tone to limit craving and withdrawal 
(Coe et al., 2005). Furthermore, it is not believed to be addictive (Foulds et al., 2004). 
Varenicline was developed from the structural starting point provided by cytisine, which is 
also a partial agonist of a4|32 nAChRs (Coe et al., 2005). Cytisine has a mechanism of 
action similar to that of nicotine but with rather low toxicity and short-lived effects. As of 
yet, no clinical studies have been published of varenicline, but research is underway 
comparing varenicline with bupropion (Foulds et al., 2004).
Mecamylamine
Mecamylamine is a potent non-competitive nAChR antagonist. The rationale for 
using mecamylamine to aid smoking cessation is that it should reduce the satisfaction 
associated with smoking and the urge to smoke. When this drug was given to smokers, 
cigarette consumption increased in an attempt to overcome nAChR blockade (George and 
O'Malley, 2004). Early attempts to use mecamylamine alone for smoking cessation were 
unsuccessful as it also induced side-effects such as abdominal pain, constipation, dry 
mouth and headaches. However, recent studies have suggested that mecamylamine in 
combination with nicotine patch produces a superior outcome compared to nicotine patch 
and placebo (Covey et al., 2000). The success is owed to the belief that nicotine 
(delivered by an alternative route than cigarette smoking) and mecamylamine would work 
in concert to attenuate the rewarding effects of cigarette smoking, suppress withdrawal 
symptoms, and thereby facilitate smoking abstinence. The combination treatment of 




1.5.2.3 Cannabinoid receptor antagonist
It has been hypothesised that drugs affecting cannabinoid mechanisms may have 
a role in smoking cessation. Drugs that selectively block cannabinoid-1 (CB1) receptors 
are believed to modulate energy balance systems in the brain, which are thought to be 
altered in smokers (Foulds et al., 2004). Preclinical pharmacological studies show that 
rimonabant (SR-141716-A), a CB1 receptor antagonist, reduces nicotine self­
administration (Cohen et al., 2005), nicotine-conditioned place preference (Le Foil and 
Goldberg, 2004) and nicotine-induced DA release in the NAc (Cohen et al., 2005). 
Rimonabant also abolishes the maintenance of nicotine seeking behaviour induced by 
cues associated with nicotine that are crucial for nicotine craving and relapse (Le Foil and 
Goldberg, 2005). Although studies using knockout mice have attempted to clarify the 
involvement of CB1 receptors in nicotine rewarding properties, the results obtained have 
provided conflicting data. However, pharmacological data suggest that rimonabant could 
have anti-smoking activity. Accordingly, it is presently being tested in placebo-controlled 
Phase III trials (Cryan et al., 2003b).
1.5.2.4 DA D3 receptor antagonist
In contrast with D1 and D2, D3 receptors have a restricted expression pattern in 
the brain, being selectively expressed in the N A c Sheii (Cryan et al., 2003b). Chronic 
administration of nicotine is associated with marked increases in D3 receptor binding and 
m R N A  expression in the N A c sheii (Le Foil et al., 2003). The selective D3 receptor 
antagonist, SB-277011 - A ,  is efficacious in animal models of nicotine-seeking behaviour 
(Heidbreder and Hagan, 2005) and awaits clinical validation for prevention of relapse to 
smoking in humans.
1.5.2.5 a2-adrenoceptor agonist
Clonidine is an a2-adrenoceptor agonist that reduces sympathetic activity by 
decreasing NA release. It was originally approved for its use as an antihypertensive and 
for the prevention of recurrent migraine, but has recently found to be effective in the 
treatment of opioid and alcohol dependence (George and O'Malley, 2004). Several clinical 
trials have demonstrated that clonidine taken orally or as a transdermal patch, has modest 
efficacy in smoking cessation. However, significant side-effects such as postural 
hypotension, sedation, constipation, dizziness and dry mouth, have limited its use. Thus 





Opioid antagonists, such as naloxone and its longer-acting formulation naltrexone, 
are used in the treatment of other chemical dependencies, such as opioid, cocaine and 
alcohol. The rationale for using these antagonists in treating tobacco dependence comes 
from the principle that endogenous opioids may play a role in the reinforcing effects of 
nicotine (Foulds et al., 2004). A number of studies on the effects of naloxone and 
naltrexone on smoking behaviour in humans have been conducted, but with mixed results. 
Some studies with naloxone observed a reduction in cigarette consumption compared 
with placebo, whilst others failed to demonstrate this effect (Covey et al., 2000). There is 
little evidence that naltrexone alone facilitates smoking cessation. However, more 
encouraging results were obtained when naltrexone was combined with nicotine patch 
(George and O'Malley, 2004) or behavioural counselling (Covey et al., 2000). Increased 
side-effects, especially sedation, are a common feature of naltrexone treatment. In 
experimental studies of drugs that have such adverse effects, it is difficult to determine 
whether the side-effects are making the subjects too sedated or nauseous to smoke or 
whether the drug is having a direct and substantial therapeutic effect (Foulds et al., 2004).
1.5.2.7 Anxiolytics
Smoking has long been interpreted as a form of “stress management”, or a means 
of reducing anxiety. As a result, a number of efforts had been made to investigate the 
potential efficacy of anti-anxiety drugs as an aid to smoking cessation. Studies with 
traditional sedatives, such as barbiturates and benzodiazepines, and other sedative-like 
drugs, such as p-blockers, have not been found to aid smoking cessation (Covey et al.,
2000). On the contrary, buspirone, an atypical anxiolytic, has attracted some interest. 
Buspirone is a selective 5-HT1A receptor agonist, with mild D2 receptor activity. It is 
prescribed for the management of anxiety disorders, but is pharmacologically unrelated to 
barbiturates and benzodiazepines, and so is non-sedative and non-addictive. Early un­
controlled studies indicated that buspirone decreased nicotine withdrawal symptoms and 
reduced the urge to smoke, whilst recent long-term studies comparing buspirone with 
placebo showed no benefit of using buspirone for smoking cessation. However, buspirone 
has been shown to enhance short-term smoking cessation rates only in those smokers 
who are anxious (Covey et al., 2000). Hence, buspirone may be helpful for smokers with a 
high level of anxiety, but there is insufficient evidence to support the general usefulness of 




The idea of oral dextrose (glucose) for smoking cessation is based on the premise 
that the urge to smoke arises in part from a mislabelling of a physiological “desire” for 
carbohydrates (Covey et al., 2000). Its advantage is that it is relatively inexpensive and 
may be a safer alternative to other tobacco-dependent medications. Placebo-controlled 
studies have provided some support for the idea that glucose relives craving for 
carbohydrate and hence overall craving (Foulds et al., 2004). Not all studies using glucose 
alone have yielded positive results on smoking cessation. However, preliminary data from 
a randomised placebo-controlled trial suggests that glucose tablets increase quit rates 
compared to placebo among patients using concurrent bupropion or NRT (Foulds et al.,
2004).
1.5.2.9 Nicotine vaccine
After the introduction of vaccines against cocaine (Kosten and Owens, 2005), 
efforts to develop a nicotine vaccine soon followed. The principle behind vaccination is 
that a small amount of a substance (antigen) is injected into a host. The host’s immune 
system will recognise this antigen as foreign and subsequently produce antibodies against 
it (immune response). Since nicotine is a small molecule, it is bound to a larger molecule 
such as bovine serum albumin (BSA) or inactivated bacterial toxins, which increase its 
antigenicity. This is likely to augment the probability of an immune response by the host. 
After the initial vaccination, the host immune system memorises the antigen such that if it 
was introduced in the future, the immune cells would be able to produce large amounts of 
antibodies, which would bind to the antigens and allow for other host defences to 
eliminate them. The blood-brain barrier (BBB) acts as a filter and prevents molecules that 
are too large to pass through. The nicotine molecule is small enough to pass into the 
brain. However, as a result of vaccination, the nicotine-antibody complex becomes too 
large to pass through the BBB. Therefore, vaccination would reduce or eliminate the 
effects of nicotine in the brain. This would in theory, prevent the psychoactive effects of 
nicotine by reducing the rewarding effects of smoking and drive for continued 
consumption (Foulds et al., 2004).
In rats, the nicotine vaccine elicits antibodies that reduce nicotine distribution to the 
brain by 40-60% (Kosten and Owens, 2005). Immunisation also decreases nicotine- 
induced DA release, acquisition of nicotine self-administration, and nicotine seeking 
behaviour in animal models of relapse (Kosten and Owens, 2005).
Three nicotine vaccines are presently undergoing human testing. NicVAX (Nabi 
Biopharmaceuticals), which is presently being tested in Phase II trials, consists of nicotine
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conjugated to a carrier protein called recombinant exoprotein A. Phase I trails showed that 
a single dose of NicVAX produced antibodies as early as 7 days post-vaccination and 
these were maintained over 4 months (Foulds et al., 2004). Nicotine-Qbeta (Cytos 
Biotechnology), which is also currently being tested in Phase II trials, uses antigens 
delivered in a repetitive configuration that can directly activate B cells. A double-blind 
placebo-controlled trail for nicotine addiction showed that 57% of patients with a high 
antibody response to Nicotine-Qbeta met the primary end-point of continuous abstinence 
(Kosten and Owens, 2005). Finally, TA-NIC (Xenova Research Ltd) comprises nicotine 
conjugated to a carrier protein and an adjuvant, and so designed to induce nicotine 
antibodies that would bind free nicotine in the blood making the nicotine-antibody complex 
unable to cross the BBB (Foulds et al., 2004). TA-NIC is presently being tested in Phase I 
clinical trials. Preliminary data suggest that this vaccine is safe and well tolerated but there 
is a 20-fold variation in individual patient responses (Kosten and Owens, 2005).
The nicotine vaccine approach raises issues that still need to be addressed. These 
include the lack of protection against a structurally dissimilar molecule that produces the 
same effects as nicotine, as well as the individual variability in antibody formation. 
Furthermore, vaccination in animals shows the highest titres of antibody in serum, which 
highlights the importance of producing high antibody titres in humans to avoid overcoming 
antibody therapy to aid vaccine efficacy. Vaccination is not expected to show efficacy 
against nicotine craving or withdrawal, and so may be used in conjunction with other 
current medications (Heidbreder and Hagan, 2005).
1.5.2.10 Other non-nicotinic pharamcotherapies
Although both GABA and glutamate systems have been implicated in nicotine 
addiction, largely because of their close interactions with the mesolimbic DA neurones, 
few clinical studies have tested their utility in the treatment of nicotine dependence. A 
human laboratory study with the GABA-B receptor agonist, baclofen, indicated that it 
could reduce the rewarding effects of smoking (George and O'Malley, 2004). However, 
one of the drawbacks of baclofen therapy is the marked muscle relaxation and sedative 
properties of the drug, which hamper its widespread use in indications outside of that as 
an antispastic medication (Cryan et al., 2003b). Preclinical data suggest a role for 
presynaptic metabotropic glutamate receptors (mGluR) in nicotine dependence. For 
example, blockade of mGluR-5 with 6-methyl-2-(phenylethynyl)-pyridine decreases the 
reinforcing effects of nicotine, whilst blockade of mGluR-2/3 with LY-354740 reverses the 
affective signs of nicotine withdrawal (Cryan et al., 2003b). Some of these agents look 





Despite bupropion having been in clinical use for 25 years, the neurochemical 
mechanisms underlying its actions as a smoking cessation aid are still not well-elucidated 
(Ascher et al., 1995). Various preclinical studies have suggested that bupropion produces 
its therapeutic antidepressant effects by blocking DA and NA reuptake (Ascher et al., 
1995). As these neurotransmitters have a pivotal role in the rewarding properties of 
nicotine and the aversive state of nicotine withdrawal, the antidepressant properties of 
bupropion may be significant in smoking cessation. Recent in vitro data indicate that 
bupropion may be a noncompetitive, functional inhibitor of neuronal nAChRs (Fryer and 
Lukas, 1999; Slemmer et al., 2000). This anti-nicotinic activity of bupropion could act to 
acutely attenuate the rewarding effects of nicotine, thus increasing the likelihood of 
smoking cessation. Bupropion’s mode of action is complicated by differences in its in vitro 
vs. in vivo pharmacological profile (Richelson and Pfenning, 1984; Stathis et al., 1995) 
along with interspecies variations in the metabolism of bupropion (Suckow et al., 1986; 
Tatsumi et al., 1997). Hence, this section will summarise previous evidence from 
preclinical studies to facilitate the understanding of bupropion’s mechanisms of activity in 
encouraging smoking abstinence.
1.6.1 Pharmacokinetics of bupropion
Bupropion (Fig. 1.21) is an aminoketone that is highly lipophilic, enabling the drug 
to enter many tissues, including the brain. In healthy humans, peak concentration (Cmax) of 
approximately 136 pg/l in the plasma, is achieved within 3 h after an oral dose of 150 mg 
bupropion (Hsyu et al., 1997). The volume of distribution estimated from a single 150 mg 
dose is approximately 2000 I (Johnston et al., 2002). Plasma protein binding of bupropion 
is approximately 85% over a wide range of concentrations in humans, and only a little less 
in three other species (75-80%; Schroeder, 1983).
Bupropion is extensively metabolised by multiple pathways to three active 
metabolites: hydroxybupropion, which is formed via hydroxylation of the tert-butyl group 
and the amino alcohol isomers; threohydrobupropion and erythrohydrobupropion, which 
are formed by the reduction of the carbonyl group (Fig. 1.22; Johnston et al., 2002). 
Bupropion and the metabolites undergo further biotransformation and conjugation to form 
meta-chlorohippuric acid, which is the major urinary metabolite (Holm and Spencer,
2000). In vitro studies in human liver microsomes have shown that the conversion of 
bupropion to hydroxybupropion is catalysed primarily by the CYP 2B6 and to a much 
lesser extent by CYP 1A2, 2A6, 2C9, 2E1, and 3A4 isoenzymes (Johnston et al., 2002).
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Fig. 1.22 The major pathways of bupropion metabolism in humans.
(adapted from Hsyu et al., 1997).
The potency of hydroxybupropion is comparable to that of bupropion, whilst the 
other metabolites threohydrobupropion and erythrohydrobupropion are one-fifth as potent 
as bupropion (Johnston et al., 2002). After the administration of a single 150 mg dose of 
bupropion in humans, area under the concentration curve (AUC), Cmax, and time to reach 
Cm ax (tm ax) values in plasma for hydroxybupropion are considerably greater than those of 
the parent compound (Table 2a; Hsyu et al., 1997; Holm and Spencer, 2000). Combined, 
the metabolites threohydrobupropion and erythrohydrobupropion also have a greater 
plasma AUC value, and longer tmax and ty2e than bupropion (Hsyu et al., 1997). A similar 
pharmacokinetic pattern is seen in mouse plasma and brain after a systemic injection of 
40 mg/kg bupropion, whilst rats form little of the metabolites as compared to mice (Table 
2b; Suckow etal., 1986).
In a study using radiolabelled bupropion in healthy humans, 87% and 10% of 
bupropion was recovered, primarily as metabolites, in the urine and faeces, respectively. 
The fraction of the radioactivity excreted in the urine as unchanged bupropion was only
0.5%, whilst less than 10% of the dose was accounted for in the urine as active 
metabolites. The remaining radioactivity in the urine was associated with at least nine
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other metabolites, some of which have not been fully characterised. Overall, this study 
shows that: (1) essentially all of the dose could be accounted for in the urine or faeces; (2) 
bupropion is extensively metabolised; (3) renal elimination is a more important pathway 
for the removal of the inactive metabolites of bupropion than the active metabolites 











Bupropion Smokers 1164 144 3.0 19 133
Non-smokers 1161 143 2.9 18 138
Hydroxybupropion Smokers 15239 430 6.2 22
Non-smokers 16651 433 7.7 23
Threohydrobupropion + Smokers 5698 135 5.5 48











Bupropion Rat Plasma 3.22 3.85 0.26 0.83 12.41
Brain 30.13 36.51 0.26 0.79
Mouse Plasma 1.71 2.15 0.26 1.18 23.44
Brain 16.48 20.66 0.26 0.65
Hydroxybupropion Rat Plasma 0.42 0.20 0.68 0.79
Brain 2.58 1.14 0.68 0.71
Mouse Plasma 7.96 2.13 0.39 2.44
Brain 58.57 20.22 0.50 1.71
Threohydrobupropion Rat Plasma 0.15 0.07 0.46 0.92
Brain 2.36 1.17 0.60 0.68
Mouse Plasma 0.88 0.14 0.26 5.17
Brain 9.47 1.99 1.15 2.49
Table 2 Summary of pharmacokinetic parameters for bupropion and its metabolites.
(a) Pharmacokinetics of bupropion and its major metabolites in plasma after a single oral 
150 mg dose in humans.
(b) Pharmacokinetics of bupropion and its major metabolites after a systemic injection of 
bupropion (40 mg/kg, i.p) in rats or mice.
AUCo-., area under the concentration curve from time 0 extrapolated to infinity; Cmax, peak 
concentration; tmax. time to reach peak concentration; ti/2e, elimination half-life; Cl, clearance 
(adapted from Suckow et al., 1986; Holm and Spencer, 2000).
1.6.2 Pharmacodynamics of bupropion
1.6.2.1 Bupropion and dopaminergic systems
Studies from rat synaptosomes show that bupropion is twice as potent at inhibiting 
DA (Kj = 0.6 pM) than NA reuptake (Kj = 1.5-2.3 pM), and has little influence on 5-HT  
reuptake (Kj = 15.6-19.0 pM; Hyttel, 1982; Richelson and Pfenning, 1984). Lesion studies 
reveal a preferential affinity of bupropion for DAT in the brain, since it selectively
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antagonises DA (ID50 = 54 mg/kg, i.p) but not NA depletion (ID50 > 1 0 0  mg/kg, i.p) induced 
by 6-hydroxydopamine (Cooper et al., 1980; Ferris et al., 1982; Ascher et al., 1995), which 
depletes DA and NA only after being taken into DA- or NA-releasing cells via the 
respective transporters. Bupropion also suppresses activity of midbrain DA cells (ID50 = 
42-44 mg/kg, i.p; Cooper et al., 1994). However, bupropion doses used in those studies 
appear to be far higher than those that produce antidepressant effects (Ascher et al., 
1995). As doses of bupropion prescribed for smoking cessation are equal to or lower than 
those prescribed for depression, bupropion levels required to antagonise DA reuptake will 
also bear little resemblance to those effective in smoking cessation (Warner and Shoaib, 
2005). However, the antidepressant effects of bupropion, as measured by immobility in 
the forced swim test, are prevented by prior destruction of DA neurones by 6- 
hydroxydopamine (Cooper et al., 1980), indicating that the antidepressant actions of 
bupropion, at least, are dependent on dopaminergic activity.
In vivo brain microdialysis studies reveal that bupropion-mediated effects on DA 
neurotransmission vary according to different areas of the brain and on the duration of 
treatment (acute vs. chronic). Local application of bupropion into the striatum dose- 
dependently increases striatal extracellular DA levels (Nomikos et al., 1990). Increased 
levels of extracellular DA are also seen in the striatum and NAc after acute systemic 
bupropion (Nomikos et al., 1989). Furthermore, these bupropion-induced increases in 
extracellular DA are blocked by TTX, indicating that its effects rely on action potential- 
dependent processes in DA neurones (Nomikos et al., 1989; Nomikos et al., 1990). 
Chronic treatment with bupropion significantly enhances the increase in extracellular DA 
in the NAc, when rats are challenged with systemic bupropion after a 3 day withdrawal 
period (Nomikos et al., 1992). This apparent sensitised effect is not seen in the striatum 
(Nomikos et al., 1992), thereby highlighting a regional selectivity for the effects of 
bupropion after chronic treatment. Furthermore, as these effects of bupropion occur at 
doses that have been associated with antidepressant activity in animal models, it 
suggests that the relatively weak DA reuptake antagonism by bupropion can still affect the 
dopaminergic system primarily implicated in nicotine dependence (Ascher et al., 1995; 
Warner and Shoaib, 2005).
In behavioural studies that measure locomotor activity, acute systemic 
administration of bupropion dose-dependently increases hyperlocomotion (Cooper et al., 
1980; Nielsen et al., 1986). However, rats with depleted DA neural systems fail to display 
significant locomotor stimulation after bupropion treatment (Cooper et al., 1980), thus 
demonstrating that motor activity is a DA-mediated behaviour that requires intact DA 
neurones. Chronic administration of bupropion has shown to result in augmented 
locomotor activity after a systemic bupropion challenge (Cooper et al., 1980; Nielsen et 
al., 1986). This sensitised effect is comparable to the enhanced increase in extracellular 
DA in the NAc following chronic bupropion treatment (Nomikos et al., 1992). Bupropion-
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induced sensitisation could be attributed to an upregulation of DAT, which is seen in the 
NAc after chronic bupropion self-administration (Telia et al., 1997). In a recent study, 
locomotor-stimulating effects of bupropion were observed at different ages, with late 
adolescent mice being more active than early adolescent or adult mice (Redolat et al., 
2005). This is pertinent in the use of bupropion to combat nicotine dependence, as 
differential sensitivity to nicotine has also been reported to be age-dependent (Belluzzi et 
al., 2004).
A positron emission tomography study that examined the occupancy of DAT 
showed that there is a real possibility of bupropion having an effect on DA reuptake during 
clinical treatment in humans. By measuring the displacement of a selective and reversible 
DAT-binding radioligand (11C-pCIT-FE), chronic bupropion was found to occupy an 
average of 26% of striatal DAT over a period of 24 h at steady-state oral dosing in non­
depressed humans (Learned-Coughlin et al., 2003). The relationship between the level of 
DAT occupancy and the therapeutic effects of bupropion is unknown. However, to exert 
an effect on DA reuptake, DAT must be implicated in some way to bupropion’s 
mechanism of action (Warner and Shoaib, 2005).
If bupropion is capable of maintaining raised extracellular DA levels in brain 
regions such as the NAc, it could reduce the deficit of DA overflow and brain reward 
function caused by nicotine withdrawal. Therefore, it is possible that bupropion may be 
efficacious in smoking cessation by ameliorating some of the negative affective aspects of 
nicotine withdrawal, and thereby help to prevent relapse.
1.6.2.2 Bupropion and noradrenergic systems
The potency of bupropion as an inhibitor of NA reuptake is only half of that for DA 
(see section 1.6.2.1). This may not have a fundamental role in the efficacy of bupropion as 
a smoking cessation aid, but there is a small body of evidence that implicates 
noradrenergic effects in the mechanism of action of bupropion.
At high doses, bupropion significantly decreases NA-stimulated adenylate cyclase 
activity (Ascher et al., 1995). However, it is believed that this effect occurs at doses of 
bupropion that are far greater than those that demonstrate antidepressant activity in 
animal models. In vivo, acute administration of bupropion inhibits firing rates of NA 
neurones in the locus coeruleus at doses relevant to antidepressant activity (ID50 = 12.6 
mg/kg, i.p; Cooper et al., 1994). However, bupropion-induced inhibition of NA reuptake is 
thought to be an indirect effect of elevated NA levels in the synaptic cleft, stemming from 
the finding that yohimbine, an a2-adrenoceptor antagonist, blocks bupropion-induced 
inhibition of firing rates (Cooper et al., 1994). At clinically relevant doses in man, 
bupropion reduces whole-body turnover of NA without altering plasma NA levels, 
indicating that noradrenergic systems are made more efficient (Johnston et al., 2002).
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Bupropion appears to have some significant effects on noradrenergic systems, 
although, these effects probably contribute to the antidepressant activity of bupropion.
1.6.2.3 Bupropion and nAChR antagonism
There is substantial evidence to support the theory that bupropion can antagonise 
the effects of nicotine at nAChRs. The first evidence came from a study by Fryer and 
Lukas (1999), where they examined the acute functional effects of bupropion on human 
nAChR subtypes expressed in cell lines TE671/RD (muscle-type a1p1y8 nAChR) and SH- 
SY5Y cells (ganglionic a3[34a5 ± (32 nAChRs), using the 86Rb+ efflux assay. Bupropion 
was found to produce dose-dependent inhibition of muscle-type (IC 50 = 10.5 pM) and 
ganglionic nAChR (IC 50 = 1 . 4  pM) function in TE671/RD and SH-SY5Y cells, respectively 
(Fryer and Lukas, 1999). Furthermore, the functional block produced by bupropion near 
the IC50 value was insurmountable by increasing agonist concentration in both cell lines, 
indicating non-competitive inhibition of nAChR function by bupropion (Fryer and Lukas,
1999).
Another study examined the acute interaction of bupropion with nAChRs using 
different in vivo and in vitro tests. Bupropion was found to produce a dose-dependent 
blockade of nicotine-induced antinociception, as measured by the tail-flick (ID50 = 2.4 
mg/kg, s.c) and hot-plate tests (ID50 = 8.0 mg/kg, s.c). Bupropion also inhibited nicotine- 
induced hypothermia (ID50 = 8.5 mg/kg, s.c), hypomotility (ID50 = 4.0 mg/kg, s.c) and 
seizure activity (ID50 = 4.5 mg/kg, s.c; Slemmer et al., 2000). Together, these in vivo tests 
suggested that bupropion possesses some selectivity for neuronal nAChRs underlying 
these various nicotinic effects. In Xenopus oocytes expressing the ot4(32, a3(32 and a l  
nAChR subunit combinations, bupropion antagonised the effects of ACh in a 
concentration-related manner with IC50 values of 8 pM, 1.3 pM and 60 pM bupropion, 
respectively (Slemmer et al., 2000). The blockade by bupropion was reversible, 
dissipating after a 5 min washout period, but insurmountable by increasing concentrations 
of ACh, indicative of non-competitive nAChR blockade. In addition, bupropion failed to 
displace brain [3H]nicotine binding sites, suggesting that bupropion does not bind to the 
active site of the nAChR. Also, inhibition of ct4(32 and cc3(32 nAChRs by bupropion 
exhibited voltage-independent properties, suggesting that bupropion may not be acting as 
an open channel blocker (Slemmer et al., 2000).
Miller and colleagues (2002) extended the findings that propose bupropion to 
inhibit nAChRs. Their study used radiolabelled DA and NA in rat striatal and hippocampal 
slices, respectively, to measure functional neurotransmitter release. To eliminate the 
interaction of bupropion with DA or NA transporters, nomifensine or desipramine, 
respectively, were included in the superfusion buffer. Bupropion inhibited both nicotine-
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evoked [3H]DA (IC50 = 1.27 |jM) and [3H]NA overflow (IC50 = 0.32 |jM) in striatal and 
hippocampal slices, respectively (Miller et al., 2002). Bupropion had no effect on electrical 
field stimulation-evoked [3H]overflow in [3H]DA-preloaded striatal slices (Miller et al.,
2002), suggesting that its inhibition of nicotine-evoked [3H]DA overflow is specific to 
nAChRs, and not just a generalised effect on neurotransmitter release.
The evidence that bupropion may act as a nAChR antagonist suggests that its 
clinical activity in smoking cessation may involve reducing or attenuating the acute effects 
of nicotine reinforcement prior to cessation, thereby making it easier to abstain. To build a 
consistent plasma level, bupropion is only taken for a week prior to quit date (see section
1.5.2.1) and so is unlikely to be at a concentration that is able to exert a profound effect on 
nicotine reinforcement over a short period. This is very important when considering 
bupropion treatment for chronic smokers as they would have been reinforced to the 
effects of nicotine in tobacco over many years. However, it is possible that bupropion- 
induced blockade of nicotinic effects may enable it to prevent relapse in long-term 
treatment. Therefore, bupropion combined with long-term abstinence, which itself could 
break the strength of nicotine reinforcement, may assist smokers to recover from single 
relapse episodes rather than completely relapsing from renewed reinforcing effects 
(Warner and Shoaib, 2005).
1.6.2.4 Bupropion and models of nicotine reinforcement
Previous findings suggest that bupropion affects extracellular DA in the NAc 
(Nomikos et al., 1989; Nomikos et al., 1990). Therefore, the actions of bupropion on 
nicotine reinforcement may be relevant to its mechanism of action in smoking cessation. 
Intravenous nicotine self-administration is a preferred model of tobacco dependence and 
various studies have addressed the effects of bupropion on the reinforcing properties of 
nicotine.
Shoaib and colleagues (2003) used this model to examine the effects of bupropion 
on nicotine self-administration. The study found that bupropion failed to attenuate nicotine 
intake at either dose of bupropion (10 and 30 mg/kg, i.p). In fact, the larger dose of 
bupropion showed a tendency for rats to self-administer more nicotine over the course of 
the 28 day treatment period (Shoaib et al., 2003). One reason for this increased behaviour 
may reflect an attempt to overcome the blockade of nicotine reinforcement. Comparable 
findings have been observed in the clinic, which saw increased cigarette consumption in 
smokers treated with mecamylamine (see section 1.5.2.2). A more likely explanation for 
the increased nicotine intake following bupropion pre-treatment arises from the mild 
stimulant effects of bupropion that may enhance responding maintained by nicotine.
The findings of Shoaib and colleagues (2003) have been replicated in other 
studies with different emphasis on the results. One study reported that bupropion has a
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biphasic dose-response pattern on nicotine self-administration. At bupropion doses tested 
in the range by Shoaib and colleagues (2003), nicotine self-administration was increased. 
However, a very high dose of bupropion (78 mg/kg, s.c), which is probably not clinically 
relevant, was found to decrease nicotine self-administration (Rauhut et al., 2003). 
Interpretation for this decreased responding for nicotine was attributed to non-specific 
effects, such as activation of bupropion-induced hyperlocomotion, which was incompatible 
with performing the lever-press response for nicotine self-administration. Another study 
found that acute pre-treatment with bupropion (40 mg/kg, i.p) produces a small significant 
decrease in nicotine self-administration (Bruijnzeel and Markou, 2003).
An important point to consider is that nicotine intake modelled in laboratory rodents 
does not accurately mimic that of a chronic smoker. For example the 28 day treatment 
period studied by Shoaib and colleagues (2003) cannot be compared directly to the 
nicotine intake regime of a chronic smoker. The nicotine self-administration procedure 
does, however, allow for short repeated sessions of nicotine intake that are separated by 
longer periods, which enable plasma nicotine levels to return to normal. Therefore, the 
evidence presented above seems to suggest that bupropion’s mechanism of action does 
not to lie in altering the reinforcing effects of nicotine (Warner and Shoaib, 2005).
1.6.2.5 Bupropion and models of nicotine withdrawal
Nicotine withdrawal is likely to reduce the positive affect of nicotine reward and 
thereby influence its reinforcing properties. As bupropion has mild dopaminergic effects, 
the reward pathway is a possible target underlying the clinical efficacy of bupropion. The 
use of intracranial self-stimulation (ICSS) procedure has provided a reliable behavioural 
readout, in laboratory rodents, to assess alterations in brain reward after cessation of drug 
administration (i.e. drug withdrawal). In this paradigm, electrodes are implanted into brain 
areas to stimulate sites that animals find rewarding. ICSS has previously shown that 
withdrawal from chronic nicotine induces a dramatic decrease in brain reward function as 
reflected by elevations in brain reward threshold (Epping-Jordan et al., 1998). This 
threshold is one of a few operational measures of the affective aspects of the nicotine 
withdrawal syndrome (Kenny and Markou, 2001).
Cryan and colleagues (2003) are the only group to have examined the effects of 
bupropion on brain reward function in relation to nicotine or nicotine withdrawal. They 
found that under baseline conditions, acute bupropion treatment (10-40 mg/kg, i.p) 
induced a pronounced lowering of brain reward thresholds, suggesting that it has some 
effects on DA reward systems independent of nicotine. When co-administered with 
nicotine, bupropion (10, 20 mg/kg, i.p) had no significant effect on nicotine-induced ICSS. 
Withdrawal from chronic nicotine administration, which was precipitated by the removal of 
subcutaneous osmotic mini-pumps that delivered 3.16 mg/kg/day of nicotine for 7 days,
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significantly elevated brain reward thresholds. Bupropion dose-dependently (10-40 mg/kg,
i.p) lowered the reward thresholds of animals that had been pre-treated with nicotine 
(Cryan et al., 2003a), suggesting that bupropion clearly attenuates deficits in brain reward 
function during nicotine withdrawal. This provides an important mechanism of action for 
bupropion in preventing relapse.
In addition to the ICSS work, Cryan and colleagues (2003) also measured the 
effects of bupropion on the somatic signs of nicotine withdrawal. Unlike in humans, only 
the visible somatic signs of withdrawal can be measured in animals. This study measured 
abdominal constrictions (writhes and gasps), facial fasiculations, eyeblinks, and ptosis 
(Cryan et al., 2003a). Indeed, withdrawal from chronic nicotine administration significantly 
increased the amount of total somatic signs of abstinence. Bupropion (20, 40 mg/kg, i.p) 
significantly reversed the expression of total somatic signs at 12 h post-withdrawal. 
However, when examined for the effects of bupropion on the individual somatic signs at 
12 h post-withdrawal, it demonstrated a significant decrease in the amount of abdominal 
constrictions but not the other signs (Cryan et al., 2003a).
Together these results suggest that the efficacy of bupropion as an aid to smoking 
cessation may be due to its ability to alter the rewarding aspects of acute nicotine and 
reverse the negative affective and somatic aspects of the nicotine withdrawal syndrome. 
Studies that assess the effects of chronic bupropion treatment on brain reward and 
nicotine withdrawal would provide better comparisons to bupropion treatment in humans.
1.6.2.6 Bupropion and models of nicotine discrimination
Drug discrimination studies allow animals to respond to the strength of subjective 
effects of a drug, which determine whether it can be distinguished from vehicle. If drug 
discrimination is strong, then drug generalisation tests can examine whether other 
compounds can be substituted for the drug, by sharing similar discriminative effect 
(Warner and Shoaib, 2005). Hence, another mechanism of action for bupropion may be 
based upon the subjective effects of nicotine.
Various experiments have tested the effects of bupropion on nicotine’s 
discriminative properties (Wiley et al., 2002; Young and Glennon, 2002; Shoaib et al.,
2003). As part of the training process, animals learn to discriminate between the effects of 
nicotine and vehicle. Following either nicotine or vehicle injections, animals are 
encouraged to make a specific response (e.g. lever press), which leads to the 
presentation of reward (usually food pellets). Ultimately, in animals that have learnt to 
discriminate nicotine from vehicle, challenge injections will inform the animal which 
response to make in order to receive the reward (Warner and Shoaib, 2005). All the 
studies used similar discriminating training procedures. However, rats tested by Wiley and 
colleagues (2002) were trained to discriminate 0.4 mg/kg nicotine from vehicle, Young and
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Glennon (2002) used 0.6 mg/kg nicotine, and Shoaib and colleagues (2003) used 0.2 
mg/kg nicotine. The difference in training dose may affect the relative strengths and 
specificity of the discriminative effects and nicotine cue, respectively (Warner and Shoaib, 
2005).
Two of the three studies conducted a range of generalisation tests, which found 
bupropion to substitute for nicotine in a dose dependent manner with complete stimulus 
generalisation observed at 56 mg/kg bupropion (Wiley et al., 2002) or 21 mg/kg bupropion 
(Young and Glennon, 2002). These findings suggest that bupropion may aid during 
nicotine abstinence because of its similarity to the subjective effects of nicotine.
Tests of stimulus antagonism revealed that bupropion failed to block the
discriminative effects of nicotine in all three studies (Wiley et al., 2002; Young and
Glennon, 2002; Shoaib et al., 2003). These findings appear to correlate with the results of 
the various nicotine self-administration studies by indicating that bupropion does not 
ameliorate the acute subjective or reinforcing effects of nicotine. Whilst co-administration 
of mecamylamine blocked the stimulus effects of nicotine, it failed to antagonise the 
nicotine-like responses produced by bupropion (Wiley et al., 2002; Young and Glennon, 
2002; Shoaib et al., 2003). This suggests that although bupropion shares similar 
discriminative stimulus effects to nicotine, their effects are not mediated by the same 
mechanisms of action. Bupropion probably produces nicotine-like responses through its 
ability to increase extracellular DA by inhibiting DAT.
1.7 Project aims
Section 1.6 highlights the uncertainties about the mechanism of action of 
bupropion in smoking cessation with observations from studies so far producing
inconclusive results. Some suggest that its inhibition of DA and NA reuptake are 
fundamental to the efficacy of bupropion in the treatment of nicotine dependence, as it 
replaces the positive effects of nicotine during abstinence by maintaining raised
extracellular levels of DA and NA in brain reward areas. Others propose that bupropion 
may aid smoking cessation through its ability to antagonise neuronal nAChRs, thereby 
attenuating the reinforcing properties of nicotine. These inconsistent findings have raised 
a few questions: (1) do these mechanisms of bupropion work in concert or does one 
predominate to help break the smoking habit, (2) are bupropion’s mechanisms of action 
dependent on its concentration and/or type of model in which its effects are examined (in 
vitro vs. in vivo). With this in mind, the overall aim of this thesis is to systematically explore 
the interactions of nicotine and bupropion with respect to DA release, using various in vitro 




The first part of the project (Chapter 2) examines the acute effects of bupropion on 
nAChR-evoked DA release in vitro. This is approached using two in vitro preparations of 
increasing complexity: synaptosomes that allow analysis of presynaptic terminals in 
isolation; and slices that maintain some anatomical integrity, thereby facilitating 
neurotransmitter crosstalk (see section 2.1.1.1). As a model system to study nAChR- 
evoked DA release, we utilised striatal preparations (see section 2.1.2) as they comprise 
DA terminals densely populated with nAChRs responsible for mediating the rewarding 
effects of nicotine. Therefore, the specific aims of this chapter are:
- To analyse the effects of bupropion on nicotine-evoked [3H]DA release using an in 
vitro superfusion assay (see section 2.1.1).
- To probe the DAT and nAChR blocking properties of bupropion.
- To investigate how these effects of bupropion relate to the neuronal models in
which they are examined.
The second part of the project (Chapter 3) elaborates on the findings from Chapter 
2 by examining the acute effects of bupropion on nAChR-induced responses in vivo. This 
is approached by examining the interactions of bupropion and nicotine, with respect to 
DA-mediated responses, in more physiologically relevant models. Therefore, the specific 
aims of this chapter are:
- To examine whether the interactions of bupropion and nicotine observed in vitro,
translate in vivo.
- To analyse the effects of bupropion on nicotine-evoked DA release in the NAc
using in vivo microdialysis (see section 3.1.1), as DA release in the NAc is 
responsible for the motivational properties that maintain nicotine-seeking 
behaviour.
- To compare the neurochemical interactions of bupropion and nicotine to
behavioural responses, by examining their effects on rat locomotor activity.
An additional part of the project was to construct an in vivo microdialysis set-up, 
and optimise a high pressure liquid chromatography (HPLC) system for the 




Actions of bupropion on nicotinic receptor- 
mediated r3H!DA release
2.1 Introduction
The overall aim of this thesis was to study the interaction of bupropion with 
nicotine-evoked DA release. In this chapter, this is approached using in vitro methods that 
exploit the widespread occurrence of nAChRs at presynaptic locations (Wonnacott, 1997). 
Various experimental strategies adopted to monitor nAChR-evoked neurotransmitter 
release in brain preparations have shown presynaptic nAChRs to modulate the release of 
several neurotransmitters, including ACh, DA, NA, 5-HT, glutamate and GABA, from 
different brain regions (MacDermott et al., 1999). However, DA release from rodent 
striatum has been the most extensively studied example using neurochemical techniques, 
such as in vitro superfusion (Rapier et al., 1990; Soliakov et al., 1995; Prince et al., 1996; 
Kaiser et al., 1998; Wonnacott et al., 2000; Kulak et al., 2001; Grady et al., 2002).
2.1.1 In vitro superfusion
Superfusion allows the direct measurement of transmitter release from brain 
preparations (synaptosomes or slices) in vitro. The term “superfusion” was coined by J. H. 
Gaddum (1953), and refers to the flow of liquid, typically physiological buffer, over tissue, 
as opposed to perfusion in which liquid flows through the tissue (Gaddum, 1953). Usually 
several samples are superfused in parallel, and serial fractions of superfusate are 
collected for analysis of released transmitter. After establishing a stable baseline, 
transmitter release can be evoked by drug application or electrical stimulation in the 
presence or absence of antagonists or other drugs (see Fig 2.1 for the summary of a 
typical superfusion process). As most assay methods for endogenous transmitter are 
generally too insensitive to detect amounts in the individual fractions of superfusate, tissue 
is commonly loaded with radiolabelled transmitter prior to superfusion, and the release of 
radioactivity measured (Wonnacott et al., 2002). The validity of this approach rests largely 
on the assumption that radiolabelled transmitter accumulates in and is released from a 
transmitter pool that is identical to the one from which endogenous transmitter is released.
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Automated superfusion systems, designed for brain slices, are produced 
commercially. Typically, customised systems that measure nicotine-evoked transmitter 
release over seconds to minutes are routinely used (Rapier et al., 1990; Prince et al., 
1996; Wonnacott et al., 2000; Kulak et al., 2001; Grady et al., 2002). However, a 
superfusion system, with subsecond time resolution, has been developed (Turner et al., 
1989) but there have been no published reports yet of nicotine-evoked transmitter release 
measured over such brief time scales (Wonnacott et al., 2002). Recently, a higher 
throughput release assay has been described (Puttfarcken et al., 2000). This is a static 
release system carried out in 96 well filter plates equipped with a support membrane to 
separate tissue slices from the bathing medium (containing the released transmitter) that 
can be removed by vacuum filtration (Wonnacott et al., 2002). This method has the added 
advantage of being useful for rapid screening of novel ligands, but unlike conventional 
superfusion systems, fails to provide a temporal profile for drug effects, and so is less 
suitable for the analysis of more complex interactions (e.g. effects of indirect agonists, 
such as bupropion, on transmitter release).
2.1.1.1 Synaptosomes or slices?
Synaptosomes were first identified by Hebb and Whittaker (1958) as sealed 
presynaptic nerve terminals, generated when brain tissue is homogenised under 
appropriate conditions (Whittaker, 1993). These structures retain all the features of the 
intact nerve ending making them the simplest system in which the complete chain of 
events from plasma depolarisation to transmitter release can be studied in isolation. 
Crude synaptosome preparations, produced by differential centrifugation, include free 
mitochondria and plasma membrane fragments, whilst highly purified preparations can be 
prepared by density gradient centrifugation that separates synaptosomes from membrane 
fragments and mitochondria (Wonnacott et al., 2002). As anatomical connections are 
severed in their preparation, superfusion of synaptosomes is considered to avoid cross­
talk between nerve terminals, and so modulation of transmitter release reflects a direct 
effect via presynaptic receptors. However, preparations are rather frail, being prone to 
osmotic or mechanical damage. Typically, for investigating the effects of presynaptic 
nAChRs on transmitter release, a single stimulation with nicotinic agonist is given, and 
different agonist concentrations or the effect of antagonist or other drugs compared in 
parallel chambers (Wonnacott et al., 2002).
Slices or minces (about 250 pm) are conventionally prepared using an automated 
device, such as a Mcllwain tissue chopper. They are quickly and easily prepared, and 
retain local anatomical integrity, making them more representative of the intact brain. The 
disadvantage of the latter aspect is that indirect effects on transmitter release, via synaptic 
connections, can complicate the interpretation of results. The protocol typically used to
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study the effects of presynaptic nAChRs on transmitter release from slices is to determine 
and compare the absolute values of transmitter release (in cpm, typically expressed as a 
percentage of baseline or of total radiolabel originally accumulated by the preparation) 
between parallel chambers with or without various concentrations of drug of interest. Slice 
studies have been used for the pharmacological characterisation of nAChR-mediated 
[3H]DA release in the striatum (Dwoskin et al., 1995; Marshall et al., 1996; Wonnacott et 
al., 2002).
2.1.2 Striatal preparations as a model system
The nicotinic modulation of [3H]DA release from striatal preparations has been 
exploited as a model system for examining native nAChR responses (Wonnacott et al.,
2000). Nicotinic agonists elicit Ca2+-dependent [3H]DA release from rat striatal 
synaptosomes in a concentration-dependent, mecamylamine-sensitive manner (Rapier et 
al., 1990; Grady et al., 1992; el Bizri and Clarke, 1994; Soliakov et al., 1995; Soliakov and 
Wonnacott, 1996), consistent with the activation of presynaptic nAChRs (Wonnacott,
1997). Insensitivity to the a7-selective antagonists, a-Bgt (Rapier et al., 1990; Grady et 
al., 1992) and a-conotoxin Iml (Kulak et al., 1997) argues against the direct involvement of 
a l  nAChR. Initial studies indicated that aCtxMII was a specific antagonist of nAChRs 
composed of a3  and p2 subunits (Cartier et al., 1996; Harvey et al., 1997). However, 
studies using transgenic mice, suggest that the toxin may recognise a6p2* nAChRs as 
well (see section 1.4.6.2; Champtiaux et al., 2002; Whiteaker et al., 2002). This toxin 
partially inhibited [3H]DA release from rat striatal synaptosomes stimulated with nicotine 
(Kulak et al., 1997) or anatoxin-a (Kaiser et al., 1998), providing evidence for the 
heterogeneity of presynaptic nAChRs on DA terminals, with one population containing an 
a6(32 interface. Pharmacological studies with the novel partial agonist UB-165, led to the 
hypothesis that ct4p2* nAChRs may comprise the other nAChR population on DA 
terminals (Sharpies et al., 2000). This is consistent with the loss of [3H]nicotine binding 
sites, following lesioning of the nigrostriatal pathway (Clarke and Pert, 1985). The 
requirement of the p2 subunit for the formation of the two putative subtypes of presynaptic 
nAChRs on striatal DA terminals is consistent with the localisation of p2 nAChR subunits 
immunoreactivity in most dopaminergic terminals in the dorsal striatum (Jones et al.,
2001) and the absence of nicotine-evoked [3H]DA release from synaptosomes or slices 
prepared from the striata of p2-null mutant mice (Grady et al., 2001; Zhou et al., 2001).
There is considerable in vitro evidence that glutamate can elicit DA release, by 
acting at AMPA and NMDA receptors on DA terminals in the striatum (Wang, 1991; Desce 
et al., 1992; Cheramy et al., 1996). Consistent with this view, is that locally applied 
nicotine can provoke striatal DA (Marshall et al., 1997) and glutamate release (Toth et al.,
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1993), measured by in vivo microdialysis. Moreover, local application of NMDA 
antagonists diminish the ability of locally applied nicotine to elicit DA release in vivo (Toth 
et al., 1992). Recent studies on striatal slices, have interpreted an indirect nicotinic effect 
on [3H]DA release, whereby stimulation of a7 nAChRs on glutamatergic terminals causes 
the release of glutamate that in turn promotes the release of DA via presynaptic glutamate 
receptors on dopaminergic terminals (Kaiser and Wonnacott, 2000). This component was 
not seen in synaptosomes, due to the absence of neurotransmitter crosstalk.
2.1.3 nAChRs and Ca2+ signalling
Intracellular Ca2+ has a pivotal role in regulating diverse aspects of neuronal 
processes such as transmitter release, excitability, synaptic plasticity and gene expression 
(Berridge, 1998; Dajas-Bailador and Wonnacott, 2004). Like other cells, neurones are 
endowed with a variety of voltage- and ligand-gated ion channels that normally serve as 
the principal Ca2+ entry pathway for cells. Activation of these channels allow Ca2+ entry 
down an electrochemical gradient resulting in elevated cytoplasmic free Ca2+ 
concentration above the normal range of 50-100 nM (Berridge, 1998). Additional Ca2+ 
entry routes across the plasma membrane involve the Na+-Ca2+ exchange and store- 
operated Ca2+ channels. However, with regards to this thesis, the focus will be on voltage- 
and ligand-gated Ca2+- channels.
There are a family of VOCC that are highly selective for Ca2+. Plasma membrane 
depolarisation results in a rapid increase in intracellular Ca2+ concentration ([Ca2+]j) and 
influx of Ca2+ through VOCC is the classical mechanism of transmitter release (Berridge,
1998). Characteristically, these channels also inactivate rapidly. A combination of 
electrophysiological and pharmacological criteria suggests that there are five distinct 
subtypes of VOCC: L, N, P, Q, R and T. The subtypes vary according to their activation 
and inactivation kinetics, conductance, and sensitivity to blocking agents. L stands for 
long-lasting due to the slow inactivation of the channel. L-channels are particularly 
important in regulating contraction of cardiac and smooth muscle. T stands for transient 
due to the fast inactivation of the channel. T-channels mediate Ca2+ entry into neurones, 
and thereby control various Ca2+-dependent functions. N stands for neither long-lasting 
nor transient. N channels (and also P/Q) are involved in neurotransmitter and hormone 
release. R carries on alphabetically from N, P and Q, with O omitted. The location and 
function of R-channels is yet unknown (Rang et al., 2003).
In addition to VOCC, ligand-gated channels are the other major class of channels 
that facilitate Ca2+ entry. These are present in the plasma membrane of nerve terminals. 
The nAChR is a well-defined example of a ligand-gated channel with the capacity to elicit 
local changes in intracellular Ca2+. The activation of this channel often results in a
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substantial rise in intracellular N a \ too. The relative permeability of nAChRs to Ca2+ over 
Na+ is governed by the subunit composition, such that altering the molecular make-up of a 
channel has a substantial impact on the Ca2+ permeability (Rang et al., 2003). This is 
consistent with a 7 nAChRs having the highest permeability to Ca2+ compared to other 
homomeric or heteromeric nAChRs (Seguela et al., 1993; Dajas-Bailador and Wonnacott,
2004).
Nicotine-evoked DA release requires the entry of extracellular Ca2+ into the 
presynaptic terminus, consistent with the activation of exocytotic mechanisms (Wonnacott,
1997). In principle, this could come about in two ways. Extracellular Ca2+ could enter 
directly through the ion pore of nAChRs by virtue of their intrinsic Ca2+ permeability. 
Alternatively, depolarisation of the presynaptic membrane produced by activation of 
nAChRs, would be sufficient to open VOCC associated with the release machinery, and 
Ca2+ entering through VOCC would be responsible for transmitter release. There is 
evidence for the operation of both mechanisms. In striatal DA synaptosomes bearing p2* 
nAChRs, nAChR-evoked DA release is mediated by VOCC (Prince et al., 1996; Soliakov 
and Wonnacott, 1996; Kulak et al., 2001). In contrast, activation of a3(34 nAChRs on 
hippocampal synaptosomes evokes the release of [3H]noradrenaline without the 
involvement of VOCC (Kulak et al., 2001). Indeed, nAChRs also modulate transmitter 
release through other Ca2+-dependent mechanisms that involve key signalling molecules 
such as protein kinases (Dajas-Bailador and Wonnacott, 2004). Also, in addition to the 
role of extracellular Ca2+, there is increasing evidence that exocytosis may be regulated by 
Ca2+ release from intracellular stores (Dajas-Bailador et al., 2002).
2.1.4 SH-SY5Y cells as a model system
The human neuroblastoma SH-SY5Y cell line has been well characterised with 
respect to its complement of nAChRs. It expresses several nAChR subunits, including a3, 
a5, a7, p2 and p4, which form a3* and a l  subtypes of nAChRs (Lukas et al., 1993). 
Previous studies have shown that nAChR activation results in NA release through a 
cellular mechanism attributed to Ca2+ influx through the nAChR itself and VOCC (Wade et 
al., 1998). Additionally, it has also been shown that stimulation of SH-SY5Y cells with 
nicotinic agonists can increase [Ca2+]j (Ridley et al., 2002). Together, these findings 
suggest that SH-SY5Y cells are a valuable neuronal model for investigating the cellular 
consequences of nAChR activation (Ridley et al., 2001; Dajas-Bailador et al., 2003; Barik 
et al., 2005).
Changes in [Ca2+]i were first successfully measured by Ridgeway and colleagues 
in 1967. However, Tsien and colleagues in the 1980s produced a variety of chemical 
fluorescent indicators that provided reliable methods for measuring [Ca2+]i (Takahashi et
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al., 1999). The most widely used C a2+ indicators are chemical fluorescent probes because 
their signal (light) is quite large for a given change in [Ca2+]j. For the study in this chapter, 
we utilised the non-ratiometric dye, Fluo-3, as its fluorescent properties were compatible 
with the instrument available. Fluo-3 is one of many C a2+ indicators used to measure 
changes in fluorescence indicative of altered [Ca2+]j. Fluo-3 is essentially non-fluorescent 
unless bound to Ca2+, after which it is reported to undergo a 40- to 200-fold increase in 
fluorescence (Takahashi et al., 1999). As fluo-3 is cell impermeable, it is typically 
derivatised with an AM ester that is cell permeable. Therefore, fluo-3 AM can passively 
diffuse across cell membranes, and once inside the cell, esterases cleave the AM group 
off the probe leaving a cell impermeable indicator. The AM esters have low aqueous 
solubility and so dispersing agents such as pluronic F127 are often used to facilitate cell 
loading. Pluronic F127 is a non-ionic dispersing agent that helps solubilise large dye 
molecules such as fluo-3 AM in physiological media (Takahashi et al., 1999).
2.1.5 Aims of this chapter
It is clear from various approaches that bupropion can interact with nAChRs (see 
section 1.6.2.3). What is uncertain, however, is how this interaction (that would decrease 
nicotine-evoked DA release) integrates with DAT blockade by bupropion (that would exert 
the opposite effect, namely an increase in extracellular DA). The present chapter aims to 
explore this relationship in two in vitro preparations of increasing complexity: striatal 
synaptosomes that allow analysis of DA terminals in isolation, and striatal slices that 
preserve some anatomical relationships that facilitate transmitter crosstalk.
Therefore, the particular aims of this chapter are:
- To explore the interactions of bupropion with nicotine-evoked DA release in vitro.
- First, using synaptosomes as the simplest system, to define nicotine-evoked 
[3H]DA release and compare the effects of bupropion and nomifensine.
- Then, to extend the study to slices, allowing for more complex neurotransmitter 
crosstalk.
- To obtain a measure of the direct interaction of bupropion and nomifensine with
nAChRs, by measuring Ca2+ fluorimetry in SH-SY5Y cells.
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2.2 Materials and Methods
Cell Culture
Tissue culture media, serum and plastic ware were obtained from Gibco BRL 
(Paisley, UK). Media supplements were purchased from Sigma-Aldrich Co. Ltd 
(Gillingham, Dorset, UK). Fluo-3 AM and pluronic F127 were purchased from Molecular 
Probes (Eugene, Oregon, USA).
Drugs and Reagents
[7, 8- 3H]dopamine ([3H]DA; specificity 43-47 Ci/mmol, 1.67-1.81 TBq/mmol) was 
purchased from Amersham Biosciences Ltd (Bucks., UK). (-)-Nicotine hydrogen tartrate, 
bupropion, nomifensine, raclopride, mecamylamine, cadmium chloride and pargyline were 
purchased from Sigma-Aldrich Co. Ltd (Gillingham, Dorset, UK). DL-2-amino-5- 
phosphonopentanoic acid (AP-V) and 6,7-dinitroquinoxaline-2,3-dione (DNQX) were 
obtained from Tocris Cookson Ltd (Bristol, UK). a-Bgt was purchased from Molecular 
Probes (Cambridge, UK). All other chemicals were of analytical grade and obtained from 
standard commercial sources.









Scintillation counting, data analysis
Load preparation"with" racfiolalielleern^urotransmitter 
_________________ (pri]dopamine)_________________
Perfuse with buffer, containing inhibitors of reuptake and 
enzymatic degradation, with or without test drug
(agonist, e g. nicotine)
lease
Fig. 2.1 Scheme summarising the steps involved in superfusion experiments with
either synaptosomes or slices.
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2.2.1.1 Dissection and preparation of striata
Male Sprague-Dawley rats (250-300 g) obtained from the University of Bath 
Animal House breeding colony, were killed by cervical dislocation, and the brains 
removed. Striata (80-120 mg wet tissue/rat) from two (for synaptosome preparations; Fig.
2.1) or three rats (for slice preparations; Fig. 2.1) were rapidly dissected and placed in ice- 
cold 0.32 M sucrose, pH 7.4. A crude P2 synaptosome preparation was prepared by 
differential centrifugation as previously described (Soliakov et al., 1995; Kaiser et al.,
1998). In brief, tissue was homogenised in 0.32 M sucrose and centrifuged at 1000 x g for 
10 min. The supernatant was decanted and centrifuged at 20,000 x g for 20 min to give a 
P2 pellet that was resuspended in Krebs buffer of the following composition: 118 mM 
NaCI, 2.4 mM KCI, 2.4 mM CaCI2l 1.2 mM MgS04, 1.2 mM KH2P 0 4, 25 mM NaH C 03 and 
10 mM glucose, gassed with 95% 0 2 / 5% C 0 2, pH 7.4, supplemented with 1 mM ascorbic 
acid and 8 pM pargyline, to prevent DA degradation. The P2 synaptosomes were re­
centrifuged at 20,000 x g for 10 min, resuspended in 1.5 ml Krebs buffer and incubated 
with [3H]DA (0.1 pM, 0.185 MBq/ml) for 15 min at 37°C. Only for the preliminary nicotine- 
concentration response experiments, 0.5 pM nomifensine was added to the Krebs buffer, 
after the synaptosomes had been loaded with [3H]DA, to inhibit DA re-uptake. The 
synaptosomes were then distributed, using a peristaltic pump, between 12 open 
superfusion chambers, each containing a double layer of Whatman GF/B filters, in a 












Fig. 2.2 Superfusion machine configured for the superfusion of synaptosomes.
Arrows indicate the direction of buffer flow. The temperature of the heating block is adjusted 
such that the water bath is maintained at 37°C. Inset: Open superfusion chamber showing 
the double thickness of Whatman GF/B filters (grey) and the direction of buffer flow.
Striatal slices (0.25 mm prisms) were prepared as previously described (Kaiser 
and Wonnacott, 2000) using a Mcllwain tissue chopper. The slices were rinsed in Krebs
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buffer and incubated with [3H]DA (0.1 pM, 0.185 MBq/ml) in 1.5 ml buffer for 15 min. The 
slices were diluted with Krebs buffer and excess radioactive label removed. Aliquots of the 
slice suspension (120 pi, 20-30 mg slices per chamber) were loaded into 12 closed 
chambers of a Brandel superfusion apparatus. A nylon mesh and GF/B filter were placed 












Fig. 2.3 Superfusion machine configured for the superfusion of slices.
Arrows indicate the direction of buffer flow. The temperature of the heating block is adjusted 
such that the water bath is maintained at 37°C. Inset: Closed superfusion chamber showing 
the position of Whatman GF/B filters (grey), nylon meshes (black) and the direction of buffer 
flow.
2.2.1.2 Drug application
Synaptosomes (open chambers) or slices (closed chambers) were superfused with 
Krebs buffer at a flow rate of 0.5 ml/min, at 37°C and serial fractions were collected every 
2 min. After a 20 min washout period, synaptosomes or slices were superfused for a 
further 10 min in Krebs buffer with or without bupropion and / or test drug. In the case of 
a-Bgt (100 nM), the preincubation time was extended to 1 h. Nicotine was then applied for 
40 s, separated from the bulk buffer flow by 10 s air bubbles, in the presence or absence 
of test drug. Superfusion was continued for a further 10 min in Krebs buffer with or without 
test drug.
2.2.1.3 Quantification of radioactivity
Radioactivity remaining in the synaptosomes or slices at the end of the experiment 
was determined by counting the GF/B filters from the superfusion chambers. In the case
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of slices, solvable (200 pi) was added to the GF/B filters for 1 h, to lyse the slices, followed 
by addition of propan-2-ol (0.5 ml). Optiphase Safe™ scintillation fluid (4 ml) was added to 
all samples, and they were counted for radioactivity in a Packard TRI-CARD Liquid 
Scintillation Counter (model 1600; counting efficiency 44%).
2.2.1.4 Protein estimation
Protein content was determined using the Bio-Rad Protein Assay kit, which is 
essentially based on the method of Bradford (Bradford, 1976). The assay reagent was 
diluted 1:4 in distilled water and filtered through Whatman filter paper. A standard protein 
curve was constructed using samples (n = 7) of BSA, dissolved in Krebs buffer, over a 
concentration range of 0.2-1.4 mg/ml (Fig. 2.4). Brain samples were diluted 1:4 in Krebs 
buffer. Each sample (5 pi of BSA or diluted brain sample) was added to 8 wells in a 96 
well plate and 250 pi of the assay reagent added to each well. Protein content was 
determined by measuring the optical density at 595 nm versus blank (Krebs buffer plus 
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Fig. 2.4 Typical protein standard curve.
Points represent the mean absorbance ± S.E.M. obtained at 595 nm using increasing 
concentrations of BSA (0.2-1.4 mg/ml) assayed in a 96 well plate using the Bio-Rad protein 
assay.
2.2.2 Calcium fluorimetry
Human neuroblastoma SH-SY5Y cells (ECACC, Salisbury, UK; passages 14-20) 
were cultured as previously described (Dajas-Bailador et al., 2002). They were plated (1:5 
dilution from culture media) into 96 well Primaria plates (Falcon, New Jersey, USA) and 
experiments performed 72 h afterwards with confluent cultures. After removal of the
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medium from the confluent cultures, SH-SY5Y cells were washed twice with Tyrode’s salt 
solution (TSS: 137 mM NaCI, 2.7 mM KCI, 1.0 mM MgCI2, 1.8 mM CaCI2, 0.2 mM 
NaH2P 0 4, 12 mM N aH C 03, 5.5 mM glucose; pH 7.4) and incubated with fluo-3 AM (10 
pM) and 0.02% pluronic for 1 h at room temperature in the dark. Cells were then washed 
twice with TSS, before adding 80 pi buffer, with or without test drugs, per well. After 10 
min pre-incubation at room temperature in the dark, changes in fluorescence (excitation 
485 nm, emission 538 nm) were measured using a Fluroskan Ascent fluorescent plate 
reader (Labsystems, Helsinki, Finland).
Basal levels of fluorescence were monitored for 5 s before addition of an agonist 
(20 pi). Changes in fluorescence were monitored for a further 20 s. For normalising 
fluorescence signals, responses from each well were calibrated by determination of the 
maximum and minimum fluorescence values at the end of each experiment, by addition of 
0.2% Triton X100 (Fmax), followed by 40 mM MnCI2 (Fmin). Data were calculated as a 
percentage of Fmax -  Fmin. Values in the presence of test drugs were expressed as a 




The baseline was derived by fitting the following double exponential decay equation 
to the data, using SigmaPlot (v 2.0) for Windows:
y  = ae~bx + ce~dx
where a and c are the initial (x = 0) release in each phase, b and d are the decay 
constants in each phase, and x is the fraction number (Soliakov et al., 1995). For 
comparison between different experiments, superfusion profiles were normalised as 
percentages of fitted baselines.
Evoked [3H]DA release was calculated as the area under the peak, after subtraction 
of the baseline, and expressed as a percentage of the total radioactivity present in the 
synaptosomes or slices at the time of agonist stimulation (the sum of subsequently 
released [3H]DA plus that remaining on the filters at the end of the experiment) to give 
fractional release. Data are also presented by expressing fractional release as a 
percentage of the corresponding control, assayed in parallel. Values represent the mean ± 
S.E.M. of the number of independent experiments carried out; each experiment consisted 
of two or three replicate chambers for each condition.
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To examine concentration-inhibition relationships, data were fitted to the Hill Equation 
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where nH is the Hill Number, [Drug] is the concentration of the antagonist, and /C50 is the 
concentration at which half-maximal inhibition of [3H]DA release by antagonist was 
obtained. To examine concentration-response relationships, data were fitted to the above 
Hill Equation, and IC50 values were replaced by EC50 values. EC50 is the concentration at 
which half-maximal [3H]DA release in response to agonist was obtained.
Statistical analyses were performed using the unpaired Student’s t-test or one-way 
ANOVA with Dunnett’s post-hoc test, as stated in the figure legends. Values of p<0.05 
were taken to be statistically significant.
2.2.3.2 Calcium fluorimetry
To examine concentration-inhibition relationships, data were fitted to the Hill 
Equation (as in the superfusion experiments - see section 2.2.3.1) using the non-linear 
least squares curve fitting function of SigmaPlot, where nH is the Hill Number, [Drug] is the 
concentration of the antagonist, and IC50 is the concentration at which half-maximal 
change in fluorescence by antagonist was obtained.
Values represent the mean ± S.E.M. of three or more independent experiments 
(each with four replicates). Statistical analyses were performed using the unpaired 
Student’s t-test or one-way ANOVA with Dunnett’s post-hoc test, as stated in the figure 




2.3.1 Superfusion of striatal synaptosomes and
slices
2.3.1.1 Nicotine concentration-response relationship
To monitor the reproducibility of the in vitro superfusion assay in comparison with 
previous results from the laboratory (Kaiser et al., 1998; Wonnacott et al., 2000), a 
preliminary experiment examining nicotine-evoked [3H]DA release from rat striatal 
synaptosomes was conducted (Fig. 2.5). A 40 s pulse of nicotine (10 pM) elicited a peak 
of radioactivity above basal release that was almost totally abolished in the presence of 
the general nAChR antagonist, mecamylamine (10 pM; Fig. 2.5a). Firstly a range of 
concentrations of nicotine (0.03-100 pM) was tested to yield a dose-response curve for 
nicotine-evoked [3H]DA release (Fig. 2.5b). An EC50 value of 4.8 ± 0 . 1  pM nicotine was 
obtained. Next, a similar range of concentrations of nicotine (0.3-100 pM) was tested in 
the presence of 10 pM mecamylamine to distinguish nAChR-mediated and non-specific 
[3H]DA release (Fig. 2.5c). These data were expressed as a percentage of the response 
to a 10 pM nicotine control, since this concentration elicited responses that were just 
below the maximum on the dose-response curve (Fig. 2.5b). Fig. 2.5c shows that 
mecamylamine (10 pM) blocked the response to a range of concentrations of nicotine- 
evoked [3H]DA release (0.3-100 pM), but failed to do so at the highest concentration of 
nicotine (100 pM).
2.3.1.2 Effect of DA reuptake inhibitors on nicotine-evoked [3H]DA 
release
[3H]DA release profiles
To explore the interaction between bupropion and nicotine with respect to [3H]DA 
release, the effect of bupropion (0.1-10 pM) on nicotine-evoked [3H]DA release was 
examined in rat striatal synaptosomes and slices, by superfusion. To study bupropion’s 
ability to block DA reuptake, it was compared with a well-defined DAT inhibitor, 
nomifensine (10 pM), thereby representing a positive control. [3H]DA release was evoked 
by 10 pM nicotine (as this concentration was sensitive enough to detect any drug-induced 
changes above or below this level; Fig. 2.5b) in the absence (experimental control) and 
presence of test drug. Initially, nomifensine (10 pM) was examined for its effect on 
nicotine-evoked [3H]DA release, in synaptosomes and slices, by superfusion. The effects
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of both nomifensine and bupropion are illustrated firstly as typical superfusion profiles 
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Fig. 2.5 Nicotine-evoked [3H]DA release from striatal synaptosomes.
Synaptosomes were loaded with [3H]DA and superfused as described in section 2.2.1.2. 
Mecamylamine was added to the perfusing buffer 10 min prior to stimulation with nicotine for 
40 s; 2 min (1 ml) serial fractions were collected and counted for radioactivity. Nicotine- 
evoked responses in the absence of mecamylamine were determined in parallel chambers. 
Representative superfusion profiles show evoked [3H]DA release from striatal 
synaptosomes in the absence ( • )  and presence (■) of 10 pM mecamylamine (a). Mean 
values from a single experiment are expressed as a percentage (± S.E.M. of triplicate 
chambers) of the mean basal release. Concentration-response curves for [3H]DA release in 
response to nicotine in the absence (b) and presence (c) of 10 pM mecamylamine. Evoked 
[3H]DA release was calculated as a fraction of total radioactivity present at the time of 
stimulation and presented as raw fractional release (b) or percentage of the response to 10 
pM nicotine alone (c), measured in parallel. All values are the mean ± S.E.M. of at least 
three separate experiments, each consisting of two or more replicate chambers. 
Concentration-response data were fitted to the Hill Equation, as described in section 2.2.3.1. 
The EC50 value for nicotine-evoked [3H]DA release (b) was 4.8 ± 0.1 pM.
A 40 s pulse of 10 pM nicotine elicited a peak of radioactivity above basal release 
that was affected, in the presence of 10 pM nomifensine. The effect of nomifensine was 
markedly different in synaptosomes (Fig. 2.6a) as compared to slices (Fig. 2.6c). In 
synaptosomes, nicotine-evoked [3H]DA release in the presence of nomifensine, exhibited 
a similar peak height but a narrower peak shape with respect to control. In slices, 
however, evoked release in the presence of nomifensine exhibited a similar peak shape 
but an increased peak height, as well as an increased baseline, with respect to control 
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Fig. 2.6 Superfusion profiles showing the effect of nomifensine on nicotine-evoked 
^HIDA release from striatal synaptosomes and slices.
Synaptosomes (a, b) and slices (c, d) were loaded with [3H]DA and superfused as described 
in section 2.2.1.2. Nomifensine (10 pM) was added to the perfusing buffer 10 min prior to 
stimulation with 10 pM nicotine for 40 s; 2 min (1 ml) serial fractions were collected and 
counted for radioactivity. Nicotine-evoked responses in the absence of nomifensine were 
determined in parallel chambers. Mean values (± S.E.M. of triplicate chambers) from a 
single experiment are expressed as raw cpm (a, c) or percentage of the mean basal release 
(b, d). All values are the mean ± S.E.M. of at least three separate experiments, each 
consisting of two or more replicate chambers.
The effects of bupropion (0.1, 10 pM) on nicotine-evoked [3H]DA release in 
synaptosomes (Fig. 2.7a) were also different to those in slices (Fig. 2.7c). In 
synaptosomes, the effect of 0.1 pM bupropion was difficult to differentiate from that of 
control, whilst 10 pM bupropion produced a lower peak height with respect to control. Both 
concentrations of bupropion produced variations in baseline when compared to that of 
control. In slices, both concentrations of bupropion (0.1, 10 pM) produced lower peak 
heights and similar peak shapes, with respect to control (The interpretations of these 
results are considered later in this section).
To clarify the different effects of nomifensine and bupropion, evoked [3H]DA 
release was normalised as a percentage of a fitted baseline (Fig. 2.6b, d for nomifensine, 
Fig. 2.7b, d for bupropion), where the mean basal release prior to superfusion with test 
drug, was expressed as 100%. This is because at this point, all drug treatments, in the 
presence or absence of test drug, were subjected to the same experimental condition, i.e. 
superfusion in Krebs buffer only (as described in section 2.2.1.2). Note that the y-axes of
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Fig. 2.7 Superfusion profiles show ing the effect o f bupropion on n icotine-evoked  
^HJDA release from  striatal synaptosom es and slices.
Synaptosomes (a, b) and slices (c, d) were loaded with [3H]DA and superfused as described 
in section 2.2.1.2. Bupropion (0.1 pM or 10 pM) was added to the perfusing buffer 10 min 
prior to stimulation with 10 pM nicotine for 40 s; 2 min (1 ml) serial fractions were collected 
and counted for radioactivity. Nicotine-evoked responses in the absence of bupropion were 
determined in parallel chambers. Mean values (± S.E.M. of triplicate chambers) from a 
single experiment are expressed as raw cpm (a, c) or percentage of the mean basal release 
(b, d). All values are the mean ± S.E.M. of at least three separate experiments, each 
consisting of two or more replicate chambers.
In synaptosomes, both concentrations of bupropion increased basal release (Fig. 
2.7b), with a slowly increasing effect in response to 0.1 pM bupropion and a rapid but 
transient increase in basal levels of [3H]DA in response to 10 pM bupropion. In slices, a 
rapid increase in basal levels of [3H]DA was seen in response to 10 pM nomifensine (Fig. 
2.6d) and 10 pM bupropion (Fig. 2.7d).
Effect o f nomifensine on nicotine-evoked [3H]DA release
In synaptosomes, nomifensine (10 pM) significantly inhibited nicotine-evoked 
[3H]DA release by 36.8 ± 5.7% (p<0.05, n = 9; Fig. 2.8a). Note that in Fig. 2.6b, nicotine- 
evoked [3H]DA release in the absence and presence of 10 pM nomifensine, showed 
similar peak heights, but in the presence of 10 pM nomifensine, exhibited a narrower peak
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shape with respect to control. Evoked release was calculated as the total radioactivity 
present under the peak, and expressed as a percentage of the mean basal release, and 
thus attributed to the significant decrease seen in nicotine-evoked [3H]DA release in the 
presence of 10 pM nomifensine (Fig. 2.8a).
In slices, nomifensine had the opposite effect to that seen in synaptosomes. It 
significantly increased the extracellular amount of [3H]DA evoked by 10 pM nicotine, by 
84.4 ± 22.9% (p<0.05, n = 13; Fig. 2.8b). This was attributed to the increased peak height 
in the presence of nomifensine, with respect to control (Fig. 2.6d).
SYNAPTOSOMES SLICES
120 i  _  220
200
2 1°0 180
S 8 ■  T | §  160
g> “  140
II -  I * i f  z
o  40 S ’ 3 .  80
0.1pM 0.3pM 1 pM 10pM Bup - -  0.1 pM 0 3pM 1pM 10pM
10pM Nom + - 10pM Nom - +
10|jM Nicotine 10pM N icotine
Fig. 2.8 Effect of DA reuptake inhibitors on nicotine-evoked [3H]DA release from 
striatal synaptosomes (a) and slices (b).
Synaptosomes and slices were loaded with [3H]DA and superfused as described in section 
2.2.1.2. Bupropion (Bup; 0.1-10 pM) or nomifensine (Nom; 10 pM) were added to the 
perfusing buffer 10 min prior to stimulation with 10 pM nicotine for 40 s; 2 min (1 ml) serial 
fractions were collected and counted for radioactivity. Data were calculated as fractional 
release and are expressed as a percentage of the response to 10 pM nicotine alone 
(control), determined in parallel. Values are the mean ± S.E.M. of at least three separate 
experiments, each consisting of two or more replicate chambers (t p<0.05, *p<0 05 
significantly different from control response; unpaired Student’s t-test, and one-way ANOVA 
with Dunnett’s post-hoc test, respectively).
Effect o f bupropion on nicotine-evoked [3H]DA release
In synaptosomes, bupropion exerted a concentration-dependent effect on nicotine- 
evoked [3H]DA release (Fig. 2.8a), with the low concentration of 0.1 pM showing no 
significant difference in [3H]DA levels with respect to control; and the high concentration of 
10 pM causing a significant inhibition by 57.3 ± 7.9% (p<0.05, n = 6). The presence of 10 
pM bupropion produced a lower peak height with respect to control (Fig. 2.7b), and so 
accounted for the significant decrease in evoked [3H]DA release (Fig. 2.8a).
In slices, nicotine-evoked [3H]DA release was reduced in the presence of both 
concentrations of bupropion (0.1, 10 pM; Fig. 2.7d). The concentration response 
relationship for the effect of bupropion on nicotine-evoked [3H]DA release has an inverted 
u-shape (Fig. 2.8b): in contrast to the results from synaptosomes, nicotine-evoked [3H]DA 
release was significantly decreased in the presence of 0.1 pM bupropion by 22.5 ± 3.8%
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(p<0.05, n = 6). At the highest concentration of bupropion (10 pM) there was a significant 
inhibition of nicotine-evoked [3H]DA release by 47.6 ± 5.7% (p<0.05, n = 6), comparable to 
that observed with synaptosomes. The intermediate concentrations of bupropion had no 
significant influence on nicotine-evoked [3H]DA release. Both 0.1 pM and 10 pM 
bupropion exhibited similar peak shapes as compared to control, and showed lower peak 
heights (Fig. 2.7d), consistent with the decrease in nicotine-evoked [3H]DA release (Fig. 
2.8b).
Combined effect of bupropion and nomifensine on nicotine-evoked [3H]DA release
Due to the contrasting effects of nomifensine on nicotine-evoked [3H]DA release in 
synaptosomes and slices (Fig. 2.8), the effect of increasing concentrations of bupropion 
(0.1-10 pM) in combination with 10 pM nomifensine on nicotine-evoked [3H]DA release 
was examined in rat striatal synaptosomes and slices, by superfusion (Fig. 2.9). Each 
experiment was performed in the presence of 10 pM nomifensine alone as a positive 
control, as well as in the absence of any DAT inhibitor (10 pM nicotine control).
The dual effect of 10 pM nomifensine and bupropion significantly decreased 
nicotine-evoked [3H]DA release in synaptosomes by 38.4 ± 6.5%, 33.6 ± 4.2%, 46.4 ± 
15.9% and 75.5 ± 2.5% (p<0.05, n = 3) at 0.1 pM, 0.3 pM, 1 pM and 10 pM bupropion, 
respectively (Fig. 2.9a). Nomifensine alone, also exhibited a similar level of inhibition, to 
that observed when it was present with either 0.1 pM, 0.3pM or 1pM bupropion. 
Approximately two-fold greater inhibition was seen when co-perfused with 10 pM 
bupropion. Thus, to clarify the effect of bupropion in this combination treatment, results 
were expressed as a percentage of the response to 10 pM nicotine in the presence of 10 
pM nomifensine alone (Fig. 2.9b), on nicotine-evoked [3H]DA release. Here, the effect of 
bupropion was concentration-dependent, exhibiting a significant decrease in evoked 
release at the highest concentration (10 pM) by 41.8 ± 14.9% (p<0.05, n = 4); a pattern 
that was similar to that seen in Fig. 2.8a, when increasing concentrations of bupropion 
alone were examined for their effect on nicotine-evoked [3H]DA release.
In slices, the dual effect of 10 pM nomifensine and bupropion exhibited a 
concentration-dependent profile with significant increases in evoked [3H]DA release by 
122.5 ± 84.0%, 92.3 ± 43.2% and 75.3 ± 8.2% (p<0.05, n = 3) at 0.1 pM, 0.3 pM and 1 pM 
bupropion, respectively (Fig. 2.9c). When the results were expressed as a percentage of 
the response to 10 pM nicotine in the presence of 10 pM nomifensine alone (Fig. 2.9d), on 
nicotine-evoked [3H]DA release, the effect of bupropion was concentration-dependent, 
exhibiting a significant decrease in evoked release at 10 pM bupropion by 53.0 ± 8.7%  
(p<0.05, n = 3), respectively. This concentration-dependent effect of bupropion was 
however, in contrast to the inverted u-shaped profile seen in Fig. 2.8b, when increasing 
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Fig. 2.9 C om bined effect o f bupropion and nom ifensine on n icotine-evoked [3H]DA  
release from  striatal synaptosom es (a, b) and slices (c, d).
Synaptosomes and slices were loaded with [3H]DA and superfused as described in section 
2.2.1.2. Nomifensine (Nom; 10 pM) alone, or nomifensine (10 pM) in combination with 
bupropion (Bup; 0.1-10 pM) were added to the perfusing buffer 10 min prior to stimulation 
with 10 pM nicotine for 40 s; 2 min (1 ml) serial fractions were collected and counted for 
radioactivity. Data were calculated as fractional release and are expressed as a percentage 
of the response to 10 pM nicotine alone (control; a, c) or 10 pM nicotine in the presence of 
10 pM nomifensine (control; b, d), determined in parallel. Values are the mean ± S.E.M. of 
at least three separate experiments, each consisting of two or more replicate chambers 
(f p<0.05, *p<0 05 significantly different from control response; unpaired Student’s t-test, and 
one-way ANOVA with Dunnett’s post-hoc test, respectively).
2.3.1.3 DA D2 receptor-induced modulation of bupropion-
mediated effects on nicotine-evoked [3H]DA release
To determine if inhibitory DA D2 receptors contributed to the concentration- 
dependent effects of bupropion on nicotine-evoked [3H]DA release in striatal 
synaptosomes (Fig. 2.8a) and slices (Fig. 2.8b), raclopride (10 nM) was co-applied with 
0.1 pM and 10 pM bupropion (Fig. 2.10). This concentration of raclopride was selected as 
it was sufficient to induce a complete blockade of DA D2 receptors (Kd = 1.8 nM; 
Professor Philip Strange -  personal communication). Raclopride alone did not significantly 
affect nicotine-evoked [3H]DA release in synaptosomes or slices. Moreover, in
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synaptosomes in the presence of raclopride, 10 pM bupropion inhibited nicotine-evoked 
[3H]DA release by the same extent as in the absence of raclopride (Fig. 2.10a). In slices, 
however, raclopride reversed the decrease in nicotine-evoked [3H]DA release observed in 
the presence of 0.1 pM bupropion (p<0.05, n = 3), while having no significant effect on the 
diminished response in the presence of 10 pM bupropion (Fig. 2.10b).








0.1pM 0.1pM 10pM 10pM
10nM Rac
£ 120 




co ^  6 0
g? 20
0.1 pM 0.1 pM 10pM 10pM
10nM Rac
10pM Nicotine 10pM Nicotine
Fig. 2.10 C ontribution o f D2 receptors on the in fluence o f bupropion on n icotine- 
evoked [3H]DA release from  striatal synaptosom es (a) and slices (b).
Synaptosomes and slices were loaded with [3H]DA and superfused as described in section 
2.2.1.2. Raclopride (Rac; 10 nM) alone, bupropion (Bup; 0.1 pM or 10 pM) alone, or 
raclopride (10 nM) in combination with bupropion (0.1 pM or 10 pM) were added to the 
perfusing buffer 10 min prior to stimulation with 10 pM nicotine for 40 s; 2 min (1 ml) serial 
fractions were collected and counted for radioactivity. Data were calculated as fractional 
release and are expressed as a percentage of the response to 10 pM nicotine alone 
(control), determined in parallel. Values are the mean ± S.E.M. of at least three separate 
experiments, each consisting of two or more replicate chambers (*p<0.05 significantly 
different from control response, one-way ANOVA with Dunnett’s post-hoc test; #p<0.05, 
significantly different from response in the presence of 0.1 pM bupropion alone, unpaired 
Student’s t-test).
2.3.1.4 Role of ionotropic glutamate receptors and a7 nAChRs on 
bupropion-induced decrease in nicotine-evoked [3H]DA 
release from striatal slices
Previous studies have provided evidence for the indirect modulation of [3H]DA 
release from rat striatal slices through the nicotine-evoked release of glutamate (Kaiser 
and Wonnacott, 2000). To determine if this component is modified in the presence of 
bupropion, two ionotropic glutamate receptor antagonists were compared for their abilities 
to influence the decrease in nicotine-evoked [3H]DA release from striatal slices observed 
in the presence of the lower concentration of bupropion (0.1 pM; Fig. 2.11a).
On its own, the AMPA/kainate receptor antagonist DNQX (100 pM) significantly 
decreased nicotine-evoked [3H]DA release by 32.2 ± 11.2% (p<0.05, n = 5, Fig. 2.11a),
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consistent with a proportion of nicotine-evoked [3H]DA release mediated by the release of 
glutamate from neighbouring terminals. When DNQX and bupropion (0.1 pM) were co­
applied, nicotine-evoked [3H]DA release was reduced by 14.5 ± 9.3%, but this was not 
significantly different from control. In contrast, the NMDA receptor antagonist AP-V (100 
pM), did not significantly affect nicotine-evoked [3H]DA release when applied on its own. 
As the Krebs buffer contained Mg2+ but lacked glycine, NMDA receptors may not have 
been activated (Cheramy et al., 1996). However, in the presence of 0.1 pM bupropion and 
AP-V (100 pM), nicotine-evoked [3H]DA release was decreased by 49.2 ± 9.6% (p<0.05, n 
= 4; Fig. 2.11a). This was not significantly different from the decrease observed in the 
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Fig. 2.11 C ontribution o f ionotropic g lu tam ate receptors (a) and a7  nAC hRs (b) in the  
presence o f 0.1 pM bupropion to  n icotine-evoked [ H]DA release from  striata l slices.
Slices were loaded with [3H]DA and superfused as described in section 2.2.1.2. Bupropion 
(Bup; 0.1 pM) alone, DNQX (100 pM) alone, AP-V (100 pM) alone, or bupropion (0.1 pM) in 
combination with either DNQX (100 pM) or AP-V (100 pM) were added to the perfusing 
buffer 10 min prior to stimulation with 10 pM nicotine for 40 s. For a-bungarotoxin (a-Bgt; 
100 nM), the preincubation time was extended to 1 h. Two min (1 ml) serial fractions were 
collected and counted for radioactivity. Data were calculated as fractional release and are 
expressed as a percentage of the response to 10 pM nicotine alone (control), determined in 
parallel. Values are the mean ± S.E.M. of a t je a s t  three separate experiments, each 
consisting of two or more replicate chambers (*p<0.05 significantly different from control 
response, one-way ANOVA with Dunnett’s post-hoc test; #p<0.05, significantly different from 
response in the presence of 0.1 pM bupropion alone, unpaired Student’s t-test).
The indirect modulation of nicotine-evoked [3H]DA release by glutamate is 
controlled by a7 nAChRs postulated to reside on striatal glutamatergic nerve terminals 
(Kaiser and Wonnacott, 2000). In agreement with this hypothesis, the a7-selective nAChR 
antagonist a-Bgt (100 nM) significantly blocked nicotine-evoked [3H]DA release by 43.7 ± 
13.6% (p<0.05, n = 4; Fig. 2.11b). Co-application of a-Bgt (100 nM) with bupropion (0.1 
pM) resulted in a decrease in nicotine-evoked [3H]DA release of 59.7 ± 10.3% (p<0.05, n 





To examine the initial response to nAChR activation, drug-induced changes in 
fluorescence as an index of [Ca2+]j were measured in SH-SY5Y cells using fluorimetry 
(Dajas-Bailador et al., 2002). Evoked responses in the presence of nomifensine alone, 
bupropion alone, and the combination of nomifensine and bupropion, were examined in 
this cell line. Receptor and VOCC activation was induced by stimulation with nicotine in 
the absence and presence of the above drugs; whilst any effect on VOCC only, was 
examined by stimulation with KCI in the absence and presence of the above drugs.
2.3.2.1 Effect of DA reuptake inhibitors on Ca2+ fluxes in SH-SY5Y
cells
Nomifensine-induced effects on Ca2+ fiuxes in S H -S Y 5Y  celis
Due to the unexpected inhibition by 10 pM nomifensine on nicotine-evoked [3H]DA 
release in rat striatal synaptosomes (Fig. 2.8a), pre-incubation with nomifensine was 
examined for its effects on nicotine- or KCI-evoked changes in fluorescence in SH-SY5Y  
cells (Fig. 2.12). Nomifensine (0.5-10 pM) concentration-dependently inhibited increases 
in fluorescence evoked by 30 pM nicotine, by 19.8 ± 7.9% and 31.3 ± 4.4% (p<0.05, n = 5 
and n = 9) at 1 pM and 10 pM, respectively (Fig. 2.12a). Furthermore, 10 pM nomifensine 
significantly decreased KCI-evoked changes in fluorescence by 14.9 ± 2.3% (p<0.05, n = 
9) (Fig. 2.12b).
Bupropion-induced effects on Ca2+ fluxes in S H -S Y 5Y  cells
To determine the concentrations of bupropion likely to interact directly with 
nAChRs, we examined the same concentrations of bupropion for their effects on nicotine- 
or KCI-evoked changes in fluorescence in SH-SY5Y cells (Fig. 2.13; Dajas-Bailador et al., 
2002). Bupropion resulted in a concentration-dependent inhibition of nicotine-evoked 
increases in fluorescence with blockade of 24.8 ± 4.6%, 30.0 ± 2.9%, 51.1 ± 3.6% and 
93.9 ± 0.8% (p<0.05, n = 5) at 0.1 pM, 0.3 pM, 1 pM and 10 pM bupropion, respectively 
(Fig. 2.13a). Pre-incubation with the general nAChR antagonist mecamylamine (10 pM) 
almost completely prevented the nicotine-evoked increase in fluorescence (94.4 ± 0.8%  
block, p<0.05, n = 4; Fig. 2.13a), confirming that nicotine exerted its effects through 
nAChRs. However, bupropion had no significant effect on increases in fluorescence 
evoked by KCI (Fig. 2.13b). In contrast, the VOCC blocker, cadmium chloride (100 pM), 
inhibited KCI-evoked increases in fluorescence by 89.8 ± 1.1% (p<0.05, n = 4; Fig. 2.13b). 
Data from the pre-incubation with bupropion on nicotine-evoked changes in fluorescence
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in SH-SY5Y cells were fitted to the Hill Equation (see section 2.2.3.2) to give an IC50 value 
of 0.82 ± 0.10 pM bupropion (Fig. 2.13c).
Nom - 0.5 |jM 1pM 10pM Nom - 10pM
30jjM Nicotine 40mM KCI
Fig. 2.12 Effect o f nom ifensine on n icotine- and K C I-evoked increases in fluorescence
in SH-SY5Y cells.
SH-SY5Y cells were loaded with fluo-3 AM and incubated with or w ithout nomifensine (Nom) 
for 10 min before stimulation with 30 pM nicotine or 40 mM KCI. Fluorescence changes at 
20 s after addition of nicotine (a) or KCI (b) were measured and expressed as a percentage 
of the nicotine or KCI control response, measured in parallel in the absence o f nomifensine. 
Values are the mean ± S.E.M. of at least four independent experiments, each carried out in 
quadruplicate (f p<0.05, *p<0.05 significantly different from control response; unpaired 
Student’s t-test, and one-way ANOVA with Dunnett’s post-hoc test, respectively).
Combined effect o f bupropion and nomifensine on Ca2+ fluxes in SH-SY5Y cells
The effect of bupropion (0.1-10 pM) in combination with 10 pM nomifensine on 
nicotine-evoked [3H]DA release in rat striatal synaptosomes (Fig. 2.9a, b) and slices (Fig. 
2.9c, d), illustrated a different effect as compared to that in the presence of bupropion 
alone (Fig. 2.8a, b). Here pre-incubation with increasing concentrations of bupropion (0.1- 
10 pM) in combination with 10 pM nomifensine were examined for their effect on nicotine- 
or KCI-evoked changes in fluorescence in SH-SY5Y cells (Fig. 2.14).
The collective effect of 10 pM nomifensine and bupropion exhibited concentration- 
dependent inhibition of nicotine-evoked increases in fluorescence by 41.6 ± 3.3%, 49.3 ± 
4.7%, 69.9 ± 2.3% and 95.3 ± 0.4% (p<0.05, n = 4) at 0.1 pM, 0.3 pM, 1 pM and 10 pM 
bupropion, respectively (Fig. 2.14a). When the results were expressed as a percentage of 
the response to 30 pM nicotine in the presence of 10 pM nomifensine alone (Fig. 2.14b), 
bupropion maintained its concentration-dependent profile, exhibiting significant inhibition 
by 47.1 ± 4.2% and 91.9 ± 0.6% (p<0.05, n = 4) at 1 pM and 10 pM bupropion, 
respectively.
The combined effect of 10 pM nomifensine and bupropion on KCI-evoked changes 
in fluorescence, exhibited significant inhibition of KCI-evoked increases in fluorescence by 
14.1 ± 4.9%, 20.2 ± 6.2%, 15.0 ± 5.4% and 21.2 ± 4.3% (p<0.05, n = 4), at 0.1 pM, 0.3 
pM, 1 pM and 10pM bupropion, respectively (Fig. 2.14c). However, when the results were
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expressed as a percentage of the response to 40 mM KCI in the presence of 10 pM 
nomifensine alone (Fig. 2.14d), on KCI-evoked changes in fluorescence, bupropion did 
not show any significant change in KCI-evoked increases in fluorescence.
Data from the co-incubation of 10 pM nomifensine and bupropion (0.1-10 pM) on 
nicotine-evoked changes in fluorescence in SH-SY5Y cells, were fitted to the Hill Equation 
(see section 2.2.3.2) to give an IC5o value of 0.24 ± 0.09 pM bupropion (Fig. 2.14e).
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Fig. 2.13 Effect of bupropion on nicotine- and K C I-evoked increases in fluo rescence
in SH-SY5Y cells.
SH-SY5Y cells were loaded with fluo-3 AM and incubated with or w ithout bupropion (Bup; 
0.1-10 pM), mecamylamine (Mec; 10 pM) or cadmium chloride (CdCI2; 100 pM) for 10 min 
before stimulation with 30 pM nicotine or 40 mM KCI. Fluorescence changes at 20 s after 
addition of nicotine (a) or KCI (b) were measured and expressed as a percentage of the 
nicotine or KCI control response, measured in parallel in the absence of bupropion, 
mecamylamine or cadmium chloride. Values are the mean ± S.E.M. o f at least four 
independent experiments, each carried out in quadruplicate (f p<0.05, *p<0 05 significantly 
different from control response; unpaired Student’s t-test, and one-way ANOVA with 
Dunnett’s post-hoc test, respectively). Concentration-response data were fitted to the Hill 
Equation, as described in section 2.2.3.2. The IC50 value for the inhibition by bupropion of 
nicotine-evoked increases in fluorescence (c) was 0.82 ± 0.1 pM.
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Fig. 2.14 C om bined effect o f bupropion and nom ifensine on n icotine- and K CI-evoked  
increases in fluorescence in SH-SY5Y cells.
SH-SY5Y cells were loaded with fluo-3 AM and incubated with or w ithout nomifensine (Nom; 
10 pM) alone, or nomifensine (10 pM) in combination with bupropion (Bup; 0.1-10 pM) for 10 
min before stimulation with 30 pM nicotine or 40 mM KCI. Fluorescence changes at 20 s 
after addition of nicotine (a, b) or KCI (c, d) were measured. Data are expressed as a 
percentage of the response to 30 pM nicotine in the absence (control; a) or presence 
(control; b) of 10 pM nomifensine, or 40 mM KCI in the absence (control; c) or presence 
(control; d) of 10 pM nomifensine, determined in parallel. Values are the mean ± S.E.M. of 
at least four independent experiments, each carried out in quadruplicate (t p<0.05, *p<0.05 
significantly different from control response; unpaired Student’s t-test, and one-way ANOVA 
with Dunnett’s post-hoc test, respectively). Concentration-response data were fitted to the 
Hill Equation, as described in section 2.2.3.2. The IC50 value for the inhibition by bupropion 
in combination with 10 pM nomifensine, of nicotine-evoked increases in fluorescence (e) 




Results presented in this chapter show that 10 pM bupropion decreases nicotine- 
evoked [3H]DA release in both striatal synaptosomes and slices, consistent with the 
blockade of nAChRs. Furthermore, in slices but not in synaptosomes, bupropion produced 
a bell-shaped concentration-response, with inhibition of nicotine-evoked [3H]DA release 
also observed in the presence of 0.1 pM bupropion. Reversal of the latter effect by the D2 
antagonist raclopride leads us to propose that modest blockade of DAT by bupropion 
results in feedback inhibition via D2 receptors. This is overcome at higher concentrations 
of bupropion, before inhibition of nAChR occurs. Nomifensine, on the other hand, 
functions as a DAT blocker, but in the absence of DAT, may inhibit nAChRs and VOCC. 
These findings highlight the important role of in vitro neuronal models in dissecting drug 
pharmacology.
2.4.1 Validity of in vitro superfusion
The regulation of DA release by presynaptic nAChRs in brain preparations has 
been previously reported, using in vitro superfusion (Giorguieff-Chesselet et al., 1979; 
Kaiser et al., 1998; Wonnacott et al., 2000; Grady et al., 2002; Cui et al., 2003; Salminen 
et al., 2004). Further studies using this technique have revealed the presence of a602* 
(Klink et al., 2001; Champtiaux et al., 2003) and a4p2* nAChRs (Sharpies et al., 2000; 
Klink et al., 2001; Champtiaux et al., 2003) on dopaminergic terminals in the striatum.
In the present study, brain preparations were in the form of synaptosomes and 
slices. Synaptosomes retain all features of the intact nerve ending and enable aspects of 
nerve terminal function to be studied in isolation; whilst slices retain local anatomical 
integrity, making the preparation more representative of the intact brain (see section 
2 .1.1.1).
Preliminary results (Fig. 2.5) indicate that nicotine-evoked [3H]DA release from rat 
striatal synaptosomes was robust, reproducible and sensitive to mecamylamine, since 
nicotine-evoked [3H]DA release above basal was almost totally abolished in the presence 
of the general nAChR antagonist (Fig. 2.5a). The concentration-response effect of nicotine 
on [3H]DA release (Fig. 2.5b), which yielded an EC50 value of 4.8 ±0 .1  pM nicotine, was 
comparable to that obtained previously (Prince et al., 1996; Wonnacott et al., 2000), 
thereby confirming the reproducibility of the assay. Mecamylamine (10 pM) blocked a 
range of concentrations of nicotine-evoked [3H]DA release (0.3-100 pM), but failed to do 
so at the highest concentration of nicotine (100 pM), thereby distinguishing nAChR- 
mediated and non-specific [3H]DA release (Fig. 2.5c). Nicotine-evoked [3H]DA release in 
striatal synaptosomes assayed by in vitro superfusion, yielded consistent results within
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and between experiments, hence emphasising the reproducibility of the method. On this 
basis, a concentration-response curve for the effect of nicotine-evoked [3H]DA release in 
striatal slices was not conducted. However, it would have enabled valuable comparisons 
to be made with the effect of nicotine-evoked [3H]DA release in striatal synaptosomes.
2.4.1.1 Significance of [3H]DA release profiles
The superfusion profiles showing the effects of nomifensine (Fig. 2.6) and 
bupropion (Fig. 2.7), on nicotine-evoked [3H]DA release, were a particularly useful process 
of analysis. This method not only illustrated a difference in the effects of the drugs in 
synaptosomes and slices, by showing the variations in evoked and basal [3H]DA release, 
but also illustrated drug effects throughout the course of the experiment. This 
characteristic was not evident in histograms, which quantitatively represented the effects 
of nomifensine and bupropion on nicotine-evoked [3H]DA release (Fig. 2.8). Furthermore, 
normalising the effects of nomifensine (Fig. 2.6b, d) and bupropion (Fig. 2.7b, d) on 
nicotine-evoked [3H]DA release, by expressing the results as a percentage of a fitted 
baseline, clarified any drug-induced effect on basal release. This was particularly 
important when evaluating any inhibitory actions on DAT provoked by either drug 
(discussed in section 2.4.2).
2.4.2 Inhibition of nAChR by DA reuptake blockers
Superfusion of synaptosomes results in the efficient removal of released 
neurotransmitter, due to the continuous flushing by the perfusing buffer flow. This 
minimises DA reuptake, and so application of bupropion produces only a transient 
increase in basal release (Fig. 2.7b). Hence blockade of DAT by bupropion is expected to 
have little discernable impact on the level of nicotine-evoked [3H]DA release measured in 
these experiments (Fig. 2.15). The diminished response in the presence of increasing 
concentrations of bupropion (Fig. 2.8a) is in good agreement with the observations of 
Miller and colleagues (2002) who monitored the effects of bupropion on nicotine-evoked 
[3H]DA release from striatal slices in the presence of nomifensine in the perfusing buffer, 
in order to eliminate any contribution from DAT blockade by bupropion (Miller et al., 2002). 
Indeed a similar inhibition of nicotine-evoked [3H]DA release by 10 pM bupropion was 
observed in striatal slices in the present study (Fig. 2.8b).
The interpretation that inhibition of nicotine-evoked [3H]DA release by bupropion 
reflects the drug’s direct interaction with nAChRs is consistent with its selective inhibition 
of nicotine-evoked increases in fluorescence in SH-SY5Y cells (Figs. 2.13a, 2.16) and 












Fig. 2.15 Model of the actions o f bupropion on n icotine-evoked DA release in striatal
synaptosom es.
Nicotine induces DA release by stimulating a4|32* and a6(32* nAChRs on dopaminergic 
terminals. The continuous removal of released DA under the conditions of superfusion 
minimises DA reuptake by DAT, so that inhibition of DAT by low concentrations of bupropion 
has little impact. Similarly, DA does not accumulate to activate inhibitory D2-autoreceptors. 
At higher concentrations, bupropion inhibits the presynaptic nAChRs, reducing nicotine- 
evoked DA release.
Moreover, this blockade is specific to nAChR sites on dopaminergic terminals in the 
striatum, since bupropion inhibited nicotine-evoked [3H]DA overflow in striatal slices, but 
did not inhibit [3H]DA overflow, evoked by electrical field stimulation (Miller et al., 2002). 
Bupropion interaction with specific nAChR subtypes has been investigated using cell 
expression systems. Bupropion has been reported to inhibit Rb+ efflux through a3(34 
nAChR in SH-SY5Y cells with an I C 50 value of 1.4 pM (Fryer and Lukas, 1999), in good 
agreement with the I C 50 value of 0.8 pM for inhibition of nicotine-evoked increases in 
[Ca2+]i in the same cell line (Fig. 2.13c). ACh-evoked currents in Xenopus oocytes 
expressing a3(32 and a4(32 nAChR were inhibited with I C 5o values of 1.3 pM and 8 pM 
respectively (Slemmer et al., 2000). Failure to displace whole brain [3H]nicotine binding 
sites meant that the inhibition was noncompetitive (Slemmer et al., 2000), although recent 
contrasting findings propose a competitive nature of bupropion inhibition using native 
a3(32* nAChRs (Miller et al., 2002). The subtypes of nAChR expressed on striatal DA 
terminals are heterogeneous, with a4,a5,a6 and/or (33 subunits combined with the 
common (32 subunit (Zoli et al., 2002; Champtiaux et al., 2003; Salminen et al., 2004; Cao 
et al., 2005). Their sensitivity to bupropion is similar to that of a4(32 nAChR, with 
approximately 65% inhibition by 10 pM bupropion (Fig 2.8; Miller et al., 2002). The 
difference in level of nAChR blockade by bupropion in synaptosomes and slices, as 
compared to that in SH-SY5Y cells, may be explained by the variation in composition of
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nAChR subunit combinations that bupropion is likely to interact with: ct4p2, a4a5p2, 
a6p2p3 and a4a6p2p3 in synaptosomes and slices (Wonnacott et al., 2005), versus 
a3p2, a3p4, a3a5p2, a3a5p4 and a3a5p2p4 in SH-SY5Y cells (Fryer and Lukas, 1999; 
Dajas-Bailador et al., 2002).
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Fig. 2.16 Schem atic representation of the actions o f bupropion on [Ca2+]j evoked by
nicotine and KCI in SH -SY5Y  cells.
SH-SY5Y cells express a7 and a3* nAChRs. In the absence of DAT, bupropion blocks 
nAChRs, thereby decreasing [Ca2+]|. It has no effect on VOCC.
It is understood that superfusion of synaptosomes minimises DA reuptake, but 
what could account for the significant inhibition of nicotine-evoked [3H]DA release in the 
presence of nomifensine (Fig. 2.8a), a well defined DAT blocker? Since evoked release 
was calculated as the total radioactivity present under the peak, and as the percentage of 
mean basal release; the significant decrease in [3H]DA release was attributed to the 
narrow peak in the presence of nomifensine, as compared to control (Fig. 2.6b). 
Nomifensine-induced inhibition of nicotine- (~ 30% block) and KCI-evoked (~ 15% block) 
increases in fluorescence in SH-SY5Y cells (Fig. 2.12), was indicative of nAChR and 
VOCC blockade, respectively, by 10 pM nomifensine (Fig. 2.17). Moreover, this level of 
inhibition of nicotine-evoked responses was comparable to the approximate 40% blockade 
of nicotine-evoked [3H]DA release by nomifensine, in synaptosomes (Fig. 2.8a).
The additional inhibition of nicotine-evoked [3H]DA release in synaptosomes (Fig. 
2.9a, b), and nicotine- and KCI-evoked increases in fluorescence in SH-SY5Y cells (Fig. 
2.14) following co-administration of bupropion and nomifensine, as compared to 
bupropion alone or nomifensine alone, may in part be attributed to the inhibition of 
nAChRs in synaptosomes and SH-SY5Y cells, by 10 pM nomifensine alone (Figs. 2.8a,
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2.12), hence masking any effect of bupropion. The effects of bupropion in the combination 
treatments, which are similar to the effects of bupropion alone (Figs. 2.8a, 2.13a, b), are 
revealed when the results are expressed as a percentage of the response to 10 pM 
nicotine in the presence of 10 pM nomifensine alone (Figs. 2.9b, 2.14b, d).
Fig. 2.17 Schem atic  representation o f the actions o f nom ifensine on [C a2+]j evoked by
nicotine and KCI in S H -SY5Y  cells.
SH-SY5Y cells express a l and a3* nAChRs. In the absence of DAT, nomifensine blocks 
nAChRs and VOCC, thereby decreasing [C a 2+]j.
Striatal slice preparations preserve some local anatomical relationships allowing 
the detection of striatal [3H]DA release modulated by nAChR on neighbouring terminals, 
as well as by nAChR on DA terminals. In particular, a7 nAChR have been inferred to 
influence [3H]DA release indirectly, through the release of glutamate (Kaiser and 
Wonnacott, 2000; Hamada et al., 2004). However, we can discount any interaction of 
bupropion with a l  nAChR in the present experiments as a l  nAChR have been shown to 
be much less sensitive to blockade by bupropion (IC50 = 60 pM, Slemmer et al., 2000; 
Alkondon and Albuquerque, 2005). This is consistent with the additivity of the inhibitory 
effects of 0.1 pM bupropion and 100 nM a-Bgt in response to 10 pM nicotine (Fig. 2.11b; 
relevance discussed in section 2.4.3.1).
2.4.3 Non-nAChR-mediated effects of bupropion
In contrast to the study of Miller and colleagues (2002), we did not inhibit DAT prior 










nAChR blockade by bupropion, with respect to nicotine-evoked [3H]DA release in slice 
preparations. Somewhat surprisingly, a low concentration of bupropion (0.1 pM) 
decreased nicotine-evoked [3H]DA release from slices (Fig. 2.8b), whereas blockade of 
DAT would be predicted to result in an increase in extracellular DA, as illustrated by 10 
pM nomifensine (Fig. 2.8b). Reversal of this inhibition by raclopride (which had no effect 
on inhibition in response to 10 pM bupropion attributed to nAChR blockade; Fig. 2.10b) is 
compatible with a modest local increase in [3H]DA due to partial DAT blockade, resulting 
in D2-mediated inhibition of [3H]DA release, revealed as a net decrease in [3H]DA levels 
measured. This is consistent with the disappearance of the effect at higher bupropion 
concentrations (0.3, 1 pM) that would afford a greater degree of DAT inhibition, producing 
higher levels of extracellular [3H]DA that either mask the D2 inhibition or nullify it by 
activation of less sensitive D1 receptors. This interpretation is compatible with the potency 
of bupropion for blockade of DAT (IC50 = 0.6 pM; Hyttel, 1982; Damaj et al., 2004). 
However, the influence of 10 pM nomifensine for DAT inhibition (IC50 = 0.048 pM; Hyttel, 
1982) produced a much higher level of extracellular [3H]DA (Fig. 2.8b) than bupropion, 
and so would be more likely to mask any D2 inhibition and/or activate D1 receptors. This 
hypothesis is consistent with the concentration-dependent increase in nicotine-evoked 
[3H]DA release following co-administration of bupropion and nomifensine in slices (Fig. 
2.9c), where the effect of bupropion (0.1-10 pM) was masked by the influential effect of 
nomifensine.
Why was the decrease in nicotine-evoked [3H]DA by 0.1 pM bupropion observed in 
slices but not synaptosomes? Superfusion is more effective at removing released 
transmitter from isolated nerve terminals than from slices, where some build up within the 
slice is expected to occur. Additionally, D2 receptors residing on neighbouring non- 
dopaminergic terminals could inhibit other transmitters to indirectly regulate DA release in 
slices. D2 receptors reside on glutamatergic terminals (Maura et al., 1988) where they 
may dampen the activity of subsets of corticostriatal inputs (Bamford et al., 2004). 
Moreover, endogenous corticostriatal glutamate release is modulated by D2 receptors 
only under conditions of stimulated and not basal release, suggesting that glutamate is not 
under tonic control by DA (Yamamoto and Davy, 1992). However, 0.1 pM bupropion, the 
concentration provoking the D2 inhibitory response, is insufficient to activate a l  nAChR 
(as revealed by the additivity of the inhibitory effects of 0.1 pM bupropion and 100 nM a- 
Bgt in response to 10 pM nicotine; Fig. 2.11b) and glutamate release (Fig. 2.11a). 
Therefore it is most probable that D2 inhibition of nicotine-evoked [3H]DA release is via 
autoreceptors. This interpretation is consistent with interactions between D2- 
autoreceptors and DAT (Meiergerd et al., 1993), as D2-autoreceptors are also involved in 
controlling DA reuptake (Schmitz et al., 2002; Wu et al., 2002) during neurotransmission 
by partly compensating for the effects of DAT.
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2.4.3.1 Complexity of DA-glutamate interactions in the striatum
The ability of ionotropic glutamate receptors to modulate striatal DA release has 
been reported in both in vitro (Wang, 1991; Desce et al., 1992) and in vivo studies (Sakai 
et al., 1997; Hernandez et al., 2003; Borland and Michael, 2004), and is compatible with 
evidence that glutamate can influence DA release via heteroreceptors on dopaminergic 
terminals (Wang, 1991; Desce et al., 1992). The degree of inhibition of nicotine-evoked 
[3H]DA release seen with DNQX alone (Fig. 2 .11a), an AMPA/kainate receptor antagonist, 
is comparable to that seen previously (Kaiser and Wonnacott, 2000), although in that 
report, [3H]DA release was evoked by anatoxin-a, another nicotinic agonist. There is 
evidence that NMDA receptors also reside on striatal dopaminergic terminals and are 
capable of enhancing DA release (Desce et al., 1992). However, in that study, NMDA 
alone was ineffective, attributed to the Mg2+ block of NMDA receptors, whereas activation 
of AMPA/kainate receptors could overcome this inhibition. It has been proposed that ACh 
or (-)-nicotine, acting at presynaptic nAChRs on dopaminergic terminals, can relieve the 
Mg2+ block of NMDA receptors, to give a synergistic effect on DA release when (-)-nicotine 
and NMDA are co-applied in the presence of glycine (Cheramy et al., 1996), a co-agonist 
of NMDA receptors. Since our experiments were conducted in glycine-free conditions, 
blockade of NMDA receptors by AP-V alone (Fig. 2.11a), failed to affect nicotine-evoked 
[3H]DA release, excluding the involvement of NMDA receptors. However, failure to 
observe an additive effect on the inhibition of nicotine-evoked [3H]DA release following co­
application of DNQX and 0.1 pM bupropion (Fig. 2.11a), together with the significant 
decrease in nicotine-evoked [3H]DA release, when AP-V and 0.1 pM bupropion (Fig. 
2.11a) were co-applied, was somewhat unexpected. Probable reasons for this may be 
attributed to ionotropic glutamate receptors being expressed on non-dopaminergic 
terminals in the striatum (Avshalumov et al., 2003); and possible involvement of mGluRs 
(Zhang and Sulzer, 2003) in regulating DA release in the striatum, thereby emphasising 
the complex network of DA-glutamate interactions.
In the present chapter, the inhibition of nicotine-evoked [3H]DA release seen in the 
presence of a-Bgt alone (Fig. 2.11b), is comparable with previous work (Kaiser and 
Wonnacott, 2000), and consistent with the hypothesis that a7 nAChRs reside on striatal 
glutamatergic terminals to indirectly modulate DA release (Kaiser and Wonnacott, 2000). 
However, the added inhibition of nicotine-evoked [3H]DA release following co-application 
of a-Bgt and 0.1 pM bupropion (Fig. 2.11b), is inconsistent with the presence of D2 
receptors on glutamatergic terminals in the striatum, since co-application of raclopride and 
0.1 pM bupropion (Fig. 2.10b) reversed the decrease in nicotine-evoked [3H]DA release in 
the presence of 0.1 pM bupropion alone. However, since there are two types of cortical 
glutamatergic projections to the striatum: one being the pyramidal tract (PT) -type, which
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contacts the indirect striatopallidal pathway neurones; and the second, referred to as the 
intratelencephalically projecting (IT) -type, which contacts the direct striatonigral pathway 
neurones (Lei et al., 2004), it is possible that D2 receptors may reside on the non-a7* 
nAChR-containing glutamatergic terminals that connect to the indirect pathway neurones 
(Fig. 2.18a), whilst the a l  nAChR-containing glutamatergic terminals that connect to the 
direct pathway neurones, are devoid of D2 receptors (Fig. 2.18b).
2.4.3.2 Putative model for the effects of 0.1 ijM bupropion on 
nicotine-evoked [3H]DA release in slices
The concentration of nicotine (10 pM) used in the present study is likely to activate 
both the direct and indirect pathway neurones (Hamada et al., 2004). Following nicotine- 
evoked [3H]DA release, inhibition of DAT by 0.1 pM bupropion, increases extracellular 
[3H]DA, which may enhance the effects of inhibitory D2-autoreceptors on dopaminergic 
terminals and possibly D2 receptors on neighbouring glutamatergic neurones, with a 
subsequent decrease in [3H]DA release, providing a negative feedback loop in slices, but 
not in synaptosomes (Fig. 2.18a, b). Any interaction of [3H]DA at D2 receptors on PT-type 
glutamatergic neurones would decrease the levels of glutamate released (via a non-a7* 
nAChR-mediated mechanism) for binding at ionotropic glutamate receptors on 
dopaminergic neurones, thereby decreasing the extracellular content of [3H]DA (Fig. 
2.18a).
Nicotine-evoked stimulation of a l  nAChRs on IT-type glutamatergic terminals 
would activate ionotropic glutamate receptors on dopaminergic terminals, with the release 
of glutamate. Interaction of [3H]DA at D2-autoreceptors would dampen the activation of 
ionotropic glutamate receptors on dopaminergic terminals, thus decreasing [3H]DA release 
(Fig. 2.18b). At the high concentration, bupropion (10 pM) would inhibit nAChRs and 
subsequently decrease nicotine-evoked [3H]DA release, through the direct interaction with 
nAChRs on the dopaminergic terminals. Any effect of indirect modulation through the 
release of glutamate would not be prominent, since low quantities of [3H]DA would be 
released in the first instance, and so would not be sufficient to activate the D2 receptor- 
mediated control from neighbouring terminals. On the contrary, the high levels of [3H]DA 
produced following 10 pM nomifensine would mask any effect of D2 receptor modulation, 
due to the potency of nomifensine at DAT (see section 2.4.3). The gradual rise in nicotine- 
evoked [3H]DA release with increasing concentrations of bupropion (0.1-1 pM) in slices 
(Fig. 2.8b), could be due to the increasing effect of bupropion as a DAT blocker, with an 
equilibrium being established between the direct and indirect modulation of [3H]DA 
release. Any concentrations above 1 pM bupropion would produce nAChR inhibition, 
thereby significantly decreasing nicotine-evoked [3H]DA release.
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Fig. 2.18 Putative model of the actions of bupropion on nicotine-evoked DA release in
striatal slices.
Dopaminergic and glutamatergic afferents converge onto the spines of the GABAergic 
neurones. Pyramidal tract (PT) -type glutamatergic projections contact the indirect 
striatopallidal pathway neurones (a) and intratelencephalically projecting (IT) -type
glutamatergic projections contact the direct striatonigral pathway neurones (b). Nicotine also 
evokes DA release indirectly, by acting at a7 nAChR on neighbouring glutamatergic 
terminals, in addition to the stimulation of a4(32* and a6p2* nAChRs on dopaminergic 
terminals. Within the slice DA is removed less effectively and can be taken up by DAT. At 
low concentrations, bupropion inhibits DAT, which increases extracellular DA locally, leading 
to interaction with inhibitory D2-autoreceptors on dopaminergic terminals and possibly with 
inhibitory D2 receptors on neighbouring PT-type glutamatergic terminals. Reduced levels of 
glutamate (Glu) released from PT-type terminals for binding at ionotropic glutamate 
receptors (iGluRs) on dopaminergic neurones, contributes to the net decrease in
extracellular DA (a). Glutamate released following nicotine-evoked stimulation of a7 
nAChRs on IT-type glutamatergic terminals activates ionotropic glutamate receptors on
dopaminergic afferents. Inhibitory D2-autoreceptors dampen the activation of ionotropic
glutamate receptors on dopaminergic terminals, thereby decreasing DA release (b). At 
higher concentrations, bupropion inhibits a4[32* and a6(32* nAChRs, but not a7 nAChR, to 
reduce nicotine-evoked DA release.
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The concept of indirect modulation of [3H]DA release via glutamate secretion is 
only an example, since in reality, the situation will be further complicated by the fact that 
DA release in the striatum, can be influenced by a variety of neurotransmitters. Previous 
studies have demonstrated that activation of 5-HT2C receptors tonically inhibits striatal 
DA release (Di Matteo et al., 2004; De Deurwaerdere et al., 2004; Alex et al., 2005). 
However, where in the brain these receptors are localised is not yet known. Moreover, 
both 5-HT3 receptors, which co-localise with nAChRs on striatal nerve terminals (Nayak et 
al., 2000), and 5-HT4 receptors, selectively modulate DA exocytosis associated with 
increased DA neurone firing rate (De Deurwaerdere et al., 1997; Porras et al., 2002; 
Porras et al., 2003).
2.4.4 Implications for smoking cessation
The range of bupropion concentrations (0.1-10 pM) used in the present chapter is 
consistent with human serum concentrations of bupropion, which can rise to a peak near 
0.5-1.0 pM after oral administration (Hsyu et al., 1997). If these concentrations correlate 
with local concentrations of bupropion in the brain, substantial inhibition of nAChR 
subtypes modulating DA release would not be anticipated to occur, whereas the complex 
behaviour attributed to DAT inhibition and D2 receptor activation would dominate the 
response. However, in vivo the scenario is made more complex by the biological activity 
ascribed to the major metabolite hydroxybupropion, which can reach 10-100 times the 
concentration of the parent compound in the plasma (Hsyu et al., 1997). The active 
isomer, (2S,3S)-hydroxybupropion, preserves the potency of the parent compound with 
respect to inhibition of DAT and blockade of nAChR (Damaj et al., 2004).
The present chapter demonstrates that by employing neuronal models of 
increasing complexity, it is possible to tease out the components underlying the action of 
bupropion on nicotine-evoked [3H]DA release. Inhibition of DAT and blockade of nAChR 
appear to be separated with respect to bupropion concentration, and the latter action is 
likely to be less important at predicted concentrations of bupropion in the brain. The 
results from striatal slice preparations have also revealed an unexpected contribution of 
D2 receptors that can, to some extent, mitigate the effects of DAT inhibition. Thus, these 
comparative experiments provide some useful insights into the mechanisms underlying 
the efficacy of bupropion as an anti-smoking agent. Further investigation of the 
neurochemical interactions of nicotine and bupropion in more physiologically relevant 
models (see Chapter 3) will provide a better understanding of bupropion’s mechanisms of 




Actions of bupropion on nicotinic receptor- 
mediated DA release and locomotor activity
3.1 Introduction
Superfusion of the striatal preparations provided a valuable tool to dissect the in 
vitro pharmacology of bupropion and nicotine, with respect to DA release, in simple yet 
robust neuronal models of increasing complexity (Chapter 2). However, to obtain a better 
understanding of the physiologically relevant neurochemical interactions of these drugs, 
intact neuronal connections in the whole brain are required. Therefore, the effects of 
bupropion on nicotine-evoked DA release are best studied in vivo.
Early attempts to study neurotransmitter function were made using the cortical cup 
(1953) and push-pull (1961) techniques. Although these methods contributed a great deal 
to our knowledge of the chemical environment of the brain, one of their main drawbacks 
was that they involved an open system in which the brain came into direct contact with the 
perfusion fluid. One method which overcame this problem was the introduction of brain 
microdialysis (also known as intracerebral or intracranial dialysis). In this chapter, the 
interaction of bupropion with nicotine-evoked DA release is studied using in vivo 
microdialysis.
3.1.1 In vivo microdialysis
Microdialysis is a powerful and versatile sampling technique by which endogenous 
compounds are continuously monitored in the extracellular fluid of living organisms by 
means of an implanted hollow fibre constructed from dialysis membrane, known as the 
microdialysis probe (Westerink, 1995). In its simplest form, microdialysis provides a “snap 
shot” of the local environment revealing critical features of what a neurochemical system 
looks like before, during and after drug administration or other physiologically relevant 
stimuli (Zhang and Beyer, 2005). Microdialysis was first introduced as early as 1966 by 
Bito and colleagues with the concept of using a dialysis bag to collect samples from the 
brain. Delgado and colleagues (1972) later refined the technique by developing the first 
microdialysis probe in which a solution was slowly perfused through a dialysis bag and 
carried to a site immediately accessible to the experimenter. However, it was Ungerstedt
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and colleagues (1974) who not only improved the design of the microdialysis probe by 
enlarging the surface area of the dialysis membrane thereby increasing the efficiency of 
analyte collection, but also coupled microdialysis sample collection to liquid 
chromatography and electrochemical techniques (Benveniste, 1989).
Microdialysis is now a firmly established method for monitoring neurotransmitter 
levels in the brains of conscious, freely moving animals. Moreover, it is also used to infuse 
drugs into specific brain regions through the microdialysis probe. This process is termed 
retro-dialysis or reverse dialysis. The microdialysis procedure typically involves a 
perfusion fluid (closely resembling endogenous cerebrospinal fluid) that is constantly 
pumped within a dialysis membrane of the probe, which is surgically implanted in the brain 
region of interest. The microdialysis probe acts in a similar manner to a blood capillary, 
sampling the interstitial environment by a process of diffusion along a concentration 
gradient towards and away from the probe (Fig. 3.1). Hence, the flow of the perfusion fluid 
allows small molecules to exchange across the dialysis membrane and the interior fluid, 
termed the dialysate, is removed and externally analysed. The dialysate contains various 
neurotransmitters and their metabolites, as well as metabolic precursors and waste 
products. However, because the dialysate is analysed externally, it can be subjected to a 
variety of chemical separation techniques, providing superb chemical resolution and 
sensitivity that allows unequivocal identification of neurotransmitter. The recovery of 
neurotransmitter and delivery of drugs via the microdialysis probe is dependent on a 
number of variables, including temperature, pH, molecular weight, shape and charge of 
the substance, surface area of the dialysis membrane, the flow of the perfusion fluid, the 
speed of diffusion of the substances through the extracellular fluid and, to a lesser extent, 
the properties of the membrane (see section A1 for further details on microdialysis; 
Benveniste, 1989; Bourne, 2003).
3.1.1.1 Advantages and disadvantages
Microdialysis offers several inherent advantages over other in vivo perfusion 
techniques. For instance, by employing stereotaxic surgery, microdialysis has high 
anatomical precision, enabling small, adjacent structures (such as the core and shell of 
the NAc) to be examined independently. Moreover, simultaneous sampling from multiple 
brain sites is made possible by implanting more than one probe in the same animal. This 
particular advantage allows the effects of chemical stimulation at both cell body and 
terminal regions of specific pathways in the brain to be measured. As the microdialysis 
probe can also be used to infuse drugs directly into specific brain regions, the effects of 
local drug application on neurochemicals in the selected brain regions can be monitored. 
Moreover, this method of drug delivery enables the effects of drugs that do not readily 
cross the BBB to be examined. The microdialysis probe is smaller than devices used for
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cortical cup or push-pull techniques, and thus displaces a smaller area of tissue. The 
dialysis membrane provides a physical barrier between the perfusate and tissue thereby 
protecting the tissue not only from the turbulent flow of the perfusate but also from the 
high molecular weight substances, such as bacteria, which cannot cross the membrane. 
The perfusate flow rate is lower than that used in other perfusion techniques (typically 0.5- 




Fig. 3.1 D iagram m atic  representation of passive transfer o f endogenous substances
into the m icrodialysis probe.
The dialysate flows down the inner of the two concentric tubes of the microdialysis probe 
and exits via a small hole at the bottom of the tube. The direction of flow is then reversed 
and the dialysate flows upwards, past the osmotic membrane, capturing substances that 
have diffused across the semi-permeable membrane, such as neurotransmitters and other 
low molecular weight substances (adapted from Bourne, 2003).
Despite many distinct advantages of microdialysis, it has a few disadvantages too. 
When microdialysis probes are implanted in a specific brain region, they cause damage to 
local tissue or cellular regions that could potentially confound experimental results. 
However, it should be noted that this damage is considered to be minimal and studies 
have shown that the BBB, for example, remains intact following probe implantation 
(Benveniste, 1989). Additionally, local chemical levels and blood flow return to normal 
levels approximately 24 h post probe implantation (Zhang and Beyer, 2005). Microdialysis 
also has the time delay of diffusion (tortuosity) of transmitter from the release site through 
a trauma or damage layer (caused by the large size of the probe) adjacent to the dialysis 
membrane (> 200 pm diameter dialysis tubing is typical). Microdialysis has poor temporal 
resolution and is impractical for dose-response studies. As samples are usually collected 
in time intervals greater than 5 min to provide sufficient sample for analysis, significant 





The only method that is currently an alternative to microdialysis is in vivo 
voltammetry, in which carbon fibre microelectrodes are inserted into selected brain sites. 
The small size of these microelectrodes as compared to microdialysis probes allow a 
much more localised region to be sampled than is possible with microdialysis. Diameters 
of carbon fibres typically range from 5-30 pm with lengths of 100-500 pm (Westerink, 
1995). Voltammetry is excellent for identifying transient changes because it allows real­
time monitoring of brain chemistry (on a scale of seconds, as opposed to minutes in 
microdialysis), thereby providing a higher temporal resolution than microdialysis. 
Voltammetry works by the ability of the working electrode (carbon graphite) to act as an 
oxidising (or reducing) agent, allowing the conversion of oxidisable agents to occur on the 
surface of the electrode (Bourne, 2003). Although this allows successful monitoring of 
catecholamines and their metabolites, and indoleamines, voltammetry is limited to the 
measurement of electroactive molecules only, thus exhibiting poor chemical resolution as
compared to microdialysis. Moreover, other problems with voltammetry include the
sensitivity and stability of signals obtained and the calibration of the microelectrodes. 
Voltammetry is much faster and samples from a smaller region, but is not as sensitive as 
microdialysis. However, the ultimate sensitivity of the microdialysis method is dependent 
on the species monitored and the subsequent methods of analysis.
3.1.1.2 Analysis of microdialysates
Microdialysis is dependent on sensitive analytical methods to measure compounds 
in the dialysate present at very low concentrations (fmol-nmol). Methods including 
fluorescence, ultraviolet and ECD, have been routinely coupled to HPLC for the 
measurement of neurotransmitter concentrations (see section A2 for a detailed 
explanation of HPLC with ECD). HPLC provides the advantages of simplicity and stability, 
making it possible to quantify amino acids, catecholamines, ACh and neuropeptides 
amongst other endogenous substances in the dialysates. As blood cells, proteins and 
other large molecules cannot enter the dialysate (due to the semi-permeable dialysis 
membrane) the samples are automatically cleaned up and injected, without further 
purification, into a HPLC system. By using flexible tubing to connect the microdialysis 
probe in the brain of the experimental animal to a HPLC system, and with the help of 
electronically controlled valves, a completely automated on-line microdialysis system can 
be achieved. An advantage of this approach is that results are available within minutes 
after sampling, thus allowing feed-back handling during the course of the experiment.
Measurement of analytes using HPLC is an indirect method. For example, 
quantification of catecholamines and their metabolites using HPLC with ECD (HPLC-ECD) 
is based on detection of neurotransmitter (or metabolite) oxidation at a carbon-based
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electrochemical detector electrode following separation on an appropriate 
chromatographic column. Problems associated with this type of detection include spurious 
HPLC peaks, lengthy column equilibration time, poor HPLC peak shapes, and co-eluting 
interferences, which affect the overall accuracy of the measurements. Mass spectrometry 
provides a direct measurement of specific analytes (as detection is based on molecular 
weight of the compound) and, depending on the measured analyte, can provide a more 
sensitive platform to monitor some neurochemicals (Zhang and Beyer, 2005).
3.1.1.3 Microdialysis: fact or artefact?
A question raised frequently is whether neurotransmitters sampled by 
microdialysis reflect “true” synaptic release or a more unspecific overflow from synaptic 
and non-synaptic sources. This question has been addressed (Westerink, 2000) by 
examining the two classical criteria of neurotransmitter release: opening of fast Na+ 
channels for the propagation of action potentials, and the Ca2+-dependent exocytotic 
release of neurotransmitter. For the involvement of Na2+ channels, TTX is infused by 
reverse dialysis, whereas Ca2+ dependency is determined by either omitting Ca2+ from the 
perfusion fluid or by infusing Ca2+ channel blockers by reverse dialysis. Indeed, basal 
neurotransmitter output for the catecholamines and ACh have been shown to be TTX- 
sensitive and Ca2+-dependent to an extent, indicative of neuronal transmission (Di Chiara, 
1990). Microdialysis probes do not completely remove all the Ca2+ from the surrounding 
extracellular fluid and so a total inhibition of neurotransmitter release is difficult to achieve. 
However, an almost complete depletion of dialysate neurotransmitter level is achieved 
when Ca2+-blocking ions such as Cd2+, or Ca2+-chealating agents such as EDTA, or high 
Mg2+ concentrations are included in the perfusion fluid (Westerink, 2000). In the case of 
amino acids, basal output has been reported to be TTX-insensitive and Ca2+-independent, 
suggesting that their release is of non-neuronal (possibly glial) origin or independent of 
physiological neuronal activity (Di Chiara, 1990). The use of TTX in determining synaptic 
transmission is controversial because of its ubiquitous effects. To reflect this uncertainty, 
recovered concentrations of neurotransmitter are usually referred to as extracellular 
concentration, not release (Bourne, 2003). Extracellular levels of catecholamine 
metabolites are often difficult to interpret because processes such as synthesis, 
metabolism, conjugation and efflux rate all contribute to the steady state values of these 
metabolites. Therefore, the metabolites are slower indicators of changes in neuronal 
activity and are likely to represent more long-term changes in the release of 
catecholamines (Westerink, 1995).
It is generally believed that brain microdialysis does not directly measure 
neurotransmitter released at synaptic sites, but rather neurotransmitter that has diffused 
into the extracellular space. Hence, the final concentration of neurotransmitter sampled is
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a result of processes such as reuptake, enzymatic degradation and tortuosity. 
Consequently, estimations (based on dialysate data or in vitro recoveries) of the absolute 
concentrations of neurotransmitter in the extracellular fluid are of little relation to its 
concentration in the synaptic cleft. Instead, the relative changes in dialysate 
neurotransmitter concentration are of greater value and are, therefore, usually expressed 
as a percentage of basals.
3.1.2 Aims of this chapter
Microdialysis studies in rodents have been fundamental in demonstrating the 
effects of nicotine on DA release in brain regions of the mesolimbic pathway (refer to 
section 1.4.6). Indeed, nAChR activation by acute systemic administration of nicotine in 
nicotine-naive rats has been shown to stimulate DA transmission in most of these brain 
areas (see section 1.4.6.3). Microdialysis sampling of extracellular DA in the NACcore and 
NACsheii has also revealed the core/shell heterogeneity in response to chronic nicotine 
administration (see section 1.4.6.4). With respect to bupropion, brain microdialysis studies 
have shown that its ability to increase extracellular DA levels in the striatum and NAc after 
acute systemic and local application of bupropion in those particular brain regions is 
attributed to DAT blockade (see section 1.6.2.1).
Animal locomotor studies are commonly used to illustrate a DA-mediated 
behaviour. For example, the locomotor stimulant effects of nicotine are reduced following 
either 6-hydroxydopamine lesions, blockade of DA D1 and D2 receptors by their 
respective antagonists, or blockade of nAChRs in the VTA by DHpE, implicating a role of 
DA in the mesolimbic system for the locomotor stimulating effects of nicotine (Di Chiara, 
2000). In chronically treated rats, nicotine-induced locomotor activity is increased in a 
dose-dependent manner up to a subcutaneous dose of 0.4 mg/kg. If a higher dose (0.8 
mg/kg, s.c) is given, the animals fail to develop tolerance and the activity observed during 
the first 60 min after the injection, although higher than that observed for saline-treated 
controls, is lower than that recorded for rats treated chronically with 0.2 or 0.4 mg/kg 
nicotine (Clarke and Kumar, 1983). Indeed, bupropion administration has also been 
shown to dose-dependently increase locomotor activity in animals (see section 1.6.2.1). 
These hyperlocomotor effects of nicotine and bupropion are comparable to the increased 
extracellular DA levels in the mesolimbic brain areas observed in microdialysis studies.
It is clear from the results obtained in Chapter 2 that bupropion interacts with 
nAChRs to decrease nicotine-evoked [3H]DA release in striatal synaptosomes and slices, 
and concentration-dependently inhibit nicotine-evoked increases in Ca2+ fluorescence in 
SH-SY5Y cells, consistent with nAChR antagonism. Comparable effects have been 
demonstrated in vivo by Slemmer and colleagues (2000), who showed that bupropion
95
Chapter 3
dose-dependently blocks various nicotinic effects (see section 1.6.2.3). However, the 
neurochemical interactions of bupropion with nicotine-evoked DA release have not yet 
been examined in vivo. The present chapter aims to explore this relationship and to see if 
the nAChR-inhibiting property of bupropion observed in Chapter 2, translates in vivo. The 
neurochemical actions of nicotine and bupropion were examined using in vivo 
microdialysis, thereby increasing the level of complexity of the neuronal models employed 
in Chapter 2. Also, behavioural comparisons to these effects were made using locomotor 
activity tests.
Therefore, the particular aims of this chapter are:
- To explore the interactions of bupropion with nicotinic effects in vivo.
- Firstly, by defining the effects of bupropion on rat locomotor activity, to investigate 
any nAChR-blocking action of bupropion on nicotine-induced hyperlocomotion.
- Then, by optimising the concentrations of bupropion and nicotine for 
neurochemical comparisons, to extend the study by examining the effects of 
bupropion on nicotine-evoked DA release using in vivo microdialysis.
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3.2 Materials and Methods
Animals
Male Sprague Dawley rats (250-300 g; University of Bath Animal House breeding 
colony) were used. Prior to the experiments, rats were housed in groups of four per cage 
in a temperature- and humidity-controlled environment with free access to food and water. 
Rats were kept on a 12 h light:dark cycle. All experiments carried out in the present study 
were within the guidelines of the Animals Scientific Procedures Act (1986) and approved 
by Her Majesty’s Government Home Office.
3.2.1 Locomotor activity experiments
Experimental design
Using an appropriate dose of bupropion, obtained from the dose-response effect of 
systemic bupropion on rat locomotor activity (Experiment 1), the effects of systemic 
nicotine with or without bupropion pretreatment (Experiment 2) were examined for rat 
locomotor activity. On the day of the experiment, rats were transferred to the test room 
and placed randomly into individual clear-sided, perspex activity test cages (H. 185 mm x 
W. 265 mm x L. 425 mm) with 22 photocells equally spaced along the outer walls and a 
central light source. Rats were allowed to acclimatise to these conditions for 1 h.
Experiment 1
Following acclimatisation, rats were given an intraperitoneal (i.p.) injection of 10, 30 or 60 
mg/kg bupropion or saline. Horizontal activity was scored automatically by infrared 
detection beams at 20 min intervals for 200 min after the injection.
Experiment 2
Following acclimatisation, rats were given an i.p. injection of 30 mg/kg bupropion or saline. 
After 20 min, rats were challenged with a subcutaneous (s.c.) injection of 0.4 mg/kg 
nicotine or saline. Horizontal activity was scored automatically by infrared detection 
beams at 20 min intervals for 180 min after the second injection.
Bupropion and nicotine were dissolved in 0.9% saline and administered in a 
volume of 1 ml/kg. The pH of all drug solutions was adjusted to pH 7.4 before 




In both experiments, mean activity counts for each treatment group were 
determined at 20 min intervals. All values are mean ± S.E.M. for n = 8 rats per treatment 
group. Any significant dose-response effects of bupropion on rat locomotor activity 
(Experiment 1) were analysed by a one-way ANOVA with a main factor of treatment 
(bupropion vs. saline) and a repeated measurement factor of time (13 bins of 20 min 
each). Statistical comparisons in experiment 2, were carried out by a two-way ANOVA  
with main factors of treatment (saline + nicotine vs. saline + saline, bupropion + saline vs. 
saline + saline, bupropion + nicotine vs. bupropion + saline) and a repeated measurement 
factor of time (13 bins of 20 min each). Where statistical significance was observed in any 
data set, a one-way ANOVA with post hoc Dunnett’s test for multiple comparisons was 
used. A P  value of <0.05 was considered statistically significant. All statistical procedures 
were performed using StatView (v 5.0.1) for Windows.
3.2.2 Microdialysis experiments
Surgery and microdialysis
Rats were anaesthetised with medetomidine (1 mg/kg, i.p.) and ketamine (100 
mg/kg, i.p.) and transferred to a stereotaxic frame (David Kopf, Topanga, USA) with the 
upper incisor bar set at -3.2 mm below the interaural line. Rats were maintained on a 
homoeothermic blanket at 37°C throughout. An incision was made to reveal bregma, from 
which all coordinates were taken. Holes were then drilled for four anchor screws, and 
another for unilateral placement of a concentric microdialysis probe (O.D. 0.30 mm) with 2 
mm exposed Hospal membrane tip (manufactured in house) into the NACcore (coordinates: 
anterior: +1.2 mm; lateral: +2.0 mm; ventral: -7.8 mm; (Paxinos and Watson, 1986). Using 
dental cement, the probe and a tether screw (Instech Soloman, UK) placed posterior to 
the probe, were secured in place, and the wound sealed. Anaesthesia was reversed using 
atipamezole (1 mg/kg, s.c.). Following surgery, rats were individually housed in circular 
chambers (I.D. 395 mm x H. 360 mm) with the microdialysis probe connected to a liquid 
swivel (Instech Soloman, UK) and a counter-balanced arm to allow unrestricted 
movement. Rats were allowed a recovery period of at least 16 h with food and water 
available ad libitum and probes were continuously perfused with artificial cerebrospinal 
fluid (aCSF; 125 mM NaCI, 2.5 mM KCI, 1.18 mM MgCI2, 1.26 mM CaCI2, and 2.0 mM 
Na2H P 0 4, adjusted to pH 7.4 with 100 mM H3P 0 4) at a flow rate of 1.2 pl/min. After this 
period, the experiment started with the collection of samples from freely moving rats at 20 
min intervals into 0.3 ml polypropylene sample vials (HPLC Technology, UK) containing 5 
pi of perchloric acid (0.1 M). Drugs were delivered via the probe or by systemic 




Detection and subsequent quantification of DA in the dialysis samples involved the 
use of reverse-phase, ion-pair HPLC-ECD. Briefly, the method employed a Spherisorb 
(I.D. 100 x 2.1 mm; Higgins Analytical) reverse-phase column packed with 5 pm C i8 silica 
based octa decyl silane (ODS) material. A Bischoff solvent delivery pump with a pulse 
dampener (PD-120625, Presearch Ltd, Herts., UK) was used to circulate mobile phase 
(100 mM NaH2P 0 4, 1 mM EDTA, 1 mM octane sulphonic acid, 12% methanol, pH 4.0) at 
a flow rate of 0.2 ml/min. The mobile phase was filtered through a 0.22 pm filter (Millipore, 
Bedford, USA) and degassed under vacuum. DA concentrations in the dialysate samples 
and standards (each 20 pi) were determined by injection onto the column via a 
refrigerated (4°C) Triathlon autosampler. The standards were prepared daily from a stock 
solution of DA (1 mM) in a 1:1 mixture of deionised water and 0.1 M perchloric acid, 
stored at 4°C. Antec-lntro (Leyden, Netherlands) electrochemical detector was used in 
conjunction with an Antec “wall-jet” design cell (VT-03). The cell employs a high density, 
glassy carbon working electrode (+0.60 V) combined with an Ag/AgCI reference electrode. 
The electrode signal was integrated using a PowerChrom data acquisition system 
(ADInstruments, Oxfordshire, UK). The detection limit for DA was 1 fmol on column (see 
section A2 for the optimisation of the HPLC system).
Optimisation of nicotine and bupropion concentrations
To achieve a local concentration of 10 pM nicotine, consistent with the in vitro 
experiments (see section 2.3.1.2), 100 pM nicotine was selected for local application into 
the NACcore, on the basis that approximately 10% of drug crosses the dialysis membrane 
(see section A1.3). Hence, a preliminary experiment was conducted where rats received a 
local infusion of 100 pM nicotine into the NAcCOre, via the microdialysis probe, by addition 
to the aCSF. Control rats were infused with aCSF only.
To obtain a detectable increase in dialysate D A  in the N A c COre following nicotine 
administration, another preliminary experiment was conducted where rats received a local 
infusion of 3 mM nicotine by reverse dialysis. This concentration of nicotine was selected 
on the basis of previous work (Marshall et al., 1997). Control rats were infused with aCSF 
only.
To minimise the use of rats, two concentrations of bupropion (1, 100 pM) were 
infused locally into the NAcCOre of the same rat over different time points. These 
concentrations were selected on the basis of a 10% bioavailability when administered by 
reverse dialysis (see section A1.3), thereby achieving a local concentration of 0.1 pM and 
10 pM bupropion, respectively, since the in vitro studies revealed that 0.1 pM and 10 pM 
bupropion exhibited significant differences in nicotine-evoked [3H]DA release (Fig. 2.8b). 
Therefore, a preliminary experiment was carried out where rats received local infusions of 
1 pM bupropion followed by 100 pM bupropion with or without a recovery period. The
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recovery period was defined as the time in between the administration of 1 pM and 100 
pM bupropion, where no drug was given.
Experimental design
The effects of systemic bupropion (Experiment 3) and local bupropion, given via 
the microdialysis probe (Experiment 4), were compared with respect to DA release 
evoked by local administration of nicotine. For both experiments, rats were assigned to 
one of four treatment groups. One group was administered bupropion and nicotine; 
another group received bupropion alone; an additional group was given nicotine aione; 
and the final group had received vehicle only. Four basal samples were taken from each 
group, before rats were subjected to the microdialysis experiments.
Experiment 3
Bupropion was prepared as previously described for locomotor activity experiments and 
administered by i.p. injection. Nicotine was applied locally into the NAcCOre, via the 
microdialysis probe, by addition to the aCSF. Rats received the drugs based on the 
following regime:
- Group 1: at t = 0 min, 30 mg/kg bupropion; at t = 40 min, 3 mM nicotine (for 20 
min).
- Group 2 : at t = 0 min, 30 mg/kg bupropion.
- Group 3 : at t = 0 min, saline; at t = 40 min, 3 mM nicotine (for 20 min).
- Group 4 : at t = 0 min, saline.
Experiment 4
Bupropion and nicotine were applied locally into the NAcCOre, via the microdialysis probe, 
by addition to the aCSF. Rats received the drugs based on the following regime:
- Group 1: at t = 20 min, 1 pM bupropion (for 140 min); at t = 80 min, 3 mM nicotine
and 1 pM bupropion (for 20 min); at t = 160 min, 100 pM bupropion (for 140 min);
at t = 220 min, 3 mM nicotine and 100 pM bupropion (for 20 min).
- Group 2 : at t = 20 min, 1 pM bupropion (for 140 min); at t = 160 min, 100 pM
bupropion (for 140 min);
- Group 3 : at t = 80 and 220 min, 3 mM nicotine (for 20 min);
- Group 4 : untreated control rats received neither drug.
In both experiments dialysates were sampled for 280 min following basal sample 
collection. There were no artefacts associated with the procedure of changing from a 




After completion of the final experiment, rats were killed with a lethal dose of 
pentobarbital (i.p.) followed by cervical dislocation, and their brains rapidly removed and 
stored in 4% paraformaldehyde in phosphate buffer for a minimum of 5 days. Serial 
coronal sections (100 pm thick) were cut using a vibratome and histological verification of 
probe placement was confirmed with reference to a stereotaxic atlas (Paxinos and 
Watson, 1986). Data are reported only from animals where probe membranes were 
correctly positioned in the N A c C0re- Fig- 3 .2  depicts a typical location of the dialysis 
membrane in the N A c COre-
core
Fig. 3.2 Typical location o f a m icrodialysis probe m em brane in the N AcC0re-
Probe tract can be seen in the right hemisphere, compared to the left (control) hemisphere, 
which had no surgical manipulation. NAcC0re is outlined.
Data analysis
All data shown are mean ± S.E.M. values for at least n = 6 rats per treatment 
group. In all experiments, basal release measured in four consecutive samples before 
drug application was averaged and defined as 100%. Results for subsequent samples 
were calculated as percentages of this average basal release. Data from the optimisation 
experiments were analysed using a one-way ANOVA with main factors of treatment (100 
pm nicotine vs. aCSF; 3 mM nicotine vs. aCSF; bupropion with recovery period vs. 
bupropion without recovery period) and a repeated measurement factor of time (18 bins of 
20 min each). Data generated from experiments 3 and 4 were analysed using a two-way 
ANOVA with main factors of treatment (Experiment 3: bupropion + aCSF vs. saline + 
aCSF, bupropion + nicotine vs. saline + nicotine; Experiment 4: nicotine vs. aCSF, 
bupropion + nicotine vs. bupropion alone) and a repeated measurement factor of time (18 
bins of 20 min each). In both experiments, to test the effect of drug against its own basal 
DA levels, repeated measures ANOVA were carried out with “time” as the “within- 
subjects” factor. Where statistical significance was observed in any data set, a one-way
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ANOVA with post hoc Dunnett’s test for multiple comparisons was used. A P  value of 
<0.05 was considered statistically significant. All statistical procedures were performed 
using StatView (v 5.0.1) for Windows.
Drugs and reagents
(-)-Nicotine hydrogen tartrate, bupropion hydrochloride, DA and paraformaldehyde 
were purchased from Sigma-Aldrich Co. Ltd (Gillingham, Dorset, UK). All reagents used in 
HPLC analysis were of HPLC grade. EDTA, methanol, KCI, MgCI2, Na2H P 0 4 and H3P 0 4 
were purchased from Fisher Scientific Ltd (Loughborough, Leics., UK). NaCI, CaCI2, 
NaH2P 0 4, octane sulphonic acid and perchloric acid were obtained from VW R  




3.3.1 Locomotor activity experiments
3.3.1.1 Locomotor effects of bupropion -  Experiment 1
In order to establish a dose of systemically administered bupropion that was likely 
to evoke a significant detectable increase in extracellular DA in the NAcCOre, in future 
microdialysis experiments, the effect of systemic bupropion (10, 30, 60 mg/kg, i.p.) was 
examined for rat locomotor activity, a DA-mediated behaviour (see section 3.2.1).
Although not significant, rats exhibited a brief period of activity following the saline 
injection (Fig. 3.3). Bupropion (10-60 mg/kg) increased rat locomotor activity, with 30 and 
60 mg/kg bupropion producing a significant increase in locomotion ([F(36, 336) = 8.476, 
p<0.0001]), compared to saline-treated controls over a 200 min post-treatment period 
(Fig. 3.3). The maximal increase in locomotor activity was observed at 20 min following 30 
mg/kg bupropion (+352 ± 91%, p<0.001, n = 8) and 60 mg/kg bupropion (+341 ± 64%, 
p<0.001, n = 8), compared to saline-treated controls. Locomotor activity remained 
significantly elevated for up to 80 and 200 min following 30 and 60 mg/kg bupropion, 
respectively.
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Fig. 3.3 Effect of bupropion on rat locom otor activity.
Rats were individually placed in activity test cages for a 60 min acclimatisation period, after 
which they were injected intraperitoneally with bupropion (10, 30, 60 mg/kg) or saline. 
Locomotor activity was recorded automatically by infrared detection beams at 20 min 
intervals. Data represent the mean ± S.E.M. locomotor counts, calculated from eight rats per 
treatment group. To test for a significant difference from saline-treated (control) rats, data 
were analysed using a one-way ANOVA with repeated measures and Dunnett’s post-hoc test 
(**p<0.01, ***p<0.001 for 30 mg/kg bupropion vs. saline; f p<0.05, m p<0.001 for 60 mg/kg 
bupropion vs. saline). There was no significant difference in the activity after 10 mg/kg 








3.3.1.2 Locomotor effects of bupropion and nicotine in 
combination -  Experiment 2
Rat locomotor activity was examined for the effects of bupropion on nicotine- 
induced hyperlocomotion. Using the median dose of bupropion from experiment 1 (30 
mg/kg) because it produced hyperlocomotion followed by a steady-state decline in activity 
to saline-treated control levels, rats were pretreated with 30 mg/kg bupropion (i.p.) and 
challenged with an acute injection of nicotine (0.4 mg/kg, s.c.) after 20 min.
As in experiment 1, rats exhibited a brief period of activity following the saline 
injections (Fig. 3.4) but this failed to reach significance. Compared to saline-treated
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Fig. 3.4 C om bined effect o f bupropion and nicotine on rat locom otor activity.
Rats were individually placed in activity test cages for a 60 min acclimatisation period, after 
which they were injected intraperitoneally with 30 mg/kg bupropion or saline (injection 1). After 
20 min, rats were challenged with a subcutaneous injection of 0.4 mg/kg nicotine or saline 
(injection 2). Locomotor activity was recorded automatically by infrared detection beams at 20 
min intervals. Data represent the mean ± S.E.M. locomotor counts, calculated from eight rats 
per treatment group. To test for a significant difference from control rats, data were analysed 
using a two-way ANOVA with repeated measures and Dunnett’s post-hoc test (AAAp<0.001 for 
Saline + 0.4 mg/kg Nicotine vs. Saline + Saline; *p<0.05, **p<0.01, ***p<0.001 for 30 mg/kg 
Bupropion + Saline vs. Saline + Saline; t p<0.05, n p<0.01 for 30 mg/kg Bupropion + 0.4 mg/kg 
Nicotine vs. 30 mg/kg Bupropion + Saline). There was no significant difference in the activity 
of the different groups of rats during the acclimatisation period.
controls, systemic nicotine significantly increased locomotor activity ([F(1, 28) = 4.923, 
p<0.05]), with peak locomotion observed at 20 min following the nicotine challenge (+917 
± 382%, p<0.001, n = 8). Nicotine-induced hyperlocomotion returned to saline-treated 
control values over the next 20 min (Fig. 3.4). In the absence of nicotine, bupropion 
significantly increased locomotion ([F(1, 28) = 64.714, p<0.0001 ]), compared to saline- 
treated controls over a 200 min post-bupropion period (Fig. 3.4). Maximal locomotor 
activity was observed at 20 min following bupropion pre-treatment (+402 ± 82%, p<0.001,
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n = 8), compared to saline-treated controls. Post-bupropion, locomotor activity remained 
significantly elevated for up to 120 min. Compared to bupropion alone, nicotine 
significantly enhanced bupropion-induced hyperlocomotion (Fig. 3.4; [F(12, 336) = 2.785, 
p<0.001]). Optimal locomotor activity was observed at 20 min following the nicotine 
challenge (+170 ± 29%, p<0.05, n = 8), compared to bupropion-treated controls. Post­
nicotine, locomotor activity remained significantly elevated for up to 120 min.
3.3.2 Microdialysis experiments
3.3.2.1 Optim isation of nicotine and bupropion concentrations
To investigate the effects of presynaptic nAChRs in the NAcC0re, extracellular levels 
of DA were examined following local application of 100 pM nicotine in the NAcCOre, by 
reverse dialysis. For the current preliminary experiment, the mean ± S.E.M. basal levels of 
DA were 50.2 ± 0.7 fmol/20 pi (n = 16). These data have not been corrected for recoveries 
across the dialysis membrane. Compared to aCSF controls, 100 pM nicotine (Fig. 3.5; t = 
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Fig. 3.5 Effect of local application of 100 pM nicotine on extracellular DA levels in the
N A C c o re *
Rats were prepared for microdialysis as described in section 3.2.2; 20 min (24 pi) serial 
fractions were collected and quantified for DA levels using HPLC with electrochemical 
detection. After collection of four stable baseline samples, rats were locally infused, via the 
microdialysis probe, with aCSF in the absence and presence of 100 pM nicotine. DA release 
is expressed as a percentage of mean ± S.E.M. basal release from at least seven rats per 
treatment group. To test for a significant difference from control (aCSF) response, data were 




Since 100 |j M nicotine was unsuccessful in increasing extracellular D A  in the 
NACcore, the effect of local infusion of 3 mM nicotine, via the microdialysis probe, was 
examined in the N A c C0re- The concentration of nicotine (3 mM) infused by reverse dialysis 
was selected on the basis of previous work (Marshall et al., 1997), which showed a 
significant increase in D A  levels following nicotine administration in the N A c, by reverse 
dialysis. For this preliminary experiment, the mean ± S.E.M. basal levels of D A  were 55.6 
± 1.6 fmol/20 pi (n = 16). These data have not been corrected for recoveries across the 
dialysis membrane. Local infusion of 3 mM nicotine (Fig. 3.6; t = 80-100 min) in the 
N A c Core, significantly increased extracellular D A  levels, compared to aCSF controls ([F(17, 
187) = 5.964, p<0.0001]). Peak DA levels (t = 100 min) were 202 ± 34% (p<0.05, n = 7-9) 
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Fig. 3.6 Effect of local application of 3 mM nicotine on extracellular DA levels in the
NAcC0re.
Rats were prepared for microdialysis as described in section 3.2.2; 20 min (24 pi) serial 
fractions were collected and quantified for DA levels using HPLC with electrochemical 
detection. After collection of four stable baseline samples, rats were locally infused, via the 
microdialysis probe, with aCSF in the absence and presence of 3 mM nicotine. DA release is 
expressed as a percentage of mean ± S.E.M. basal release from at least seven rats per 
treatment group. To test for a significant difference from control (aCSF) response, data were 
analysed using a one-way ANOVA with repeated measures and Dunnett’s post-hoc test 
(*p<0.05 for Nicotine vs. aCSF). Basal levels of DA were 55.6 ± 1.6 fmol/20 pi.
Rats, with bupropion (1, 100 pM) infused locally into the NAcC0re by reverse 
dialysis, were compared for any changes in extracellular DA levels following bupropion 
administration with or without a recovery period. For this preliminary experiment, the mean 
± S.E.M. basal levels of DA were 25.4 ± 1.0 fmol/20 pi (n = 14). These data have not been 
corrected for recoveries across the dialysis membrane. Extracellular DA levels in the 
NACcore following local infusion of bupropion (1, 100 pM) administered with a recovery 
period (1 pM bupropion t = 20-140 min; 100 pM bupropion t = 240-360 min; Fig. 3.7) were 
not significantly different to those obtained when bupropion (1, 100 pM) was infused
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without a recovery period (1 pM bupropion t = 20-140 min; 100 pM bupropion t = 160-280 
min; Fig. 3.7; [F(17, 85) = 1.531, p>0.05]).
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Fig. 3.7 Effect o f locally adm inistered bupropion on extrace llu lar DA levels in the
NAcC0re.
Rats were prepared for microdialysis as described in section 3.2.2; 20 min (24 pi) serial 
fractions were collected and quantified for DA levels using HPLC with electrochemical 
detection. After collection of four stable baseline samples, rats were locally infused, via the 
microdialysis probe, with aCSF in the presence of 1 pM bupropion followed by 100 pM 
bupropion with or without a recovery period. DA release is expressed as a percentage of 
mean ± S.E.M. basal release from at least seven rats per treatment group. To test for a 
significant difference between each treatment measure, data were analysed using a one-way 
ANOVA with repeated measures. Basal levels of DA were 25.4 ± 1.0 fmol/20 pi.
3.3.2.2 System ic effects of bupropion on nicotine-evoked DA
release -  Experim ent 3
To investigate the effects of bupropion on nicotine-evoked DA release as a result 
of pharmacological interactions at both cell body and terminal regions of the mesolimbic 
dopaminergic pathway, bupropion (30 mg/kg, i.p.) was administered systemically followed 
by nicotine (3 mM), applied locally, via the microdialysis probe, in the NAcC0re- The 
concentration of nicotine (3 mM) infused via the microdialysis probe was selected on the 
basis of preliminary experiments (see section 3.3.2.1) and previous work (Marshall et al., 
1997). For this experiment, the mean ± S.E.M. basal levels of DA were 25.8 ± 0.4 fmol/20 
pi (n = 37). These data have not been corrected for recoveries across the dialysis 
membrane.
In the absence and presence of nicotine, 30 mg/kg bupropion (Fig. 3.8a, b), 
significantly increased extracellular DA levels compared to basal values ([F(5, 17) = 6.598, 
p<0.0001]; [F(7, 17) = 17.569, p<0.0001], respectively). Peak DA levels (t = 60 min) in the 
absence and presence of nicotine were 113 ± 16% (p<0.01, n = 8) and 294 ± 50% 
(p<0.05, n = 9), respectively, above basal values. DA levels returned to basal values over
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the next 20-40 min. Compared to saline-treated controls, bupropion significantly increased 
extracellular DA ([F(1, 24) = 8.774, p<0.01]) between t = 40-120 min (Fig. 3.8a). 
Compared to nicotine-treated controls, bupropion (Fig. 3.8b) enhanced nicotine-induced 
increases in extracellular DA ([F(17, 408) = 6.235, p<0.0001]). Raised DA levels were 
maintained between t = 40-60 min, with an average increase in DA of 122 ± 26% (p<0.05, 
n = 8-9) above nicotine-treated controls (Fig. 3.8b). Although not recorded as a criterion, 
rats that received bupropion (30 mg/kg, i.p.) with or without nicotine (3 mM) showed 
increased motor activity for a period of approximately 20-40 min, after being injected. The 
type of behaviour displayed was primarily grooming and investigating the surrounds of the 
microdialysis cage.
Local infusion of 3 mM nicotine (Fig. 3.8b; t = 40-60 min) in the NAccore, 
significantly increased extracellular DA levels, compared to basal values ([F(6, 17) = 
8.238, p<0.0001]), and compared to non-drug controls ([F(1, 24) = 5.506, p<0.05]). Peak 
DA levels (t = 60 min) were 126 ± 35% (p<0.01, n = 8) above basal values, similar to 
values observed previously (Fig. 3.6). DA levels returned to basal values over the next 20- 
40 min.
a. Systemic Saline + Local aCSF 
■ Systemic Bupropion + Local aCSF
b. Systemic Saline + Local Nicotine 
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Fig. 3.8 Effect of systemic bupropion on nicotine-evoked DA release in the NAcC0re-
Rats, allocated to one of four treatment groups, were prepared for microdialysis as described 
in section 3.2.2; 20 min (24 pi) serial fractions were collected and quantified for DA levels 
using HPLC with electrochemical detection. After collection of four stable baseline samples, 
two groups of rats were injected intraperitoneally with saline or 30 mg/kg bupropion followed 
by a local infusion of aCSF, delivered via the microdialysis probe (a). Another two groups of 
rats were injected intraperitoneally with saline or 30 mg/kg bupropion followed by a local 
infusion of aCSF in the presence of nicotine, delivered via the microdialysis probe (b). DA 
release is expressed as a percentage of mean ± S.E.M. basal release from at least eight rats 
per treatment group. To test for a significant difference from basal values, data were analysed 
using repeated measures ANOVA and Dunnett’s post-hoc test [(a) n p<0.01 for Systemic 
Bupropion + Local aCSF vs. basals; (b) n p<0.01 for Systemic Saline + Local Nicotine vs. 
basals, Ap<0.05, AAp<0.01 for Systemic Bupropion + Local Nicotine vs. basals]. To test for a 
significant difference from control response, data were analysed using a two-way ANOVA with 
repeated measures and Dunnett’s post-hoc test [(a) *p<0.05 **p<0.01, ***p<0.001 for 
Systemic Bupropion + Local aCSF vs. Systemic Saline + Local aCSF; (b) *p<0.05, **p<0.01 
for Systemic Bupropion + Local Nicotine vs. Systemic Saline + Local Nicotine]. Basal levels of 
DA were 25.8 ± 0.4 fmol/20 pi.
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3 .3 .2 .3  Local effects o f bupropion and nicotine on extracellu lar DA 
levels -  Experim ent 4
In this experiment, both drugs were applied locally, via the microdialysis, probe to 
iinvestigate the effects of bupropion-nicotine interactions within the NAcC0re- Two 
concentrations of bupropion (1, 100 pM), administered without a recovery period (see 
section 3.3.2.1), were tested in the same rat over different time points for a total sample 
collection period of 360 min. For this experiment, the mean ± S.E.M. basal levels of DA 
v/vere 37.9 ± 0.2 fmol/20 pi (n = 31). These data have not been corrected for recoveries 
across the dialysis membrane.
Local application of 3 mM nicotine in the absence of bupropion (Fig. 3.9a; t = 80- 
1100 min, t = 220-240 min), significantly increased extracellular DA levels, compared to 
basal values ([F(6, 17) = 3.253, p<0.001]), and compared to non-drug controls ([F(17, 
204) = 3.341, p<0.0001]). Peak DA levels (t = 120 and t = 260 min) were 56 ± 24% 
(p<0.05, n = 8) and 69 ± 29% (p<0.01, n = 8) respectively, above basal values. DA levels 
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Fig. 3.9 Effect of locally administered bupropion and nicotine on DA release in the
NACcore-
Rats, allocated to one of four treatment groups, were prepared for microdialysis as described 
in section 3.2.2; 20 min (24 pi) serial fractions were collected and quantified for DA levels 
using HPLC with electrochemical detection. After collection of four stable baseline samples, 
rats were locally infused, via the microdialysis probe, with aCSF in the absence and presence 
of 3 mM nicotine (a) or 1 pM and 100 pM bupropion in the absence and presence of 3 mM 
nicotine (b; note increased scale on y-axis). DA release is expressed as a percentage of mean 
± S.E.M. basal release from at least seven rats per treatment group. To test for a significant 
difference from basal values, data were analysed using repeated measures ANOVA and 
Dunnett’s post-hoc test [(a) fp<0.05, n p<0.01 for Nicotine vs. basals; (b) t1p<0.01 for 
Bupropion + Nicotine vs. basals, *p<0.05, **p<0.01 for Bupropion vs. basals]. To test for a 
significant difference from control response, data were analysed using a two-way ANOVA with 
repeated measures and Dunnett’s post-hoc test [(a) *p<0.05 for Nicotine vs. aCSF], Basal 
levels of DA were 37.9 ± 0.2 fmol/20 pi.
In the absence of nicotine, 100 pM bupropion (Fig. 3.9b) significantly increased 
extracellular levels of DA compared to basal values ([F(3, 17) = 13.850, p<0.0001]), but 1
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pM bupropion (t = 20-140 min) failed to produce any significant elevation. Following 100 
pM bupropion, raised DA levels were maintained between t = 180-280 min, with an 
average increase in DA of 554 ± 23% (p<0.05, n = 7) above basal values. Compared to 
non-drug controls, both 1 pM and 100 pM bupropion increased extracellular levels of DA 
([F(6, 72) = 4.409, p<0.001]; [F(6, 66) = 6.038, p<0.0001], respectively). Although not 
recorded as a standard measure, rats infused with 100 pM bupropion, but not 1 pM 
bupropion, with or without nicotine (3 mM) displayed heightened motor activity, similar to 
that seen in experiment 3 following systemic bupropion (30 mg/kg). The increased 
behavioural response was maintained during infusion of 100 pM bupropion (t = 180-280 
min). There was no main effect of treatment, following nicotine co-application (Fig. 3.9b) 
with either 1 pM bupropion ([F(6, 60) = 1.742, p>0.05]) or 100 pM bupropion ([F(6, 66) = 
0.537, p>0.05]). Even though 1 pM bupropion and nicotine (t = 20-140 min) failed to 
induce any significant rise in extracellular DA, 100 pM bupropion and nicotine (Fig. 3.9b) 
significantly increased extracellular levels of DA ([F(5, 17) = 23.919, p<0.0001]), 
compared to basal values. The average increase in DA (t = 180-280 min) was 554 ± 28%  




The main objective of the present chapter was to probe the putative antagonistic 
actions of bupropion upon in vivo effects of nicotine in rats. Bupropion failed to exhibit any 
efficacy as a nAChR antagonist. Moreover, the weak DA reuptake blocking actions of 
bupropion were inferred to explain some of the augmented effects of nicotine produced by 
this antidepressant. Unlike conventional nAChR antagonists, such as mecamylamine or 
DH|3E, that typically decrease nicotine-induced activation of dopaminergic effects 
(Marshall et al., 1997; Grottick et al., 2000), bupropion pre-treatment slightly enhanced 
nicotine-evoked DA release (Fig. 3.8) and nicotine-induced hyperlocomotion (Fig. 3.4), 
which was consistent with an absence of bupropion effect as a nicotinic antagonist.
3.4.1 In vivo microdialysis: methodological aspects
Local infusion of bupropion in the NAcCOre without a recovery period was selected 
as the appropriate paradigm, as similar levels of extracellular DA were obtained when 
bupropion was infused with or without a recovery period (Fig. 3.7). The significant 
increase in extracellular DA levels observed following local infusion of 100 pM bupropion 
(Fig. 3.9b) was in line with previous work (Nomikos et al., 1990). However, in that study, 
bupropion (100 pM) was infused locally in the rat striatum, which encompasses the 
caudate-putamen and NAcCOre (see section 1.4.5.2; Voorn et al., 2004). With a KjOf 0.6 pM 
for DA reuptake (Hyttel, 1982; Richelson and Pfenning, 1984) and assuming a 10% 
bioavailability of bupropion when given by reverse dialysis (see section A1.3; 1 pM 
bupropion infusion = 0.1 pM extracellular bupropion), it is not surprising that 1 pM 
bupropion (Fig. 3.9b) did not significantly elevate extracellular DA. At 1 pM, there is little 
possibility of sufficient bupropion being present in the NAccore to block DAT. Furthermore, 
the distance for bupropion to diffuse within the NAccore, after passing through the dialysis 
membrane, may also influence the result.
Since acute systemic administration of nicotine in rats that are naive to the 
alkaloid, does not increase dialysate DA in the NAcCOre (Nisell et al., 1997; Di Chiara, 2000; 
lyaniwura et al., 2001), the present study measured dialysate DA levels from the NAccore 
following local infusions of nicotine (Figs. 3.8b, 3.9a), via the microdialysis probe. This 
method permitted the stimulation of presynaptic nAChRs in the NAcCOre, without any 
contribution from nAChRs in the cell body regions of the mesolimbic dopaminergic 
pathway. As local infusion of 100 pM nicotine in the NAcCOre failed to increase extracellular 
DA (Fig. 3.5), 3 mM nicotine was selected for local application, via the microdialysis 
probe. The rise in extracellular DA levels observed after the local application of 3 mM 
nicotine (Figs. 3.6, 3.8b, 3.9a) was consistent with previous work (Marshall et al., 1997).
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However, in that study, nicotine (3 mM) was infused locally in the NAc, without 
differentiating between NAcCOre and NAcSheii- The study also revealed that at 3 mM nicotine, 
evoked increase in DA release was abolished by the prior administration of 
mecamylamine, via the microdialysis probe, confirming the mediation of nAChRs 
(Marshall et al., 1997). Two successive local applications of 3 mM nicotine in the NAcC0re 
(Fig. 3.9a) gave similar increases in extracellular DA (56 ± 24%, 69 ± 29% above basal 
values) suggesting that there was no evidence of an elevation or reduction in DA efflux 
after the second nicotinic challenge. Confirmation that nicotine-evoked increases in 
extracellular DA returned to baseline levels was depicted (Fig. 3.6).
3.4.2 Differences in pharmacological interactions of 
nicotine and bupropion: systemic vs. local 
administration
Systemic administration of drug, compared to local application of drug, closely 
resembles a more physiological state, since the former allows for cell body regulation of 
neuronal firing and neurotransmitter efflux (Ferrari et al., 2002). Hence, the effects of 
systemic bupropion (Figs. 3.3, 3.4, 3.8a, b) or nicotine (Fig. 3.4) would be under cell body 
control, whilst those of local bupropion (Fig. 3.9b) or nicotine (Figs. 3.8b, 3.9a) in the 
NAcCore, would not. This can explain why the effects of systemic bupropion and local 
application of nicotine in the NAcCOre (Fig. 3.8b), were significantly different to those of 
systemic bupropion in the absence of local nicotine (Fig. 3.8a), whereas, the combination 
of bupropion and nicotine applied locally into the NAcC0re (Fig. 3.9b), failed to show any 
significant difference to the effects of bupropion in the absence of nicotine (Fig. 3.9b).
It is interesting to note that bupropion evoked a transient increase followed by a 
swift decline (similar to the effects of a releasing agent) in extracellular DA when 
administered systemically (Fig. 3.8a, b), compared to a sustained increase (similar to the 
effects of a reuptake inhibitor) when applied locally in the NAcC0re (Fig. 3.9b). A possible 
explanation lies in understanding the pharmacokinetics of bupropion in rats. Bupropion 
induces its own metabolism (Schroeder, 1983) and the major metabolites are 
hydroxybupropion, threohydrobupropion and erythrohydrobupropion (Hsyu et al., 1997). 
Bupropion is widely distributed among rat tissues with brain having a tissue:plasma ratio 
of approximately 28:1, 1 hr post-dose (Schroeder, 1983). Bupropion has a short half-life in 
rats (tvs = 26 min; Suckow et al., 1986) and rapid inhibition of DAT binding occupancy rate 
in the striatum (1 min; Stathis et al., 1995). Therefore, following systemic administration 
(Fig. 3.8a, b), the short half-life of bupropion (30 mg/kg) would limit its occupancy of DAT 
before being metabolised, which would subsequently limit its effect in increasing
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extracellular DA levels via DAT inhibition. Furthermore, systemic administration of 
bupropion would mean that the concentrations of bupropion reaching the N A c C0re would be 
divided amongst various other brain regions comprising DAT, as well as other organs of 
metabolism and excretion. Therefore, the increase in extracellular DA and subsequent 
raised baseline following systemic bupropion (Fig. 3.8a, b) would be attributed to DAT 
blockade of dopaminergic neurones in the mesolimbic pathway, as opposed to just the 
NACcore- The sustained increase in extracellular DA following local application of 100 pM 
bupropion (Fig. 3.9b) was due to stable levels of bupropion being maintained throughout 
the infusion period (t = 160-280 min), which allowed for a steady state effect of bupropion. 
Moreover, local application meant that bupropion was delivered directly into the N A c C0re, 
thereby substantially circumventing the pharmacokinetic factors that occur after systemic 
administration.
Elevated rat locomotor activity observed after systemic administration of bupropion 
and nicotine (Fig. 3.4), compared to bupropion alone (Fig. 3.4) is comparable to the 
enhanced extracellular DA levels seen in the microdialysis experiments following systemic 
administration of bupropion and local application of nicotine in the NACcore (Fig. 3.8b). 
However, the pharmacological actions responsible for these effects may be different as 
nicotine was administered systemically in the locomotor activity experiments (Fig. 3.4) and 
locally in the NACcore, in the microdialysis experiments (Fig. 3.8b). Additionally, bupropion- 
induced potentiation of nicotine-evoked DA efflux (Fig. 3.8b), and locomotor activity (Fig. 
3.4), cannot be a pharmacokinetic effect on the half life of bupropion, since the same 
effect was observed when nicotine was infused locally into the NACcore (Fig. 3.8b), and 
systemically (Fig. 3.4).
3.4.3 Behavioural comparisons to the neurochemical 
interactions of nicotine and bupropion
Although relative increases in extracellular neurotransmitter levels measured by 
microdialysis are important, they provide limited support for the functional consequences 
of such changes in vivo. To obtain a handle on this latter issue, rat locomotor activity was 
measured as an index of enhanced limbic dopaminergic function (Rowley et al., 2000). 
The magnitude and time-course of bupropion-induced hyperlocomotion were dose-related 
(Fig. 3.3). Bupropion, at doses above 10 mg/kg, resembles psychomotor stimulants in 
increasing locomotor activity (Nielsen et al., 1986; Redolat et al., 2005). Moreover, at 30 
mg/kg, bupropion has been shown to generalise to d-amphetamine in drug discrimination 
studies (Heal et al., 1992). However, another study revealed an absence of 
psychostimulant-like effect of bupropion (Shoaib et al., 2003), when tested for nicotine 
discrimination. A maximal effect in locomotion following 30 and 60 mg/kg bupropion was
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probably due to rats displaying stereotypy after a certain level of locomotor activity was 
achieved (Cooper et al., 1980). Acute administration of 30 mg/kg bupropion (Fig. 3.3) 
resulted in a significant increase in locomotor activity over a period of 80 min post­
injection. In contrast, extracellular levels of DA in the NAcCOre were significantly elevated 
over a period of only 40 min (Fig. 3.8a) post-injection. Similar dissociations between 
stimulant-induced behaviours and increases in interstitial DA concentrations have been 
reported previously (Nomikos et al., 1989; Nomikos et al., 1992). It raises the question as 
to whether rapidly occurring postsynaptic adaptive mechanisms exist that compensate for 
the increased extracellular levels of DA in the NACcore-
Systemic injections of nicotine activates nAChRs both in the cell body (VTA) and 
terminal regions (NAc and PFC) of the mesolimbic DA pathway, whilst local application of 
nicotine in the NAcCOre. will activate nAChRs in the NAcCOre only (Di Chiara, 2000; Ferrari et 
al., 2002). The locomotor stimulant property of nicotine appears to be initiated by nAChR 
activation within the VTA (Corrigall et al., 1994; Panagis et al., 1996) resulting in 
increased DA release in the NAc (Nisell et al., 1994b). Furthermore, DA release in the 
core subregion of the NAc, rather than shell, contributes preferentially to the locomotor 
stimulant effects of nicotine (Boye et al., 2001). Knockout studies have suggested a role 
for the a3 and (34 subunits in mediating nicotine-induced hyperlocomotion (Salas et al., 
2004), with a7 nAChRs having a negligible role (Grottick et al., 2000). However, the a3 
and p4 subunits, which are thought to co-assemble with the a5 subunit, are only 
expressed at relatively high levels in the habenular/interpeduncular nucleus system (Salas 
et al., 2004). Subunit compositions (a4)2a5(p2)2 and a4a6a5(p2)2 nAChRs have been 
proposed to reside on dopaminergic cell bodies (Klink et al., 2001) in the ratio 80:20 
(Champtiaux et al., 2003). However, it is not known if these are segregated to distinct 
populations of dopaminergic neurones. In the terminal fields, four populations of nAChRs 
have been defined to exist on dopaminergic neurones, namely (a4)2(p2)3, (a4)2a5(p2)2, 
(a6)2(p2)2p3 and a4a6(p2)2p3 nAChRs (Wonnacott et al., 2005). Together, these studies 
establish multiple loci through which nicotine might exert its effects when administered 
systemically (Fig. 3.4) compared to locally (Figs. 3.8b, 3.9a).
3.4.4 Putative mechanisms underlying bupropion’s 
mode of action
Previous findings report that systemic and local effects of bupropion in the striatum 
are action potential-dependent, as they are attenuated by TTX (Nomikos et al., 1989; 
Nomikos et al., 1990). Additionally, bupropion does not affect monoamine oxidase activity 
(Ferris et al., 1982; Ascher et al., 1995). Hence, bupropion-induced increases in 
extracellular DA (Figs. 3.8a, b, 3.9b) and locomotor activity (Figs. 3.3, 3.4) may be
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attributed to its ability to block DAT. However, the effects of bupropion on inhibitory 
autoreceptors or regulation of DA synthesis are unclear.
Re-uptake of DA by DAT, rather than metabolism or diffusion, is the major 
mechanism for clearing evoked DA from the extracellular milieu of the NAc (Cass et al., 
1993). Nicotine, through the activation of nAChRs, is posited to modulate DAT function 
thereby contributing to the regulation of synaptic DA concentrations (Hart and Ksir, 1996; 
Middleton et al., 2004). One possible mechanism is that nicotine-evoked increases in DA 
release may indirectly lead to an enhancement of the reuptake process as a means to 
clear the augmented amounts of DA in the synapse. Once DA is released, nicotine may 
modulate DAT through activation of presynaptic DA D2 receptors or D2 autoreceptors 
(Hart and Ksir, 1996). This would explain why nicotine-evoked DA release (Fig. 3.8b, 
3.9a) and hyperlocomotion (Fig. 3.4) returned to baseline over a shorter time period than 
bupropion-induced increases in extracellular DA (Fig. 3.8a, b) and locomotor activity (Figs. 
3.3, 3.4). Following bupropion-induced inhibition of DAT, elevated levels of DA would be 
regulated by cell body or terminal D2 receptors. However, due to the absence of DAT 
function, the time taken for DA clearance would be subsequently increased, thereby 
prolonging the effects of DA at the synapse. Hence, when administered together, 
bupropion and nicotine would increase and extend DA-mediated effects as compared to 
when applied alone, which is consistent with our present findings (Figs. 3.4, 3.8b), but not 
with those in vitro (Chapter 2). This may be explained by the disparities in local tissue 
concentrations of these drugs in vitro and in vivo, together with the increased complexity 
of their neurochemical actions in vivo (discussed in Chapter 4, section 4.1). Based on the 
present findings, it can be speculated that the enhanced effects on dopaminergic function 
following nicotine and bupropion administration (Figs. 3.4, 3.8b) are a result of additive, as 
oppose to synergistic, processes. However, when applied locally into the NACcore. the 
combination of bupropion and nicotine (Fig. 3.9b) failed to enhance the effect of bupropion 
in the absence of nicotine (Fig. 3.9b). Plausible explanations may be the lack of cell body 
control on extracellular DA and absence of drug metabolism, since both drugs were 
applied directly into the NAcC0re- Another possibility may be that the small increases in 
extracellular DA following local application of nicotine in the NAcC0re (Fig. 3.9a), could have 
been masked by the large within-group variability seen following local application of 100 
pM bupropion and nicotine (Fig. 3.9b).
3.4.5 Conclusions
Recent preclinical studies have shown that bupropion may inhibit nAChRs (see 
section 2.4.2; Fryer and Lukas, 1999; Slemmer et al., 2000; Miller et al., 2002). 
Furthermore, the actions of bupropion may be concentration-dependent, where
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bupropion-induced blockade of DAT occurs at low concentrations of bupropion, whilst at 
higher concentrations, bupropion-induced inhibition of nAChRs prevails (see section 2.4.4; 
Rauhut et al., 2003; Bruijnzeel and Markou, 2003). Some of the observations made in the 
present chapter, particularly the enhancement of nicotine effects (Figs. 3.4, 3.8b), may be 
due to the weak inhibitory effects on DA reuptake by bupropion. The present in vivo 
experiments focusing on the effects of local application of bupropion and nicotine in the 
NACcore (Fig. 3.9) were conducted in order to replicate the conditions and concentrations of 
bupropion used in our previous in vitro study (see Chapter 2). However, consistent with a 
previous study (Shoaib et al., 2003), the present in vivo experiments failed to illustrate any 
nAChR inhibiting property of bupropion (Fig. 3.9b). A likely rationalisation is the complexity 
in anatomical features, and therefore, the pharmacodynamics of the in vivo compared to 





It is largely accepted that nicotine is one of the, if not the main, active ingredient in 
tobacco smoke that leads to and maintains tobacco addiction. Its ability to modulate the 
release of DA in brain areas central to reward mechanisms, has resulted in extensive 
research efforts dedicated at developing interventions that prevent nicotine dependence 
(section 1.5). Currently, the most successful pharmacotherapy that facilitates smoking 
cessation is bupropion. Although the precise mechanism by which bupropion aids 
smoking cessation remains unclear, there is substantial evidence to implicate 
dopaminergic, noradrenergic and nicotine antagonistic components in its efficacy as an 
anti-smoking agent. How these components interact is yet unclear, and is probably very 
complex. Therefore, the work presented in this thesis has attempted to methodically 
evaluate nicotine-bupropion interactions, with respect to DA release, in neuronal models 
of increasing complexity.
4.1 In vitro and in vivo models of increasing
complexity: advantages and limitations
Synaptosomes permit the study of responses by neurotransmitter receptors in 
isolated nerve terminals, without interference from neurotransmitters released from 
neighbouring boutons (Chapter 2). This model initiated the idea that bupropion may have 
a dual action of inhibiting DA reuptake at lower concentrations (0.1-1 pM), and blocking 
nAChRs at the higher concentration (10 pM). This was proposed from results showing a 
concentration-dependent decrease in nicotine-evoked [3H]DA release (Fig. 2.8a). 
Although the interaction of bupropion at DAT was ambiguous due to the continuous 
removal of released [3H]DA under the conditions of superfusion, which minimised DA 
reuptake by DAT, bupropion did, however, produce a transient increase in basal release, 
thereby accentuating some interaction with DAT. The finding that bupropion inhibits 
nAChRs at the higher concentration is in good agreement with previous work (Miller et al., 
2002) and was also supported by the slice model in the present study. Moreover, the 
selective inhibition of nicotine-evoked increases in Ca2+ fluorescence in SH-SY5Y cells 
(Fig. 2.13a) was consistent with the direct antagonism of nAChRs by bupropion.
Slices allow the study of dynamic interactions between neurotransmitters on 
neighbouring terminals, which are not evident in synaptosomes due to their spatial
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separation, and so represent a higher level of complexity (Chapter 2). This model 
illustrated a different effect of bupropion to that seen in synaptosomes, by exhibiting an 
inverted u-shaped concentration-response profile (Fig. 2.8b), as compared to the 
concentration-related profile seen in synaptosomes. As slices allow for neurotransmitter 
cross-talk from adjoining terminals, a putative model, which implicated the involvement of 
inhibitory DA D2 receptors and glutamate release from neighbouring glutamate terminals, 
was proposed to elucidate the effects of DAT blockade at the lower concentrations of 
bupropion. The slice preparation also corroborated bupropion-induced inhibition of 
nAChRs at the higher concentration, consistent with that seen in synaptosomes. 
Furthermore, data obtained when examining the effects of a-Bgt on nicotine-evoked 
[3H]DA release were comparable with previous work (Kaiser and Wonnacott, 2000), 
thereby emphasising the interpretation that a7 nAChRs reside on striatal glutamatergic 
terminals to indirectly modulate DA release (Kaiser and Wonnacott, 2000). The intricacy of 
neurotransmitter interactions in slices, as compared to synaptosomes, revealed the kind 
of effects that the weak DAT blocking property of bupropion may have on overall 
extracellular levels of [3H]DA following nicotine administration.
The synaptosome model contradicted the well-defined property of nomifensine as 
a DAT blocker, by illustrating a significant decrease in nicotine-evoked [3H]DA release in 
its presence (Fig. 2.8a). However, considering the high concentration of nomifensine (10 
pM) used in the study and that synaptosomes probably allow only minimal DA reuptake by 
DAT, it was no surprise that nomifensine had non-specific effects in the synaptosome 
preparation. In fact, the model indicated that the non-specific effects of 10 pM nomifensine 
may be attributed to nAChR blockade. This inference was confirmed by nomifensine- 
induced inhibition of nicotine- (Fig. 2.12a) and KCI-evoked increases in Ca2+ fluorescence 
in SH-SY5Y cells (Fig. 2.12b), indicative of nAChR and VOCC blockade by nomifensine. 
The same concentration of nomifensine (10 pM) examined in slices, produced effects 
characteristic of a well-known DAT blocker, by increasing nicotine-evoked [3H]DA release 
in its presence (Fig. 2.8b). As slices permit greater interaction of nomifensine at DAT, 
compared to synaptosomes, the potency of 10 pM nomifensine at DAT was proposed to 
overcome any indirect modulation of [3H]DA release via glutamate release seen in the 
presence of the lower concentrations of bupropion (0.1-1 pM), thereby producing a net 
increase in extracellular [3H]DA levels.
The in vitro neuronal models revealed that bupropion does in fact interact with 
DAT and nAChRs and that its effects appear to show differential concentration- 
dependency. Hence, the in vitro examination of bupropion’s effects provided a framework 
for in vivo modelling. Microdialysis sampling of extracellular DA provided a more 
physiological representation for studying nicotine-bupropion interactions and thus 
increased the level of complexity from the in vitro models (Chapter 3). As an index of 
enhanced limbic dopaminergic function, locomotor activity measures provided a
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behavioural correlate to the relative increases in extracellular DA as measured by 
microdialysis (Chapter 3). Microdialysis experiments showed that although local 
application of 100 pM bupropion into the NACcore notably increased basal levels of 
extracellular DA, characteristic of its ability to inhibit DAT, neither 1 pM or 100 pM 
bupropion significantly affected nicotine-evoked DA release (Fig. 3.9b), unlike that seen in 
slices at 0.1 pM and 10 pM bupropion. Various factors may account for these differences:
(1) the distance for bupropion to diffuse to before reaching brain tissue after passing 
through the microdialysis probe is likely to be different to that when applied to the slice 
preparation by superfusion. This disparity will probably result in different local 
concentrations of bupropion at the brain tissue, depending on the method of application;
(2) the duration of bupropion infusion via the microdialysis probes was different to that via 
superfusion. Also microdialysates were sampled every 20 min, whereas fraction collection 
in the superfusion experiments were done every 2 min. The difference in temporal 
resolution may contribute to the varying effects of bupropion on nicotine-evoked DA 
release; (3) the degree of preservation of brain anatomical integrity when sampling by 
microdialysis in conscious freely-moving rats is greater than in dissected brain tissue used 
in the superfusion experiments. This is likely to affect the pharmacodynamics of bupropion 
and therefore its effects on nicotine-evoked DA release; (4) microdialysis and superfusion 
experiments examined the effects of bupropion on extracellular DA in the NACcore and 
striatum, respectively. Although the NAcCOre is part of the ventral striatum, differences in 
local circuitry may influence the effects of bupropion on nicotine-evoked DA release; (5) 
the magnitude of effects, if any, as a result of nicotine-bupropion interactions may have 
been too low for in vivo, as opposed to, in vitro detection. Although the increases in basal 
extracellular DA by bupropion, in striatal slices and following local application into the 
NACcore via the microdialysis probe, may be credited to its ability to block DAT, bupropion, 
however, failed to exhibit any nAChR inhibiting property following local application, in 
combination with nicotine, into the NAcC0re. Therefore, comparisons between the effects of 
local application of bupropion on nicotine-evoked DA release as measured by the in vivo 
and in vitro paradigms should be made with a degree of caution.
Systemic administration, as opposed to local application of bupropion to the 
NACcore permits cell body modulation of neuronal firing and neurotransmitter efflux. 
Furthermore, systemic administration of bupropion enables its concentration to be divided 
to various target regions throughout the body and so is subject to metabolism and 
excretion, whereas local application of bupropion into the NAcC0re significantly evades the 
pharmacokinetic factors that occur after systemic administration. These factors suggest 
that systemic administration of bupropion represents a more physiological state than local 
application, and so is comparable, to a certain degree, to oral delivery of bupropion in 
humans. When administered systemically, bupropion (30 mg/kg, i.p) at a dose relevant to 
clinical treatment, enhanced the effects of nicotine-evoked DA release (Fig. 3.8b).
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Furthermore, this effect correlated with the enhanced motor activity following systemic 
bupropion (30 mg/kg, i.p) and nicotine (0.4 mg/kg, s.c), as compared to bupropion (30 
mg/kg, i.p) alone (Fig. 3.4). However, these effects were contrary to those seen in the in 
vitro slice experiments. The effects of systemic bupropion on nicotine-evoked DA release 
in vivo, failed to exhibit any indirect modulation of DA release through DAT blockade, as 
postulated to explain the decreased effect of bupropion (0.1 pM) on nicotine-evoked 
[3H]DA release. Moreover, the enhanced nicotine-evoked DA release and nicotine- 
induced hyperlocomotion following bupropion pre-treatment were consistent with an 
absence of bupropion acting as a nicotinic antagonist. However, as mentioned previously, 
the effects of systemic bupropion are likely to differ from the local application of bupropion 
by superfusion.
The present findings from the in vitro and in vivo experiments, with respect to the 
effects of bupropion on nicotine-evoked DA release, indicate complex mechanisms of 
action that depend on the concentration of bupropion and type of model that its effects are 
examined in. In the in vitro models, bupropion exhibited a clear antagonism of nAChRs, in 
particular at the higher concentration (10 pM). This property of bupropion is consistent 
with other in vitro studies (see section 1.6.2.3; Fryer and Lukas, 1999; Slemmer et al., 
2000; Miller et al., 2002). However, its effects as a DAT blocker in vitro were somewhat 
multifaceted. Bupropion’s effects in the in vivo models were attributed to its ability to block 
DAT. When administered systemically, alongside nicotine, it seemed to potentiate 
nicotinic responses. This is comparable with previous studies that have examined its 
effects in rodent models of nicotine reinforcement (see section 1.6.2.4; Shoaib et al., 
2003; Rauhut et al., 2003), where bupropion has shown to increase nicotine self­
administration. However, bupropion’s ability to inhibit DA reuptake and increase 
extracellular levels of DA, thereby mimicking, in part, some of the effects of nicotine may 
be useful in alleviating the negative affective symptoms of nicotine withdrawal, as seen in 
clinical trials (Shiftman et al., 2000). In support of this hypothesis, bupropion has shown to 
ameliorate the decreases in brain reward function induced by nicotine withdrawal (see 
section 1.6.2.5; Cryan et al., 2003a). Furthermore, the fact that bupropion can substitute 
for nicotine in drug discrimination experiments (see section 1.6.2.6; Wiley et al., 2002; 
Young and Glennon, 2002; Shoaib et al., 2003) is indicative that it shares nicotine 
mimicking properties. In the present study, bupropion failed to exhibit any nAChR 
antagonism in vivo. So far, only one study (Slemmer et al., 2000) has shown bupropion to 
inhibit nAChRs underlying various in vivo nicotinic effects (see section 1.6.2.3). However, 
it must be noted that these effects were observed in mice, which metabolise bupropion to 
the same extent as humans, whereas rats do not extensively convert bupropion to its 
metabolites (see section 1.6.1).
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4.1.1 Bupropion metabolism and pharmacokinetics
Human studies on the metabolism of bupropion have shown that plasma levels of 
its major metabolite, hydroxybupropion, are much greater than the concentration of the 
parent compound (see Table 2a). In mice, hydroxybupropion isomers have proved to 
possess greater potency in targeting DAT and nAChRs compared to bupropion (Damaj et 
al., 2004). Moreover, drug discrimination studies in rats have shown that R,R- 
hydroxybupropion attenuates nicotine’s effect by as much as 50% (Bondarev et al., 2003), 
indicating that the metabolite has significant nicotine antagonism activity in an animal 
model that has previously not shown this effect when examined with bupropion itself 
(Wiley et al., 2002; Young and Glennon, 2002; Shoaib et al., 2003). It follows that 
bupropion’s antagonism of the effects of nicotine is probably attributable to the active 
metabolites, and so could possibly be observed in humans. Therefore, a reason why the 
present study failed to observe any bupropion-induced inhibition of nicotinic responses in 
the in vivo models is probably due to the fact that bupropion’s antagonism of nAChRs is 
likely to be mediated by its active metabolites, which were probably not as abundant as 
bupropion in the rat plasma or brain, and so were unlikely to block any nAChR-mediated 
effects.
4.2 Animal models of human cigarette
addiction
Studies related to nicotine dependence profit from animal models as they offer the 
possibility to examine the mechanisms of dependence at a depth not possible with human 
studies, and to investigate the risk factors for addiction and potential treatment 
interventions at a preclinical stage. For many years, rat models have routinely been used 
to replicate various effects that characterise nicotine dependence, such as nicotine 
reinforcement, as modelled by intravenous nicotine self-administration and conditioned 
place-preference procedures in rats (Le Foil and Goldberg, 2005). Moreover, as rats are 
easily bred and produce large litters, they offer the flexibility to conduct a variety of short- 
or long-term experiments, thereby increasing data productivity. However, as in the present 
study, the use of rats may have some limitations. For example, we learnt that rats do not 
metabolise bupropion to the same extent as humans, and so we were unable to observe 
the nAChR-inhibiting property of bupropion in our in vivo models. To overcome this 
problem, animal models with a bupropion metabolism profile similar to humans (e.g. mice) 
could be used, or bupropion metabolites, instead of bupropion, could be examined in our 
rat models. The concept of systematically analysing the interactions of nicotine and
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bupropion, with respect to DA release, in simple, robust in vitro models to more complex, 
physiological in vivo representations, was an important one. These comparative 
experiments, which would not have been possible in humans, provided some useful 
insight into the mechanisms underlying the clinical efficacy of bupropion in smoking 
cessation and also emphasise the difficulties in trying to identify all the components that 
contribute to a complex response in vivo. However, human studies are ultimately the 
clinical endpoint in research to develop tools to augment treatment efficacy and so are 
necessary to validate the animal models.
4.2.1 Is nicotine enough?
Ideally, a successful treatment that aids smoking cessation should attenuate at 
least the primary reinforcing properties of nicotine, and the pathways that mediate the 
symptoms of nicotine withdrawal. Along with others, the present study has provided some 
insight into the acute pharmacological effects of bupropion, which suggest that its clinical 
success in smoking cessation may be due to the fact that it fulfils the above criteria. 
However, further clarity into its mechanisms of action need to be addressed in chronic 
regimes that emulate human intake of the drug during treatment for nicotine dependence. 
This may be tackled by examining the effects of chronic bupropion and its metabolites in 
rat and/or mouse models of nicotine dependence and withdrawal. Another approach could 
be similar to the systematic one illustrated in the present study, by exploring the chronic 
effects of bupropion and its metabolites on nAChR-evoked neurotransmitter release in 
neuronal models of increasing complexity. It should be noted that conditioned cues (see 
section 1.1) paired with the reinforcing properties of nicotine also serve to maintain and 
reinstate tobacco smoking. Examining the effects of bupropion on the reinstatement of 
nicotine-seeking behaviour in animal models of nicotine dependence and withdrawal 
would further our understanding of bupropion’s actions as an anti-smoking agent.
4.3 Future perspectives
From the present study, it appears that bupropion is capable of blocking DAT and 
nAChRs, and that these actions may be separated with respect to bupropion 
concentration. Bupropion’s ability to increase extracellular DA by inhibiting DAT, 
particularly in the NAc, could reduce the deficit in DA overflow and brain reward function 
caused by nicotine withdrawal, thereby helping to prevent relapse. Bupropion-induced 
blockade of nAChRs is likely to be less important at predicted concentrations of bupropion 
in the brain. However, it is possible that inhibition of nicotinic effects by bupropion may 
contribute to its ability to prevent relapse in long-term treatment. As longer periods of
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nicotine abstinence alone could help break the strength of nicotine reinforcement, 
bupropion could combine with this effect to help smokers recover from single relapse 
episodes.
The multifaceted effects that contribute to the clinical efficacy of bupropion in 
smoking cessation have made it a challenge to design more effective small-molecule 
therapies, based solely on the knowledge of bupropion’s pharmacology. However, its 
interaction with nAChRs has provided insight into developing agents that can modulate 
nicotinic effects. Prime candidates are nAChR partial agonists, which can exhibit nicotine­
like pharmacology, yet simultaneously display anti-nicotinic effects. A promising candidate 
is verenicline, an a4p2 nAChR partial agonist, which is presently in Phase III clinical trials 
as a smoking cessation aid (see section 1.5.2.2). The use of bupropion has also propelled 
research into other neuropharmacological mechanisms outside of the nicotinic cholinergic 
system that might lead to effective smoking cessation therapies. Some of the more 
promising strategies have targeted specific neurotransmitter receptors such as the 
cannabinoid- or DA D3 receptors, shown to be involved in nicotine dependence (see 
sections 1.5.2.3 and 1.5.2.4).
In summary, further research exploring the mechanisms owed to the clinical 
success of bupropion as an anti-smoking agent is clearly required. Using a systematic 
approach that ranges from simple to more complex animal models that closely resemble 
human intake of nicotine has the potential to further our understanding of the 




A1 Microdialysis in rats
Microdialysis is an established sampling technique for the in vivo measurement of 
a variety of substances in both blood and tissue. These include neurotransmitters and 
neuropeptides, enzymes, electrolytes, as well as various hormones and pharmacological 
agents.
The principle of brain microdialysis is very simple. A physiological medium, closely 
resembling endogenous cerebrospinal fluid, is applied to a discrete part of the brain via 
the inlet of a stereotactically implanted probe. The critical part of the probe consists of a 
semi-permeable membrane and presents a closed perfusion system to the tissue. Once 
the probe is in place, compounds in the surrounding tissue diffuse down a concentration 
gradient across the membrane into the perfusate. Continuous removal of this perfusate 
maintains the concentration gradient. The pore size in the membrane is limited to 
introduce a cut-off Dalton weight ensuring that the larger molecules such as proteins 
cannot cross the membrane. This serves to aid perfusate analysis, keeping the perfusate 
relatively clean due to the exclusion of large molecular weight compounds. The closed 
system of the probe helps to preserve the integrity of the brain tissue around the probe 
and avoids continual washing of the tissue that is associated with open-ended perfusion 
probes.
A1.1 Microdialysis system
Fig. A1 illustrates a typical microdialysis set-up used routinely in laboratories 
around the world.
With this as background, part of the project involved constructing a microdialysis 
set-up (Fig. A2) for measuring brain extracellular neurotransmitters, in particular DA, in 
conscious freely moving rats. This would allow correlations to be made between changes 
in extracellular DA levels and behaviour.
Fig. A2 illustrates one of six rat microdialysis set-ups constructed with the help of 
the workshop engineers at the Department of Biology & Biochemistry. The animal 
enclosure is represented by a large circular plant pot, which has no sharp corners where 
the tether could catch or tangle due to slack. To it, is attached a counter-balanced lever 
arm (workshop engineers at the Dept, of Biology & Biochemistry), which minimises stress 
on the microdialysis probe, by moving vertically and horizontally with the animal to prevent 





Fig. A1 A standard rat microdialysis system.
This includes an animal enclosure, counter-balanced lever arm, swivel and a head block 
tether. The apparatus is connected to a swivel pump, via specialised tubing that delivers 
smooth-flow rates required for microdialysis (source: www.instechlabs.com).
Fig. A2 A rat microdialysis set-up produced at the University of Bath.
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A low-torque quartz-lined dual 
channel swivel (375/D/22QM,
Instech, USA) is attached at the 
end of the lever arm (Fig. A4). It 
functions by rotating so as to 
prevent the connecting tubing 
from tangling. The swivel is 
connected to a head block 
tether (M115, Instech, USA), which is supplied with a V* inch slotted screw that is partly 
embedded in dental cement along with the microdialysis probe, onto the animal’s skull
(Fig. A5). A blade 
on the end of the 
stainless steel 
spring tether slides 
into the head mount 
screw and is 
secured with a 
knurled tubular nut. 
The spring tether 
and the counter­
balanced lever arm 
work together to 
give the animal
greatest possible freedom of movement. A syringe pump (Harvard Apparatus, USA) is 
placed in close proximity to the microdialysis set-up (Fig. A1). It delivers aCSF (125 mM 
NaCI, 2.5 mM KCI, 1.18 mM MgCI2, 1.26 mM CaCI2, 2.0 mM Na2H P 04, adjusted to pH 7.4 
with 100 mM H3P 0 4) at a constant flow rate (1.2 pl/min), via FEP tubing (I.D. 0.12 mm, 
internal volume 1.2 pl/100 mm length; CMA Microdialysis, Sweden). With excellent 
resistance to chemicals, ozone, and UV radiation, FEP tubing maintains its chemical 
resistance. Its non-stick characteristics ease the transfer of product lowering the incidence 
of protein binding/absorption, making it ideal for the transfer of fluids like 
neurotransmitters.
A1.2 Microdialysis probe
The microdialysis probe to be used is of a concentric type. It consists of a semi- 





The tether is secured with a tubular nut, to the head mount screw 
that is partly embedded in dental acrylic onto the animal’s skull 
(source: www.instechlabs.com).
Fig. A4 Swivel.
The swivel incorporates a 
miniature system for ultra-low- 
torque and quartz lining on both 
the centre and side channels for 
the lowest possible dead volume 





are available commercially, but are expensive. Therefore, homemade concentric probes 
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Membrane
2mm
Fig. A6 Microdialysis probe.
(a) Diagrammatic representation of the structure of a concentric microdialysis probe.
(b) Picture of a homemade concentric microdialysis probe. Graduations on the ruler give an 
indication of the relative size of the probe.
Dialysis tubing (I.D. 0.22 mm, O.D. 0.30 mm, made from polyacrylonitrile with a 
molecular weight cut-off at 20000 Daltons; Hospal UK Ltd) was obtained from a renal 
dialysis pack. A 60 mm piece of fine fused silica glass capillary tubing (I.D. 0.11 mm, O.D. 
0.17 mm; Scientific Glass Engineering, UK) was threaded into the lumen of a length (~ 50 
mm) of dialysis tubing so that it protruded from both ends of the membrane. This 
supported the membrane during the initial stages of probe preparation. The shaft of the 
probe consisted of a stainless steel cannula (23 gauge, I.D. 0.33 mm, O.D. 0.60 mm), 22 
mm in length (Coopers Needle Works, UK). The dialysis membrane was inserted into one 
end of the cannula (~ 5 mm) and secured with quickset epoxy resin (RS Components, 
UK). The resin was allowed to dry for at least 1 h. Once secure, the silica glass was 
removed and the membrane cut to the desired length (2 mm). A 10 mm length of Portex 
(polyethylene) tubing (I.D. 0.25 mm, O.D. 0.75 mm) was inserted over the free end of the 
cannula and a small hole pierced in the tubing, using a 25 gauge needle, close to where it 
joined the cannula. The silica glass was threaded back into the dialysis tubing, pushed 
through the steel cannula and out through the hole made in the Portex tubing. The silica 
glass was pulled through the steel cannula until none was visible inside the membrane, so 
that the tip of the membrane could be sealed with epoxy resin and left for at least 1 h to 
dry. After this time, the silica glass was pushed back into the membrane until about 0.5 
mm away from the tip of the membrane. The inlet and outlet tubes consisted of stainless
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steel cannulas (23 gauge, I.D. 0.33 mm, O.D. 0.60 mm), 11 mm in length (Coopers 
Needle Works, UK). The inlet was constructed by inserting a cannula into the Portex 
tubing whilst the outlet was made by placing a cannula over the protruding silica glass. All 
joints at the base of the probe were sealed with epoxy resin, and once this was dry, all the 
joints were encased in epoxy putty (RS Components, UK), to strengthen the probe. Care 
was taken at all stages of preparation not to touch the Hospal membrane in case the 
probes became blocked.
A1.3 In vitro probe recovery
Before the homemade probes were implanted into the rat brains, the recoveries of 
DA and nicotine across the dialysis membrane were determined in vitro. The term 
recovery or relative recovery is defined as the ratio between the concentration of a 
particular substance in the perfusate and the concentration of the same substance in the 
solution outside the probe (Benveniste, 1989).
From every batch of microdialysis probes made, at least four probes were selected 
for the recovery of DA and nicotine (two probes for each substance). The probes were 
immersed in a standard solution (of a known concentration, e.g. 50 nM) of either [3H]DA 
(specificity 43-47 Ci/mmol, 1.67-1.81 TBq/mmol) or (-)-[N-methyl-3H]nicotine ([3H]nicotine; 
specificity 60 Ci/mmol, 2.2 TBq/mmol, Amersham Biosciences Ltd, Bucks., UK) made up 
in aCSF. The probes were perfused at a constant flow rate of 1.2 pl/min and allowed to 
equilibrate for 1 h before samples were taken. Samples were collected every 20 min. 
Microscint 40 (100 pi) scintillation fluid was added to aliquots (20 pi) of the collected 
samples and of the standard solutions, and they were counted for radioactivity in a 
MicroBeta counter (counting efficiency 31%). Recoveries were calculated as a percentage 
of the radioactivity of substance ([3H]DA or [3H]nicotine) in the sample divided by the 
radioactivity of substance in the standard solution. Typical recoveries of [3H]DA and 
[3H]nicotine across the dialysis membrane were between 10-12% for both substances.
Recovery experiments provide valuable information on probe design so that in this 
way the membrane area can be optimised to give a high recovery value for the substance 
under investigation. They also serve as a measure of probe to probe variability. Hence, 
testing for probe recovery was used to determine the reproducibility of the probes and not 
for correcting results obtained from microdialysis experiments.
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A2 High Pressure Liquid Chromatography 
with Electrochemical Detection
Intracerebral microdialysis is dependent on sensitive analytical methods to 
measure compounds in perfusate present at very low concentrations (fmol-nmol). HPLC- 
ECD has provided a tool to investigate the role of neurotransmitters in the central nervous 
system. The most commonly used separation technique for DA is reverse phase ion-pair 
chromatography. This combines a column that is packed with C18 particles, with a mobile 
phase consisting of an aqueous buffer, an ion-pair reagent, and an organic solvent.
A successful HPLC system essentially requires the following:
Solvent delivery pump: this pump should have as little pump noise as 
possible so that the pulsations in the mobile phase 
are not detected by the electrochemical detection 
system. Optional use of a pulse dampner may be 
required to reduce pump noise.
• Sample injection system: either a manual-type filled loop valve injectors 
(Rheodyne) with a 5, 10, 20 or 100 pi loop together 
with an appropriate syringe (Hamilton), or an 
appropriate autosampler can be used.
Chromatographic columns: a reverse-phase ion-pair chromatography with a 3 
or 5 pm Cis silica-based ODS column.
Electrochemical detectors: a detector which uses a high density glassy carbon 
working electrode, thereby having very low residual 
current noise resulting in improved chromatographic 
baselines, and consequent improvement in 
sensitivity.
Recording output from the detector: usually the detector can be linked to a
programmable HPLC integrator or to a 
suitable computer input.
Ancillary equipment: the mobile phase should be prepared using double
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distilled deionised water and needs to be filtered and 
degassed before use.
Following the construction of a microdialysis set-up, another part of the project 
involved optimising a HPLC system for the electrochemical detection of DA. This involved 
determining (1) the optimum voltage at which DA was oxidised and, (2) the system’s 
detection limit for DA.
To determine the optimum voltage for DA oxidation, a known concentration of a 
DA standard (50 fmol) was injected into the HPLC system, and peak areas were 
measured at different voltages (Fig. A7). The voltage at which the maximum peak area of 
DA was obtained, was at 0.60 volts, signifying the optimum voltage for DA oxidation at the 
electrochemical cell.
5.2 - i









Fig. A7 Voltam ogram  show ing the optim um  voltage fo r DA oxidation .
DA standards (50 fmol) were injected into the HPLC system, and peak areas measured at a 
range of voltages. Maximum peak area of DA was obtained at 0.60 volts, implicating the 
optimum voltage of the HPLC system, for DA oxidation. Values are mean ± S.E.M. of 
duplicate standards.
Next, to determine the detection limit for DA, a range of concentrations of DA 
standards (1-10 fmol) were injected into the HPLC system, and peak heights were 
measured at two different sensitivities, 0.2 nAA/ and 0.5 nAA/ (Fig. A8). The minimum 
concentration of DA with a peak height that was approximately three fold greater than 
baseline was accepted as the system’s detection limit for DA (Fig. A8a).
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Fig. A8a suggests that at a range of 0.5 nAA/, the detection limit for DA was 10 
fmol (ratio above baseline = 2.52; -  3). However, when the range was decreased to 0.2 
nA/V (increased sensitivity), the detection limit for DA was 1 fmol (ratio above baseline = 
2.56; -  3), indicating a greater sensitivity of the system for the quantification of DA. In 
confirmation, Fig. A8b indicates that the greater slope at 0.2 nA/V reflects the greater 
sensitivity of the HPLC system.
Dopamine std DA peak height DA peak height
(fmol) at0.5nA N at 0.2nA/V
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Dopamine standard (fmol)
Fig. A8 HPLC system sensitivity results.
(a) Table showing various peak heights of DA standards, expressed as a ratio above  
baseline. DA standards w ere m easured at two different sensitivities (0 .2  and 0 .5  nAA/).
(b) The greater slope of 0.2 nAA/ reflects the greater sensitivity of the HPLC system.
A3 Final method
To summarise the detection and subsequent quantification of DA using HPLC- 
ECD (Fig. A9), the method that has been developed in this project employed a Spherisorb
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(I.D. 100 x 2.1 mm; Higgins Analytical) reverse-phase column packed with 5 pm C i8 silica 
based ODS material. A Bischoff solvent delivery pump with a pulse dampner (PD-120625, 
Presearch Ltd, Herts, UK) was used to circulate mobile phase (100 mM NaH2P 0 4, 1 mM 
EDTA, 1 mM octane sulphonic acid, 12% methanol, pH 4.0) at a flow rate of 0.2 ml/min. 
The mobile phase was filtered through a 0.22 pm filter (Millipore, Bedford, USA) and 
degassed under vacuum. DA standards (20 pi) were injected onto the column via a 
refrigerated (4°C) Triathlon autosampler. The standards were prepared daily from a stock 
solution of DA (1 mM) in a 1:1 mixture of deionised water and 0.1 M perchloric acid, 
stored at 4°C. Antec-lntro (Leyden, Netherlands) electrochemical detector was used in 
conjunction with an Antec “wall-jet” design cell (VT-03). The cell employs a high density, 
glassy carbon working electrode (+0.60 V) combined with an Ag/AgCI reference electrode. 
The electrode signal was integrated using a PowerChrom data acquisition system 
(ADInstruments, Oxfordshire, UK).
Bischoff Analytical Electrochemical Computer
pump column detector software
Sample
Fig. A9 Flow diagram  sum m arising  the basic com ponents  and steps required fo r the  
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